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Abstract
Few attempts to quit smoking are successful, making current interventions relatively 
ineffective. Evidence shows that exercise decreases nicotine withdrawal symptoms in 
humans, but the mechanism is unclear. Part of this thesis aimed to explore the 
mechanisms underpinning the effect of exercise on nicotine withdrawal in both 
human and animal models of nicotine addiction.
The role of perception of exercise intensity was investigated in temporarily abstinent 
smokers. Perceived and objective moderate intensity exercise and passive waiting all 
reduced withdrawal symptoms, and salivary cortisol was attenuated compared with 
pre-abstinence levels, but there was no difference between any of the interventions. 
These results indicate that exercise may reduce withdrawal by acting as a distraction, 
but does not preclude biochemical mechanisms from playing a role.
Nicotine-treated mice undertaking 2 or 24 hrs/day  running wheel access, 
demonstrated reduced mecamylamine-precipitated withdrawal symptoms compared 
with sedentary mice, indicating that even a low level of exercise aids in reducing 
withdrawal symptoms. This was accompanied by a significant increase in 
hippocampal a7 nicotinic receptors (nAChRs), implicating the oc7 nAChR in a 
mechanism underlying the effect of exercise in nicotine withdrawal.
The effect of nicotine on nAChR and oxytocin receptor (OTR) binding in a mouse 
model of schizophrenia was investigated using mice with a G72 protein insertion 
(G72Tg). Nicotine reversed social cognitive deficits in G72Tg mice, associated with 
attenuation of a7 nAChR and OTR binding in the cingulate cortex by nicotine in 
G72Tg mice. These results implicate both a7 nAChRs and OTR as targets for the 
development of pharmacotherapies for the treatm ent of social and cognitive deficits 
in schizophrenia.
All toghether, the results in this thesis show that the a7 nAChR may be involved in 
modulating behavioural responses in nicotine addiction. Furthermore, dysregulation 
of a7 and OT receptors may underlie the mechanism of cognitive and social deficits in 
schizophrenia.
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CHAPTER 1 
General Introduction
CHAPTER 1. GENERAL INTRODUCTION
1.1 Historical context
Tobacco for use in cigarettes is derived in the main from the plant Nicotiana tabacum, 
which produces nicotine as a defence against insects; indeed nicotine was used as a 
pesticide globally until its ban in the 1960s (Russo, et al, 2011). Tobacco was 
brought to Europe for the first time in the late 15* century CE from America. 
However, tobacco smoking did not become truly widespread until the First World 
War (1914 -  18) when cigarettes were included in the daily rations of American 
soldiers. Concern about the health implications of cigarette smoking started in the 
mid-twentieth century following epidemiological studies linking smoking and cancer 
(for review see Russo, e ta l,  2011), and in 1955 the UK officially recognised the causal 
link between smoking and cancer.
There have been various attempts in recent years to increase public awareness of the 
negative health effects of smoking (Mackay & Eriksen, 2002), and new legislation has 
been introduced to restrict the availability of, and exposure to, cigarettes ("The 
Smoke-free (Premises and Enforcement) Regulations 2006,"). However, it is 
currently estimated that 21% of adults and 6% of 11 -  15 year olds in the UK smoke 
regularly, while smoking is implicated in 18% of all deaths for those aged 35 and 
over. About 50% of smokers fail in their attempts to quit smoking, even with the help 
of the NHS Stop Smoking Service (NHS-SSS), who provide interventions such as 
cognitive behavioural therapy (CBT), nicotine replacement therapy (NRT) and other 
pharmacotherapies (e.g. varenicline). The NHS-SSS in England alone cost just over 
£88 million in 2011/12, but this figure does not include expenditure on NRT or 
pharmacotherapies (The Health and Social Care Information Centre, 2012). Research 
carried out by Allender e ta l  (2009) estimated the total cost of smoking and related 
health issues to be in the region of £5.2 billion in 2005-6, around 5.5% of the 
healthcare budget at the time. There is a clear and urgent need to find an 
intervention that will not only increase the number of successful cessation attempts, 
but also actively reduce withdrawal symptoms. Furthermore, any intervention must 
be cost effective and easily provided on a countrywide scale.
1.2 Addiction
1.2.1 Definitions of addiction
The 5* edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; 
American Psychiatric Association, 2013} describes drug addiction as a chronic 
relapsing brain disorder, characterised by a loss of control over behaviour such that a 
person becomes dependent on drug use despite numerous negative social and 
physical consequences. Addiction is characterised in the DSM-5 by the manifestation 
of two or more of the following symptoms within a twelve-month period:
1. Compulsive and persistent desire or craving for a specific substance.
2. Recurrent substance use despite negative social, interpersonal problems or 
physical consequences caused or exacerbated by substance abuse.
3. Tolerance to the hedonic effects of the substance, as defined by a need for 
markedly increased amounts of the substance to achieve the desired effect 
and /or markedly diminished effect with continued use of the same amount of 
the substance.
4. Manifestation of psychological and physical withdrawal symptoms during 
abstinence from the substance, e.g. anxiety, depression and irritability.
5. Expenditure of a great deal of time in activities necessary to obtain and use the 
substance, or recover from its effects.
6. Important social, occupational, or recreational activities given up or reduced 
because of substance use.
Other definitions of addiction consider sensitisation to drug use and the transition 
from impulsive to compulsive behaviour. Sensitisation is an im portant concept, 
particularly in cigarette addiction, as, unlike other drugs of abuse, for example 
cocaine, nicotine is not reported to induce long-term tolerance to reward, rather 
producing tolerance to the potential aversive effects of the drug. According to the 
incentive sensitisation theory of addiction (Robinson & Berridge, 1993, 2008} there is 
dissociation in reward processing between 'liking' (hedonic effect} and 'wanting' 
(incentive salience}. The theory posits that development of drug dependence is 
concomitant with a hypersensitivity to the latter component. Addicts become
hypersensitive to the drug and reward-related stimuli, while actual reward and 
'liking' may diminish compared with initial administration of the drug.
Addiction may be considered as reward-related learning or pavlovian conditioning 
leading to maladaptive behaviours [Everitt & Robbins, 2005). According to this 
theory, there is a transition from impulsive drug taking motivated by instant 
gratification to compulsive drug taking; obsessive behaviour causing stress and 
anxiety, which is only relieved by the repetitive behaviour of drug taking. As this 
transition takes place there is a shift from positive reinforcement (hedonic effect of 
the drug) to negative reinforcement (avoidance of withdrawal symptoms) (Koob & Le 
Moal, 2008; Koob & Volkow, 2010).
Baker e ta l  (2004b) also emphasise the role of negative reinforcement in addiction. 
Negative affect is known to increase during abstinence from smoking (Hughes, 2007), 
but Baker et a l (2004b) go a step further, placing negative affect at the heart of 
withdrawal symptoms; smokers are thought to be pre-consciously aware of negative 
affect and lose cognitive control over behaviour in order to overcome this feeling. In 
terms of motivation. Baker etal. (2004a) describe continuation to smoke or relapse to 
smoking as being motivated by a desire to avoid withdrawal symptoms and reduce 
the stress associated with this.
West (2009a) describes addiction in terms of motivation and response control; in 
particular, the motivation to smoke being stronger than the motivation not to smoke. 
In the PRIME theory of addiction. West (2009b) suggests that there are five 
concentric levels to behaviour: planning, response, impulse, motivation and 
evaluation. In cigarette dependence, exposure to smoking-related stimuli can act as a 
cue leading to an impulsive behavioural response (Weiss, e ta l ,  2001), i.e. smoking 
and consequent nicotine reinforcement. What constitutes a cue depends on the 
individual: it may be the image of a cigarette, the smell of one, or any action 
associated with smoking such as finishing a meal or drinking coffee. As dependency 
progresses, impulsivity begins to take precedence over the planning, response and 
evaluative aspects of behaviour. West (2009a) found that enjoying the act of smoking 
itself was a major factor in failed quit attempts, while nicotine cravings, impulsive 
responses to smoking cues and negative affect were all factors that could trigger 
relapse.
Koob and Volkow (2010) conceptualise addiction as a spiral of behaviour comprising 
three stages: binge/intoxication; withdrawal/negative affect; and craving leading to 
relapse (see Koob & Volkow, 2010). Different drugs of abuse may have greater effect 
on different phases. For example, with nicotine the binge stage is less prominent, the 
withdrawal and craving phases more so. The binge/intoxication phase is associated 
with the ventral tegmental area (VTA) and the ventral striatum; the withdrawal phase 
with the extended amygdala and craving with the dorsal striatum, orbital and 
prefrontal cortices, basolateral amygdala (BLA) and the hippocampus (for review see 
Koob & Volkow, 2010). Everitt and Robbins (2005) associate the transition from 
voluntary/impulsive to habitual/compulsive drug use not only with a transition of 
processes from the prefrontal cortex (PPG) to the striatum, but with a transition from 
the ventral striatum (nucleus accumbens) to the dorsal striatum (caudate putamen); 
a shift in reward-related dopamine (DA) transmission from the nucleus accumbens 
shell (AcbSh) to dependence in the accumbens core (AcbC). Therefore, as addiction 
progresses from impulsive to compulsive use, the underlying neuroadaptive changes 
affect a succession of different neural circuits.
Therefore, the development of nicotine addiction may be considered as a 
hypersensitivity to smoking-related cues stimulating the continued consumption of 
nicotine in order to avoid negative withdrawal symptoms.
1.3 Nicotine addiction
Nicotine is the addictive, psychoactive stimulant compound in cigarettes (Stolerman 
& Jarvis, 1995). It acts as an agonist of neuronal nicotinic acetylcholine receptors 
(nAChRs), binding with a slightly higher affinity than the endogenous ligand, 
acetylcholine (ACh). Neuronal nAChRs are located in regions of the brain highly 
associated with reward and dependence, such as the VTA and Acb, where there are 
also large populations of dopaminergic (DAergic) neurons and terminals (Zoli, et al, 
2002). As the primary target of nicotine in cigarettes, an understanding of the 
function of neuronal nAChRs and their various subunits is essential to understanding 
the process of nicotine addiction and the physiological consequences of nicotine 
administration and abstinence.
1.3.1 Neuronal nicotinic acetylcholine receptors
Considered phylogenetically, the cholinergic system is the oldest nervous pathway 
(for reviews see Woolf, 1991; Woolf & Butcher, 2011). The cholinergic system is 
widespread, innervating nearly every region of the central nervous system (CNS; 
Figure 1-1). Cholinergic neurons synthesise, store and, upon stimulation, release the 
neurotransm itter Ach. ACh signalling is implicated in cognitive processing, arousal, 
attention, learning and memory, and acts via both muscarinic and nicotinic 
acetylcholine receptors (for review see Dani & Bertrand, 2007). Based on localisation 
it is possible to separate nAChRs into neuronal- and muscle-type receptors, and it is 
the neuronal variety which will be the focus here. Neuronal nAChRs are members of 
the cys-loop ligand-gated ion channel family, a group that also includes glycine, y- 
amino butyric acid (GABA)a, GABAc and 5-hydroxytriptamine (5-HT)s receptors 
(Jones & Sattelle, 2006; see also Karlin, 2002). These are also referred to as ionotropic 
receptors and are involved mainly in fast synaptic transmission.
nAChRs are large glycoproteins at 290 kDa, and are formed by a pentameric ring of 
subunits (Unwin, 2004), see Figure 1-2. These subunits are arranged around a central 
cation-selective aqueous pore, with each subunit spanning the cellular membrane 
four times (Cooper, e ta l,  1991). The central channel of the receptor is 25 A wide at 
the synapse, but narrows in the transmembrane region. This channel is lined by the 
M2 transm em brane helix of each subunit, with a slight contribution from Ml at the 
extracellular membrane where the pore widens (Unwin, 2004). The Ml -  M4 regions 
are lined with negatively charged amino acids, which make the channel highly 
selective for cations. The N terminal is long, approximately 210 amino acids, and 
along with the C terminal is located extracellularly; there is also an intracellular loop 
between the M3 and M4 helices (for review see Karlin, 2002). The N-terminal domain 
contains a cys-loop, identifying the receptor as part of the family of cys-loop ligand- 
gated ion channels. Two cysteine residues form a loop in the amino acid chain via a 
disulfide bond, and it has been suggested that this aids in the transduction of agonist 
binding as the channel opens (Sine & Engel, 2006).
O lfactory bulbs
04(32, 07
Pineal gland
o3|34, o7
PPTg,
Striatum
o 4 p 2 , o 4 a 5 p 2 ,
0 6 P2P3, o 6 a4p2p3  Amygdala 
o 4 p 2 , 0 7
In te rpeduncu lar
N ucleus
o 4 p 2 * , o2 P 2 * , 
o 3 p 3 P 4 , 0 7
/  Thalam us
H ypothalam us
0 4 P 2 , 07
Spinal cord 
o4P2,
o 3 p 2 * , 0 7
Raphe nuclei
o 4 p 2Substan tia  nigra /  
V entral teg m en ta l a rea
o 4 p 2 , o 4 o 5 p 2 ,
o 3 p 4 * , o 6 p 2 p 3 , 07
Figure 1-1: Cholinergic pathways and nicotinic receptor localisation in the 
mouse hrain
Cholinergic neurons project from mesopontine region [green] and basal forebrain [purple], 
as well as interneurons in the striatum [red]. Regions with high concentrations of nAChRs 
are highlighted in blue. Modified from Woolf and Butcher [2011].
In mammals, neuronal heteromeric nAChRs may contain a2 -  a6 and (32 -  (34 
subunits, while their homomeric counterparts may only be formed by oc7 subunits 
[Albuquerque, et al, 2009]. The exact composition of nAChRs is yet to be fully 
elucidated as the stoichiometry, as well as the inclusion of additional subunits, can be 
altered by subunit availability and other factors [see Gotti, e ta l ,  2009]. However, a 
subunit ratio of [cx4]3:[(33]2 for cx4(32 nAChRs is generally accepted [Briggs, et al, 
2006; Cooper, et ai, 1991].
The ACh binding site is located on the extracellular side of the membrane in the N- 
terminal region of the receptor [Unwin, 2004]. Heteromeric receptors have two ACh 
binding sites, one at the interface of each of the cc subunits with an adjacent (3 subunit; 
both binding sites must be occupied by an agonist for receptor activation to occur 
[Unwin, 2004]. Homomeric receptors have five identical putative binding sites -  one 
at the interface of each subunit; however, it is not certain whether all the binding sites
must be filled for receptor activation. In both types of receptor, the binding site is 
composed of a primary and complementary component, the primary component 
containing a pair of cysteine residues. The a subunit carries the principal site and the 
P subunit the complementary site in heteromeric receptors, whereas in homomeric 
receptors each subunit contributes to both the primary and the complementary 
regions. In exception to this general rule, the «5 subunit contains no binding site 
(Wang, et al, 1996], but allows other a  subunits to act as the principal component, 
while the pS subunit does not contribute at all.
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Figure 1-2: Conformation of nicotinic receptors
The relative positioning of a and p subunits is presented, along with binding sites [black 
dots], for low- and high-affinity heteromeric a4p2* nAChRs, as well as homomeric a7nAChRs.
The a4p2*and a7 receptors are the most widely distributed and numerous subtypes 
in the mammalian brain with what appears to be a complementary distribution, 
although a4 subunits are primarily expressed in DAergic midbrain neurons (see 
Govind, et ai, 2009]. Clarke (1985] identified two nicotinic receptor subfamilies 
according to autoradiography binding studies: a-bungarotoxin (a-Bgtx] sensitive and 
a-Bgtx insensitive receptors, with a-Bgtx sensitive binding thought to correlate with 
a7 nAChRs. The a-Bgtx insensitive receptors were the most prevalent and had 
concordant distribution of PH]ACh and PHJnicotine binding. The distribution of a- 
Bgtx binding was very different, overlapping only in the inferior colliculus, cerebral 
cortex (layer 1] and superior colliculus.
Anatomical and functional evidence indicates that nAChRs are mainly located on 
preterminal and presynaptic sites involved in regulating neurotransm itter release in 
various brain regions. The a4p2* subtype is the most widely distributed, and by using
histochemical hybridisation of mRNA, the p2 subunit has been identified as the most 
common subunit [Gotti, et al, 2009). The a4p2* receptor has been located in the 
striatum, cerebral cortex, superior colliculus, lateral geniculate nucleus, substantia 
nigra (SN), VTA and cerebellum [Gotti, et al, 2006a; Gotti, et al, 2005b; Zoli, et al,
2002). In the striatum these receptors have been identified not only on DAergic 
neurons, but also on non-DAergic neurons, such as GABAergic neurons which project 
onto DAergic cells in the VTA, with both processes leading to DA release (Sher, et al, 
2004). Homomeric a7 receptors are highly expressed in the cortex, VTA, 
hippocampus and subcortical regions, and also at low levels in the thalamus and basal 
ganglia [Gotti, et al, 2009; Jones & Wonnacott, 2004). The a7 receptors located on 
presynaptic glutamate terminals innervate neurotransm itter release either directly, 
e.g. glutamate in the hippocampus and VTA [Jones & Wonnacott, 2004), or indirectly, 
e.g. DA in the striatum and prefrontal cortex [Livingstone, e ta l ,  2009).
The Hb-IPn pathway contains the highest levels of expression of nAChRs in the CNS, 
mainly of p2* and p4* populations [Gotti, et al, 2009; Salas, et al, 2004b). Medial 
habenula [MHb) p2* receptors are mainly a4p2* or aSp2*, with some contribution 
from a5 subunits, while in the interpeduncular nucleus [IPn) there is a roughly equal 
distribution of a2p2*, a3p2* and a4p2* receptors. However, only the a3(B4* and 
a3(33p4* receptors mediate ACh release in the habenulo-interpeduncular pathway 
[Grady, e ta l ,  2009).
a5 subunit expression in the rat has been found in the cerebral cortex, hippocampus, 
striatum, thalamus and superior colliculus [Mao, e ta l ,  2008), and specifically on the 
cell bodies of DAergic neurons in the SN and VTA [Azam, e ta l ,  2002). In contrast, a2 
expression is greatest in the olfactory bulbs and IPn [Whiteaker, et al, 2009). 
Immunoprepitation assays have, however, demonstrated that the a5 subunit is only 
associated with a4p2* nAChRs [Mao, e ta l,  2008).
a6 subunit mRNA has been identified in the VTA, SN and locus coeruleus, where it 
was present in greater levels than other nAChR subunits [le Novère, e ta l ,  1996); a6 
mRNA was also found in thalamic nuclei, the MHb and IPn but to a lesser extent. 
Specifically, Yang et al [2011) found a6p2* nAChRs on presynaptic GABAergic 
boutons projecting onto DAergic neurons in the VTA. Le Novère et al [1996) also
found extensive co-localisation of a6 and pS mRNA, indicating the existence of a6p3* 
nAChRs.
1.3.2 nAChR function
The arrival of an action potential at a presynaptic terminal causes membrane 
depolarisation and the release of ACh into the synaptic cleft where it acts on 
postsynaptic nAChRs [Ofek & Soreq, 2013). Acetylcholine is degraded by 
acetylcholine esterase within milliseconds, following which choline is taken up via 
carrier proteins into the presynaptic neuron. Choline acetyl transferase catalyses the 
formation of ACh from acetyl CoA and choline, which is then stored presynaptically in 
vesicles. Nicotinic receptors only open at negative membrane potentials, i.e. when 
the neuron is 'at rest'. Under physiological conditions nAChRs are activated by 
tonically released ACh. However, chronic exposure to low levels of an agonist, such as 
nicotine levels following tobacco use in humans, leads to high affinity receptors 
becoming desensitised and closed (see Ofek & Soreq, 2013).
1.3.3 nAChR upregulation
Whilst in most receptor systems exposure to an agonist decreases receptor 
expression and antagonists increase expression, chronic nicotine exposure leads to a 
paradoxical increase in neuronal nAChR expression (for reviews see Covind, et al, 
2009; Wonnacott, 1990). First identified thirty years ago (Schwartz & Kellar, 1983), 
there have been numerous studies since attempting to fully illuminate this 
phenomenon. The endogenous ligand ACh binds to nicotinic receptors in low 
concentrations; however, nicotine binds to nAChRs with greater affinity than ACh 
causing a rapid desensitisation of receptors that precipitates a compensatory increase 
in receptor number. There is as yet no full consensus as to the exact mechanism of 
action underlying upregulation (for review see Govind, et al, 2009).
In 1983, Schwartz and Kellar published the first paper describing nicotine-induced 
neuronal nAChR upregulation in an animal model. They discovered that pHJACh 
binding was decreased following acetylcholine esterase treatment, the typical 
downregulation response expected following increased levels of an agonist. In 
contrast, nicotine treatm ent caused upregulation of nAChRs, indicating that the 
profile of activity is different to that of the endogenous ligand. Similarly, Marks et al
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(1983) showed a dose-dependent increase in pH]nicotine binding in response to 
chronic nicotine treatm ent in several brain areas, including the cortex, hippocampus 
and hypothalamus; [i25i](x-Bgtx binding was also increased, but only in the midbrain 
and hippocampus. However, upregulation of these receptors does not appear to be 
permanent, returning to control levels within 7 to 10 days in the mouse (Marks, etal,  
1985).
While the exact mechanism of nAChR upregulation is yet to be fully elucidated, 
several models, which may even be concurrent, have been proposed (Figure 1-3). To 
date, no study has found an increase in a4p2* mRNA following nicotine 
administration, therefore the effect must be post-transcriptional (Bencherif, et al, 
1995; Huang & Winzer-Serhan, 2006; Marks, et al, 1992). Nicotine may promote 
assembly or decrease degradation of receptors (Darsow, et al, 2005; Nashmi, et al, 
2003; Wang, e ta l ,  1998) or slow endocytosis of receptors (Peng, e ta l ,  1994). In the 
endoplastic reticulum, nicotine binds to a  and p subunits to aid intermediate 
assembly, facilitates subunit protein folding prior to subunit assembly (Harkness & 
Millar, 2002), and /o r binds to intermediates to aid their maturation into pentamers 
(Sallette, et al, 2005). There may also be a stoichiometric change from the lower 
affinity (a4)s(p2)2 to the higher affinity (a4)2(P2)s conformation (Lester, e ta l ,  2009; 
Nelson, et al, 2003; Vallejo, et al, 2005). Moreover, Srinivasan et al (2011) 
demonstrated that nicotine stabilises the high affinity conformation, and acts as a 
chaperone promoting a4p2* release from the endoplasmic reticulum.
More recently, Covind e ta l  (2012) identified two consecutive mechanisms that could 
be discriminated according to their kinetics. Firstly, there is a fast component 
characterised by a transient reversible conformational change to the high affinity 
subtype, i.e. (a4)2(p2)s, but with no change in overall receptor number. Secondly, 
there is a slower upregulation of receptor number and assembly, coupled with 
downregulation of p2 subunit degradation and proteasome activation. The first 
mechanism occurred in live rat cortical neurons within mins of acute nicotine 
exposure at a concentration equivalent to that found in humans after 1-2 cigarettes, 
but was rapidly reversed. Therefore, it appears that the first mechanism is 
independent of the second as an initial upregulation of the high affinity conformation 
does not necessarily lead to increased receptor number. However, the question of
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multiple mechanisms needs to be investigated in an in vivo model rather than just 
single cell cultures.
The phenomenon of a4p2* receptor upregulation has also been demonstrated in 
humans. For example, positron emission tomography (PET) scans have shown a 25 -  
200% increase in receptor binding levels throughout the brain, including the 
putamen, cortex, midbrain and thalamus (Mukhin, e ta l ,  2008). Benwell e ta l  (1988) 
identified increased post-mortem [^H]nicotine binding in the gyrus rectus, 
hippocampus, cerebellar cortex and median raphe nuclei of smokers. Similarly, 
Breese and Collins (2000) identified elevated post-mortem pH]nicotine binding in 
the thalamus and hippocampus of life-long smokers. In both cases upregulation of 
receptor binding was attributed to an increase in total receptor number rather than 
receptor affinity. This is in agreement with the previously discussed in vivo rodent 
studies, strongly indicating that the binding properties of the a4(32* receptor are not 
altered by nicotine, rather that nicotine in some way promotes and maintains an 
increased number of receptors expressed on the cell surface.
The above proposed mechanisms appear to be subtype specific to a4(32* receptors. 
(32 subunits are the most readily upregulated subunit, which may explain the change 
of stoichiometry to the high-affinity conformation. In contrast, the a5 subunit, which 
only associates with a4 and (32, appears to prevent receptor upregulation (Mao, eta l,  
2008), while chronic nicotine treatm ent decreases a6 subunit binding. As the a6 
subunit is often found in combination with (32 (a6(32* receptors), it is possible that 
the decrease in a6 subunit binding is due to increased competition for the (32 subunit 
following the switch to the high affinity a4(32* receptor conformation. In contrast, the 
P3 subunit appears to promote a6 upregulation. Tumkosit e ta l  (2006) used human 
tsA201 HEK cells to show that inclusion of a p3 subunit increases the basal number of 
receptors as well as the number of nicotine-induced upregulated receptors. Similarly, 
Perry eta/. (2007) showed that inclusion of p3 subunits prevented downregulation of 
a6-containing receptors in rat striatum. The upregulation of a6* nAChRs may also 
depend on the concentration of nicotine -  sustained exposure over 24 hrs to low 
concentrations of nicotine (30 pM) upregulates a4p2* nAChRs, while high 
concentrations of nicotine (300 pM) upregulates a6 nAChRs (Walsh, e ta l ,  2008); a6* 
nAChRs are also upregulated about 10 times faster than a4p2* nAChRs. In contrast.
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Parker et al (2004) identified upregulation of a6 nAChRs in rat brain following 
chronic nicotine treatment.
The a5 subunit has been shown to only be associated with a4p2* nAChRs (Mao, etal,
2008), while a5 mRNA has been identified on DAergic neurons in the VTA (Azam, et 
al, 2002). Nashmi e ta l  (2007) found that there was no upregulation of a4-containing 
receptors on DAergic neurons in the VTA, suggesting that these a4p2* nAChRs may 
all be associated with an a5 subunit.
Homomeric a7 receptors can be upregulated, but it may not involve a nicotine- 
induced mechanism (Govind, et al, 2009). Upregulation of a7 nAChRs has been 
demonstrated in vitro following nicotine treatment, but only after exposure to 
concentrations >10 pM for several hours (Kawai & Berg, 2001). However, this level of 
nicotine is not reached in human plasma or brain tissue (Buisson & Bertrand, 2002; 
Rose, et al, 2010). a7 nAChRs may be upregulated in a Ca^+-dependent manner, 
which appears to be mediated by both protein kinase C and cyclic adenosine 
monophosphate (cAMP; Dajas-Bailador & Wonnacott, 2004). In a similar manner to 
a4p2* chronic upregulation, long-term exposure of a7 nAChRs to nicotine decreases 
proteasome-dependent degradation of the subunit (Rezvani, et al, 2007).
Few studies have demonstrated a7 nAChR upregulation in vivo. Pauly e ta l  (1991) 
found a7 upregulation in mice following 10 days of nicotine treatment. However, 
upregulation was restricted to only a small number of regions and there was little 
evidence of upregulation at doses below 2 m g/kg/hr, while a4p2* nAChRs were 
upregulated in approximately 78% of areas analysed following 2 m g/kg/hr nicotine. 
Marks et al (1983; 1986) also found nicotine-induced upregulation, this time 
confined to the midbrain and hippocampus. These studies also indicate a dose- 
dependent increase in nicotine-induced a7 upregulation. More recently, Metaxas e ta l  
(2013) also found nicotine-induced upregulation of a7 nAChRs following 14 days of 
7.8 m g/kg/day nicotine; upregulation ranged from 4.6% in the basomedial amygdala 
up to 76.7% in the posterior thalamus.
Together, these studies show that more than one subtype of nAChR can be 
upregulated in both human and animal models, however, the mechanism of a7 
upregulation is perhaps less well understood in comparison to a4(32* nAChRs.
13
a4p2 nAChR
Endosome
Lysosome
Proteasome
► a  + p d ap (0  
pentam ers
a + p subunits
interm ediates
Endoplasmic Reticulum
Nicotine
Nicotine
Figure 1-3: Mechanisms of nicotine-induced nAChR upregulation
There are various mechanisms by which nicotine is thought to upregulate «4^2* nicotinic
receptors. Theories include increased assembly of intermediate receptors and their
maturation into mature receptors in the endoplasmic reticulum; decreased degradation of
receptors or subunits by lysosomes or proteasomes; reduced endocytosis of receptors; and
promotion of a high nicotine affinity conformation of subunits. Adapted from Corringer e ta l  
[2006].
The functional status of upregulated a4p2* receptors is controversial. Visanji et al 
[2006] pretreated rats with nicotine for 4 days followed by striatal nicotine infusions 
resulting in increased DA levels, but systemic nicotine treatm ent had no effect. 
Pretreatm ent for 8 days, however, resulted not only in augmented DA following both 
intra-striatal infusions and systemic nicotine, but also increased mRNA levels for a6 
and ps nicotinic subunits. These results indicate that these subunits may be involved 
m nicotine-induced DA release in the striatum. Nashmi e ta l  [2007] found chronic 
nicotine upregulated fluorescing a4* [a4L9'A] on GABAergic but not DAergic neurons 
in the VTA and SN, increasing GABAergic suppression of DAergic neurons, while in 
the hippocampus, nicotine augmented a4* fluorescence on glutamatergic neurons in 
the medial perforant path in association with nicotine-induced long-term 
potentiation of the pathway. Similarly, Xiao e ta l  [2009a] also found chronic nicotine 
upregulated functional a4p2* nAChRs on GABAergic neurons in the substantia nigra
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pars reticulata (SNr). These studies indicate how nicotine may produce concomitant 
synaptic sensitisation and tolerance to DAergic signalling.
1.4 Nicotine withdrawal
Abstinence from an addictive substance can lead to withdrawal symptoms, the 
severity of which is the most common reason for relapse amongst abstinent smokers 
(Hughes, 2007; West, et al, 1989]. According to the DSM-5 (American Psychiatric 
Association, 2013], symptoms of nicotine withdrawal in humans include depression, 
insomnia, irritability, anxiety, restlessness and increased negative affect. In rodent 
models, somatic nicotine withdrawal symptoms include head shakes, paw tremors, 
rétropulsion, scratching, piloerection and Straub tail (Castahé, e ta l ,  2002; Damaj, et 
al, 2003], while affective symptoms include decreased time in the open arms of the 
elevated plus maze (increased anxiety] (Damaj, e ta l ,  2003] and deficits in contextual 
fear conditioning (Davis & Gould, 2009].
Use of nicotinic antagonists such as mecamylamine (MEG], methyllacaconitine (MLA] 
and dihydro-p-erythroidine (DHpE] in combination with transgenic mice indicates 
the involvement of several different nAChR subunits in withdrawal. MEG- and MLA- 
precipitated somatic withdrawal symptoms are absent in oc5 (jackson, et al, 2008; 
Salas, et al, 2009] and a7 (Jackson, et al, 2008; Salas, et al, 2007] knockout (KO] 
mice, respectively, while MEG-precipitated affective withdrawal symptoms are absent 
in p2 KOs (Jackson, et al, 2008]. Therefore, use of DhpÈ> MEG and MLA indicates 
involvement of a4p2*, a3p4* and a7 nAGhRs in nicotine withdrawal (Damaj, et al,
2003]. Indeed, a4 and P2 KO mice both display reduced nicotine-induced 
antinociception (Davis & Gould, 2007; Jackson, et al, 2008]. Other KO models 
demonstrate reduced MEG- (a5, a7 and p4 KO mice] and MLA-precipitated (a7 only] 
somatic withdrawal symptoms, while p4 KOs also exhibit hyperalgesia and reduced 
anxiety in the plus maze (Davis & Gould, 2009; Jackson, e ta l ,  2008; Salas, eta l,  2007; 
Salas, e ta l ,  2004b; Salas, e ta l ,  2009]. Jackson e ta l  (2008] showed that an antagonist 
intervention, such as mecamylamine, was required for somatic withdrawal 
symptoms; that spontaneous withdrawal via excision of a minipump was not 
sufficient. However, this situation may only exist in the short term, with spontaneous 
withdrawal taking longer to manifest its symptoms. Hildebrand e ta l  (1997] assessed 
somatic withdrawal 16 and 48 hours after the removal of minipumps and recorded a
15
significant increase in symptoms at both times. Davis and Gould (2009) showed that 
the P2 subunit mediates adaptation in hippocampal function in withdrawal and 
deficits in contextual fear conditioning.
Withdrawal in nicotine dependent animals is associated with decreased DA in the 
striatum, especially the Acb (Carboni, e ta l,  2000; Rahman, e ta l ,  2004] and is thought 
to mediate affective symptoms in nicotine withdrawal. A recent study by 
Hadjiconstantinou (2011] identified a possible mechanism for this with elevated DA 
reuptake in the striatum after 12 and 24 hours withdrawal, with concurrent 
upregulation of dopamine transporter (DAT] mRNA levels in the VTA, and to a lesser 
extent with delayed action in the SNc. These findings are concordant with those of 
another study (Janhunen & Ahtee, 2007] which found that nicotine has differential 
effects on DA in the dorsal and ventral striatum.
Carboni et al  (2000] conducted microdialysis experiments on the Acb and medial 
prefrontal cortex (mPFC ]. Nicotine induced DA release in the Acb; however, following 
MEG-precipitated withdrawal, DA was elevated in the mPFG. Moreover, the opioid 
antagonist naloxone caused somatic withdrawal symptoms, but had no effect on DA 
levels in either brain region. Altogether, these results indicate a dissociation of the 
mesolimbic (Acb] and mesocortical (mPFG] DAergic pathways in regulating DA 
release in nicotine administration and withdrawal. In addition, somatic withdrawal 
symptoms are manifested through a nAGhR-dependent mechanism.
1.5 Evidence from nAChR knockout mice
In animal studies, some receptors can be differentiated pharmacologically using 
subtype-specific ligands. However, their usage is limited as specific ligands have not 
yet been identified for all subtypes, and some ligands are only subtype-specific at a 
certain concentration. Therefore, other methods, such as the use of transgenic mice, 
have been developed in order to better understand the roles of the various receptor 
subtypes and their composite subunits. A summary of these papers is presented in 
Table 1-1.
Evidence from KO mice supports the principal role of a4p2* nAGhRs in mediating the 
effects of nicotine. Ablation of the a4 subunit results in decreased high-affinity 
nicotine and epibatidine binding and loss of nicotine-induced currents in the
16
midbrain (Marubio, et al, 1999), Moreover, these mice show loss of nicotine self­
administration behaviour (Pons, et al, 2008) and decreased DA release in the 
striatum (Marubio, et al, 2003); self-administration behaviour can be reinstated by 
selected re-expression in the VTA (Pons, et al, 2008), suggesting the importance of 
a4-containing nAChRs in the VTA in modulating nicotine self-administration and DA 
release. Interestingly, basal DA levels in the striatum of a4 KO mice are twice that of 
wild type (WT) mice; this indicates a role for non-a4 receptors, e.g. a6p2* nAChRs, in 
mediating the nicotine response (Marubio, et al, 2003). In addition, a4 KO mice 
demonstrate decreased glutamate release onto medium spiny neurons via DAergic 
terminals in the striatum concurrent with increased inhibition of DA release by 
GABAergic neurons in the substantia nigra pars compacta (Pons, et al, 2008). This 
demonstrates that nicotine can mediate DA release via interactions with multiple 
neurotransm itter systems and that these interactions may be a4-mediated; see 
Section 1.6 for further discussion of the interaction of nicotine with other 
neurotransm itter systems.
The p2 subunit also appears essential for nicotine self-administration behaviour. 
Mice lacking the p2 subunit display reduced systemic self-administration of nicotine 
(Picciotto, e ta l ,  1998), a flat dose-response (Shoaib, e ta l ,  2002), loss of intra-VTA 
self-administration (Besson, et al, 2006; Maskos, et al, 2005) and lack of nicotine 
conditioned place preference (GPP; Walters, eta l ,  2006), indicating the importance of 
the p2 subunit, particularly in the VTA, in mediating nicotine reward. There is also 
decreased striatal DA and GABA release (Maskos, et al, 2005; Mineur, et al, 2009; 
Picciotto, e ta l ,  1998), reversed by selective re-expression in the VTA (Maskos, e ta l ,  
2005; Mineur, et al, 2009; Repérant, et al, 2010). Moreover, Picciotto et al (1998) 
demonstrated that p2-containing nAGhRs on DAergic neurons projecting from the 
VTA mediate nicotine-induced firing, which supported earlier findings that 
highlighted the importance of somatodendritic nAGhRs over presynaptic accumbal 
receptors (Nisell, e ta l ,  1994). There appears to be no involvement of the |32 subunit 
in mediating somatic nicotine withdrawal (Besson, et al, 2006); however, studies 
have demonstrated a lack of withdrawal-related deficits in contextual fear 
conditioning (Portugal, et al, 2008; Raybuck & Gould, 2009). Therefore, the (32 
subunit in connection with a4, is essential for the development of nicotine reward.
17
The (32 subunit may be im portant for the initial phase of nicotine self-administration 
and reinforcement, but in long-term regulation the homomeric a7 receptors appear 
to take precedence. a7 KO mice demonstrate reduced self-administration behaviour 
(Levin, et al, 2009} and loss of nicotine-induced currents in the hippocampus (Orr- 
Urtreger, et al, 1997], indicating that a7 is the primary subtype located in the 
hippocampus. Loss of this receptor may attenuate self-administration as this region 
is associated with reward-related and contextual learning. However, Levin et al. 
(2009) only found reduced oral self-administration after five weeks, indicating that 
the effect of a7 knockdown is a delayed chronic effect. Similarly, Pons etal. (2008) 
identified no change in acute nicotine intravenous self-administration in a7 KO mice.
a7 KO mice exhibit slower decay rates for nicotine-induced prefrontal cholinergic and 
glutamatergic transients (Parikh, et al, 2010}, therefore potentially resulting in 
extended stimulation of DAergic neurons by glutamate. These findings support the 
role of a7 nAChRs in mediating glutamatergic control of nicotine-induced DA release 
(Jones & Wonnacott, 2004}. Somatic withdrawal symptoms are attenuated in a7 KO 
mice (Salas, eta l ,  2007} as are anxiety-like behaviours, indicating that the a7 subunit 
may also be involved in mediating affective withdrawal symptoms. Levin e ta l  (2009} 
also found reduced cognition in the radial arm maze paradigm, which suggests that 
a7 nAChRs modulate cognitive processes, spatial learning and memory.
The (34 subunit appears to be required for somatic symptoms of withdrawal, but not 
affective (Salas, e ta l ,  2004b}. However, the P4 subunit does appear to mediate affect 
in relation to anxiety responses, but in a context-dependent manner. In knockouts, 
anxiety is decreased in maze tests but increased in social isolation (Salas, et al, 
2003b}, implicating p4-containing receptors in mediating exploratory behaviour and 
social interactions, respectively.
As well as being located on the terminals of ganglion cells, a6-containing receptors 
are found in the VTA. In a6 KO mice there is decreased nicotine self-administration 
(le Novère, et al, 1999; Pons, et al, 2008} associated with a loss of a-Cntx Mil- 
sensitive binding in the striatum (Champtiaux, et al, 2002}. However, self­
administration behaviour is reinstated following re-expression of a6 subunits in the 
VTA, not the striatum (Pons, e ta l,  2008}.
18
There is a loss of somatic (Jackson, e ta l ,  2013; Salas, e ta l ,  2009], but not affective, 
withdrawal symptoms (Jackson, e ta l ,  2013) in a5 KO mice. In contrast, nicotine self­
administration behaviour is increased and can be reversed by re-expression in the 
MHb (Fowler, et al, 2011), indicating that the a5 subunit may provide inhibitory 
signals limiting nicotine uptake.
Use of the nAChR antagonist a-conotoxin (a-Cntx) Mil indicates at least two different 
populations of nAChR in the striatum. Using multiple KO models Salminen et al. 
(2004) confirmed that P2 subunits are essential components of ACh-induced DA 
release in both a-Cntx Mll-resistant and -sensitive receptor conformations; a4 is also 
important in mediating both mechanisms. In contrast, a5 appears to only be involved 
in a-Cntx M ll-resistant DA release, while p3 only mediates the a-Cntx-sensitive 
response. Given that immunoprécipitation studies have confirmed the presence of 
a4p2* and a6p2* receptors in the striatum, it is possible to theorise that a-Cntx MII- 
resistant receptors in the striatum mediating DA release involve a4p2* receptors, 
which may also contain a5, and a-Cntx Mil-sensitive receptors include a6p3p2 and 
a4a6p3p2 receptors.
Human genetics studies have found the chromosome 15ql4  region, which contains 
the CHRNA5-CHRNA3-CHRNB4 cluster of nAChR subunit genes, to be highly associated 
with nicotine addiction risk, heavy smoking and early onset of smoking behaviour 
(Picciotto & Kenny, 2013). In addition, CHRNA4 single nucleotide polymorphisms 
(SNPs) have been associated with nicotine dependence and number of cigarettes 
smoked per day (Han, et al, 2011), while CHRNB2 may be linked to the subjective 
response to nicotine (Hoft, et al, 2011). Wessel et al. (2010) also found a positive 
association between CHRNA4, CHRNA5 and CHRNB2 SNPs with nicotine dependence 
scores in treatment-seeking smokers. In summary, both human and animal genetics 
studies provide evidence for the primary role of a4p2* nAChRs, in association with 
other subunits, in nicotine self-administration behaviour and the development of 
dependence.
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1.6 Nicotine interactions with other neuronal systems
Nicotinic receptors are located on different types of neuron and can mediate the 
release of other neurotransmitters. A summary of nAChR-mediated release of 
selected neurotransm itters in provided in Table 1-2, while Figure 1-4 provides a 
simplified schematic of some of the neurocircuitry involved in modulating the effects 
of nicotine.
Table 1-2: Nicotinic acetylcholine receptor-mediated neurotransmitter release 
in the rodent brain
Neuro transmitter
Region Glu ACh DA GABA
Cerebellum a7 (r)
Cortex a7  (r)a a4p2* (r) «4(32* (r)a
P2*00 axp4* (r) «3 and/or «6^2* (r)
Hippocampus a l  (r)a a4p2* (r)a «3(34* (r) «7 (r)
a4px* (m)3 axp4* (r)a «4(32* (r)
Interpeduncular (34* (m)a «x(34* (m)
nucleus
Midbrain «4(32* (m, r) «4P2* (m, r)
Olfactory tubercle a7 (r) «4p2* (m)a 
«3 and/or «6(32* (m)
«4(32* (m, r)
Substantia nigra «4px* (m)a
pars reticulata
Superior colliculus cl7 (m) «3P2* and/or 
«6P 2*(m)
Striatum a7 (r) «4p2* (m)a 
«4«5(32* (m)a 
«6«4(32p3 (m)a 
«6(32P3 (m)^
«7 (r)
Thalamus « 4^ 2*(m)
Ventral tegmental «4px* (m)a
area «632* (r)a
^Tested in synaptosomes. Abbreviations: ACh, acetylcholine; DA, dopamine; GABA, y-aminobutyric 
acid; Glu, glutamate; m, mouse; r, rat. Adapted from Gotti etal. (2006a).
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LDTg
PPTg PFC
m a?
9 a4|32*/a4|36* 
w MOPr 
#  DOPr
#GABA
Figure 1-4: Neurocircuitry and receptors involved in the nicotine reward 
response
A simplified schematic of the major dopamine, y-amino butyric acid, glutamate and 
acetylcholine pathways and receptors involved in mediating the effect of nicotine. Modified 
from Wonnacott et  al. [2005}. Abbreviations: Acb, nucleus accumbens, ACh, acetylcholine; 
arcN, arcuate nucleus of the hypothalamus; p-En, P-endorphin; DA, dopamine; DOPr, ô-opioid 
receptor, GABA, y-amino butyric acid; Glu, glutamate; LDTg, lateral dorsal tegmental nucleus; 
MOPr, p-opioid receptor; PFC, prefrontal cortex; PPTg, peduncular pontine tegmental 
nucleus.
1.6.1 The dopaminergic system in nicotine addiction
Part of the DAergic system is considered to be the common reward pathway of the 
brain. Natural rewards stimulate the release of DA and adaptive changes in the 
signalling pathways correlate with associated reward-related learning (Di Chiara & 
Bassareo, 2007}. Dopaminergic neurons are a heterogeneous group localised in three 
main areas of the brain: the diencephalon, mesencephalon and the olfactory bulb.
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The mesencephalon accounts for about 90% of DAergic cells in the brain, and can be 
further subdivided into several pathways common between human and rodent brains 
(Chinta & Andersen, 2005}. The nigrostriatal pathway projects from the substantia 
nigra pars compacta [SNc} towards the striatum and is critical in the control of 
voluntary motor movement; the mesolimbic pathway projects from the SNc and VTA 
into the limbic system, including the Acb, olfactory tubercles, amygdala and 
hippocampus and mediates reward and reinforcement; and the mesocortical pathway 
projects from the medial VTA towards the frontal, perirhinal and cingulate (CgCx) 
cortices and is involved in motivational and emotional responses (Koob & Volkow, 
2010}. The mesolimbic and mesocortical pathways are often considered together as 
the mesocorticalimbic pathway to mediate the wider effects of addiction. The tubero- 
hypopheseal pathway is comprised of short neurons that link the ventral 
hypothalamus and the pituitary gland, mediating hormone secretion and is not 
implicated in addiction. Natural rewards stimulate the release of DA, and adaptive 
changes in the signalling pathways correlate with reward-related learning (Koob & 
Volkow, 2010; Pierce & Kumaresan, 2006}.
There are five DA receptor subtypes, split into two groups according to sequence 
homology and pharmacology. The Di-like receptors (DiR and DsR} are Gs-coupled 
receptors that activate cAMP signalling mechanisms, whereas the Dz-like receptors 
(DzR, DsR and D4R} are Gi/Go-coupled receptors that inhibit accumulation of cAMP 
(Seeman & Van Toi, 1994; Stoof & Kebabian, 1981}. There is subtype-specific 
localisation of DA receptors: Di is the most abundant DA receptor subtype and is 
found in all brain areas receiving DAergic stimulation, i.e. the striatum, limbic system, 
thalamus and hypothalamus, all of which are im portant in addiction; DzR expression 
is localised in the striatum; DsR is found in low levels in limbic and motor function 
areas; D4R is only expressed at low levels in the cortex and limbic system, while DsRs 
are also located in the striatal and limbic systems (for review see Beaulieu & 
Gainetdinov, 2011}.
Under normal physiological conditions, ACh is released from the terminals of 
cholinergic neurons in the peduncular pontine tegmental nucleus (PPTg} and lateral 
dorsal tegmental nucleus (LDTg} and activates DAergic and GABAergic neurons in the 
SN and VTA (for review see: Maskos, 2010}. Nicotine administration results in DA
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release, primarily in the ventral striatum /nucleus accumbens. The Acb is comprised 
of two distinct regions: the 'core' (AcbC) and the 'shell' (AcbSh). These heterogeneous 
regions are believed to differentially mediate the reinforcing effects of nicotine and to 
form the anatomical link between the motor and limbic systems. The AcbC is part of 
the basal ganglia and is thought to mediate incentive-conditioned stimuli and reward- 
based behaviour, including drug-seeking behaviour; while the AcbSh is considered 
part of the extended amygdala (Voorn, et al, 2004] and is associated with the primary 
rewarding effects of nicotine and mediating motivational stimuli, i.e. smoking cues 
such as the smell or image of a cigarette. In relation to nicotine addiction, the core and 
shell of the Acb operate separately. In nicotine-naïve rats, acute nicotine 
administration leads to increased DA in the accumbens shell, but not the core (Cadoni 
& Di Chiara, 2000; Pontieri, e ta l ,  1996]. Conversely, repeated nicotine administration 
selectively increases DA in the accumbens core, but decreases DA levels in the shell 
(Cadoni & Di Chiara, 2000). Zhang et al (2009b) also showed differential DAergic 
signalling in the AcbC and AcbSh in response to nicotine in rats. Nicotine decreased 
low-frequency tonic DAergic firing in both the core and shell, but increased high- 
frequency phasic burst firing primarily in the shell. The greater ratio between tonic 
and phasic burst firing caused by nicotine favours DA release in the shell, rather than 
the basal tonic release in nicotine-naïve rats that favours the accumbens core. 
Therefore, the AcbC is associated with nicotine sensitisation and reinforcement, while 
the AcbSh is connected with tolerance and reward.
Nicotine-induced DA release is proposed to occur through both direct and indirect 
pathways. Nicotine directly stimulates glutamate release via presynaptic a7 receptors 
in the VTA, SNc and hippocampus (Jones & Wonnacott, 2004). a7 receptors do not 
desensitise during smoking and are Ca^+.permeable, thereby enhancing glutamate 
release, presynaptic activity and DAergic burst firing (Sulzer, 2011). Burst firing of 
DAergic neurons is dependent on glutamatergic activation via postsynaptic N-methyl- 
D-aspartate (NMDA) receptors (Livingstone, et al, 2009; Sesack & Grace, 2009). 
Under normal conditions DA burst firing is inhibited by GABAergic neurons 
projecting onto midbrain DAergic neurons, particularly those located in the ventral 
pallidum, SNc and VTA (Jhou, e ta l ,  2009; Sesack & Grace, 2009; Yang, e ta l ,  2011). 
Activation and subsequent desensitisation of presynaptic of a4(32* and a6p2* 
receptors disinhibits DAergic neurons (Mansvelder & McGehee, 2002a; Sher, et al,
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2004; Xiao, eta l ,  2009b; Yang, etal ,  2011). Thus, nicotine stimulates DA release both 
directly through glutametergic signalling and also indirectly by disinhibition via 
GABAergic neurons.
Immunochemistry mRNA hybridisation studies have identified a3-7 and (32-4 
subunits on DAergic neurons (see Charpantier, et al, 1998; Zoli, et al, 2002). 
However, the use of transgenic mice has further elucidated the differential role of 
nAChR subunits in mediating nicotinic responses. a6(32* receptors, mainly located on 
the terminals of DAergic neurons in the VTA (Champtiaux, eta l ,  2003), are required 
to mediate the systemic effects of nicotine on DAergic neuronal activity and DA- 
dependent behaviours such as locomotion and reward-related reinforcement (Gotti, 
et al, 2010); deletion of the a6 subunit results in a loss of nicotine self­
administration, an effect reversed by selective re-expression in the VTA (Pons, et al,
2008). In conjunction, it was demonstrated that mice lacking the (32 subunit are no 
longer sensitive to nicotine-mediated DA release in the Acb and fail to self-administer 
nicotine (Picciotto, et al, 1998). The same study demonstrated that (32-containing 
nAChRs, present on the soma of DA neurons, mediate a nicotine-induced increase of 
their firing rate, indicating the importance of the (32 subunit control of striatal DA 
release in modulating nicotine self-administration. Furthermore, (32 KO mice 
demonstrate loss of nicotine-induced release of GABA (Lu, eta l ,  1998; Mineur, eta l,
2009), glutamate (Parikh, eta l ,  2010) and DA in the ventral striatum (Mineur, etal ,  
2009; Picciotto, etal ,  1998), which can be reversed by local re-expression (Mineur, et 
al, 2009). a4 KO mice lack a nicotine-induced striatal DA response but basal DA levels 
are higher than in wild type (WT) mice (Marubio, etal ,  2003), indicating that the a4 
subunit is required for striatal DA release. a4 is also required to mediate both 
glutamate release on to medium spiny neurons via DAergic neurons and SN reticulata 
(SNr) GABAergic inhibition of dorsal striatal DAergic neurons (Xiao, eta l ,  2009a).
The main action of nicotine is on nAChRs located on DAergic neurons projecting from 
the VTA, causing DA release in the Acb (Watkins, et al, 2000). Mesolimbic DAergic 
neurons in the rat brain express nAChRs on the soma and dendrites at their origin in 
the VTA, and on terminal regions in the Acb (Swanson, et al, 1987; Wada, et al, 
1989). In addition, behavioural studies have shown nicotine self-administration to be 
attenuated following pretreatm ent with infusions of the nicotinic antagonist Dh(3E
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directly into the VTA but not the Acb (Corrigall, etal ,  1994). Moreover, Champtiaux et 
al (2003) identified both a4(32* and a6(32* receptors on DAergic terminals, whereas 
non-a6 a4(32* receptors formed the majority of nAChRs on DAergic neuronal soma. 
Together, these studies demonstrate the importance of (32-containing nAChRs located 
in the VTA in mediating DAergic transmission in the Acb.
There is evidence to suggest that presynaptic nicotinic and Dz receptors on DAergic 
neurons may be able to functionally interact. Direct infusion of nicotine into the 
AcbSh stimulated DA release in rats, an effect blocked by either Dh(3E or quinpirole, a 
D2/3R agonist (Quarta, et al, 2007). Similarly, the D2/ 3R antagonist raclopride 
increased accumbal DA, which was reversed by Dh(3E. Quarta e ta l  (2007) also found 
that the (32 nicotinic subunit and DzR co-immunoprecipitated in both transfected 
mammalian cells and rat striatum. In support, Grilli e t a l  (2009) demonstrated that 
quipirole could inhibit nicotine-induced DA release in mice and rats; in turn, the D2/3R 
antagonists raclopride and sulpiride reversed the effect of quinpirole. Synaptosomes 
from p2 KO mice lacked nicotine-induced DA response (Grilli, e ta l ,  2009), confirming 
these receptors as important in mediating the DA response.
As discussed earlier in Section 1.6.1, there is a dissociation of tonic and phasic 
DAergic firing in the striatum during the development of nicotine dependence (Zhang, 
et al, 2009a). While phasic firing is promoted following chronic nicotine 
administration, during withdrawal tonic firing associated with DzRs is suppressed in 
the VTA; in contrast, there is no change in DiR-mediated phasic firing (Grieder, et al, 
2012). Inhibition of phasic activity prevented conditioned place aversion to nicotine 
in naïve mice but had no effect in nicotine withdrawal; meanwhile, altering DzR- 
mediated tonic firing blocked the aversive response to withdrawal from chronic, but 
not acute, nicotine. Furthermore, DzR KO mice also lack an aversive response to 
nicotine withdrawal (Grieder, eta l ,  2009). This study indicates a shift from tonic to 
phasic DAergic firing during the progression from acute to chronic nicotine 
administration, with the reverse process occurring during withdrawal. In withdrawal, 
there is decreased extracellular DA in the striatum and increased DA reuptake 
concomitant with elevated DAT mRNA in the VTA and SNc (Hadjiconstantinou, etal ,  
2011). However, these changes appear to be transitory as DA reuptake and DAT 
mRNA peaked at 12 -  48 hrs withdrawal before returning to normal by 72 hours.
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In humans, smoking is associated with augmented DA release in the basal ganglia, 
mediated by nicotine (Salokangas, etal ,  2000). Human PET studies show a reduction 
in DzR binding in the ventral basal ganglia following nicotine administration, 
indicating elevated DA transmission (Scott, et al, 2007); DAergic activity was 
positively correlated with peak plasma nicotine levels. Reduced DzR binding does not 
persist during withdrawal, returning to levels comparable with non-smokers 
following overnight abstinence from smoking (Scott, e ta l ,  2007). The magnitude of 
striatal nicotine-induced DA transmission, especially in the ventral striatum, is 
positively correlated with reward (Sharma & Brody, 2009). However, Scott et al 
(2007) found a negative association between increased DzR-mediated DA 
transmission in the ventral basal ganglia and Fagerstrom nicotine dependence scores, 
indicating that individuals with a higher dependence on nicotine have developed 
tolerance to nicotine-induced DA transmission.
1.6.2 Glutamatergic signalling in nicotine addiction
Nicotine exerts its rewarding properties partly through activation of nAChRs located 
on presynaptic glutamatergic terminals in the VTA. Subsequent release of glutamate 
into the synapse excites mesolimbic DAergic neurons projecting towards the AcbSh 
(Mansvelder & McGehee, 2002a; Picciotto & Corrigall, 2002). While high-affinity 
a4p2* nAChRs are rapidly desensitised by nicotine, the a7 nAChRs typically found on 
glutamatergic neurons are not desensitised to the same extent, with a change from 
tonic to burst DAergic firing triggered by presynaptic a7 nAChRs located on 
glutamatergic terminals (see Mansvelder, et al, 2002). Therefore, the rewarding 
effects of nicotine may be attenuated by reducing glutamate transmission, either 
through antagonism of post-synaptic excitatory receptors, e.g. mGlus or NMDA 
receptors, or activation of inhibitory presynaptic glutamate 2/3 autoreceptors 
(mGluz/s) to attenuate nicotine reinforcement (for review see D'Souza & Markou, 
2011). Indeed, conditional knockout of NMDA receptors specifically on DAergic 
neurons in the VTA of mice prevents nicotine CPP (Wang, eta l ,  2010). Rousseau e ta l  
(2005) found a-Bgtx immunopositive labelling associated with structures positive for 
glutamate transporters in the rat frontal cortex, implicating a7 nAChRs as the 
receptor subtype involved in mediating glutamate release.
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Withdrawal from chronic nicotine is characterised by decreased glutamate 
transmission associated with negative affect, therefore antagonism of mGluz/sR may 
be beneficial (see D'Souza & Markou, 2011). Thus, treatm ents that increase glutamate 
transmission may help to reduce withdrawal symptoms and prevent smoking relapse.
Memories that link exposure to environmental cues with the rewarding effects of 
nicotine can elicit cigarette cravings in abstinent humans (see D'Souza and Markou, 
2011). Indeed, animal models have shown that nicotine-associated cues can increase 
glutamate transmission, resulting in reinstatement of drug self-administration 
(Kalivas & O'Brien, 2008), while administration of glutamate antagonists attenuates 
this effect (Liechti & Markou, 2008). One approach to help smokers reduce cravings is 
to replace memories previously associated with nicotine reward with new memories; 
this process is known as extinction learning (Myers, et al, 2011) and, almost 
paradoxically, has been shown to be aided by increasing glutamate transmission.
1.6.3 GABAergic signalling in nicotine addiction
In naïve animals, nicotine initially increases GABA release via a4^2* nAChRs on 
GABAergic neurons in the VTA (Kalivas & O'Brien, 2008); these neurons project from 
the PPTg, ventral pallidum and Acb, as well as VTA interneurons. While GABAergic 
neurons are acutely activated by nicotine, chronic nicotine desensitises a4p2* located 
on GABAergic neurons (Mansvelder & McGehee, 2002a); see Section 1.3.3 and Figure 
1-4. Consequently, decreased GABA transmission causes disinhibition of DAergic 
neurons in the VTA and increased DA release in the Acb. Similarly, stimulation of 
GABAergic transmission decreases the reinforcing effects of nicotine and cue-induced 
reinstatem ent of nicotine seeking in rats (Markou, 2008; Vlachou, et al, 2011). 
Indeed, GABAb agonists such as baclofen and CGP44532, as well as GABAb positive 
allosteric modulators, have been shown to decrease nicotine self-administration 
(Paterson, et al, 2004), CPP (Le Foil, et al, 2008) and cue-induced reinstatem ent 
(Paterson, et al, 2005). Therefore, augmenting GABAergic transmission may help 
prevent nicotine reinforcement or relapse to smoking.
1.6.4 The endocrine system in nicotine addiction
Psychological stress and negative affect may be an im portant factor in nicotine 
withdrawal and the success of nicotine cessation attem pts (see Piasecki, 2006;
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Slopen, et al, 2013). The stress response is at least partially mediated by the 
hypothalamic-pituitary-adrenal (HPA) axis. Cortisol is a hormone released and 
controlled by the HPA axis, which mediates the action of biogenic amines and the 
gene expression of (3-adrenoreceptors that regulate the action of catecholamines 
(Hadcock & Malbon, 1988). Cortisol in humans (corticosterone in rodents) is derived 
from pro-opiomelanocortin (POMC) and has a negative feedback effect on its own 
release by preventing cleavage of POMC, thereby negatively affecting levels of other 
cleavage products of the pro-hormone, such as adrenocorticotropic hormone (ACTH) 
and (3-endorphin. This effect occurs through action on the pituitary, hippocampus, 
mPFC and amygdala (Diorio, etal ,  1993).
Cortisol is normally increased in response to acute stressors, including social (al'Absi, 
e ta l ,  1997), physical (al'Absi, e ta l ,  2002b) and novel situations (al'Absi & Lovallo, 
1993); the greater the intensity of the stressor, the greater the cortisol response. The 
cortisol stress response is thought to be related to an individual's expression of 
distress and the emotional salience of the moment rather than as a generalised 
response (see al'Absi, 2006). Symptoms of withdrawal from smoking include stress, 
and it is thought that one factor mediating the intensity of these symptoms is 
personal disposition and coping skills (Brown, et al, 2005); hence, nicotine 
withdrawal may trigger a physiological stress response.
It has long been accepted that nicotine can activate the HPA axis (for example 
Wilkins, eta l ,  1982) and that smokers have a higher basal level of cortisol than non- 
smokers (al'Absi, e ta l ,  2003; Field, e ta l ,  1994; Kirschbaum, e ta l ,  1992). There are 
dose-dependent increases in HPA activity in response to nicotine in areas of the brain 
associated with emotion and the HPA axis stress response, e.g. the amygdala (fear), 
Acb (reward) and PFC (decision making) (al'Absi, 2006). There is thought to be a 
decrease in cortisol following acute abstinence of 3 hrs (Scerbo, et al, 2010). 
However, after 18 hrs no difference could be found between ad libitum and abstinent 
smokers (al'Absi, etal ,  2002a).
There are distinct overlaps between the symptoms of stress and nicotine withdrawal, 
such as loss of concentration, palpitations, restlessness and anxiety (for review see 
Hughes & Hatsukami, 1986). Precipitated nicotine withdrawal in animals is 
anxiogenic; indeed, enhanced levels of corticotropin-releasing factor (CRF) are found
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in areas of the brain associated with emotional symptoms of withdrawal such as the 
amygdala (see Koob & Volkow, 2010). Moreover, local antagonism of CRFi receptors 
in the central nucleus of the amygdala attenuates anxiety-like behaviours and 
reinstatem ent of nicotine self-administration (Cohen, etal ,  2013).
Peripheral blockade of cortisol synthesis reduces nicotine craving, but only in 
humans with low impulsivity (Reuter, et al, 2002); nicotine craving of high 
impulsivity participants was not affected by cortisol blockade. Central blockade of 
cortisol synthesis also decreased craving, but to a lesser extent, possibly as 
dexamethasone, the drug used to disrupt central cortisol, can act as a cortisol 
substitute. However, participants were assessed for impulsivity only, not 
compulsivity. Since Everitt and Robbins (2005) describe the development of drug 
dependence as a transition from impulsive to compulsive drug taking (see Section 
1.2.1), it is possible that low impulsivity participants had transitioned to high 
compulsivity with a higher degree of nicotine dependence and were therefore more 
susceptible to modulation of nicotine cravings.
The balance of evidence indicates that smoking causes dysregulation of the HPA axis 
such that elevated cortisol levels become the norm, whereas decreased cortisol levels 
during abstinence may prompt 'self-medication' with nicotine in order to avoid 
withdrawal symptoms.
1.6.5 The endogenous opioid system in nicotine addiction
There are four opioid receptors: p (MOPr), 5 (DOPr), k  (KOPr) and nociceptin (NOPr) 
(le Merrer, et al, 2009). Opioid receptors are activated by endogenous opioids (13- 
endorphin, dynorphins and enkephalins) which are derived from precursor proteins: 
pro-opiomelanocortin (POMC) (Nakanishi, et al, 1979); pro-dynorphin (Kakidani, et 
al, 1982); and pro-enkephalin (Noda, etal ,  1982), respectively. Opioid receptors and 
peptides are expressed throughout the central and peripheral nervous systems, but in 
the brain they are primarily expressed in the cortex, limbic system and brain stem, 
playing a role in regulating nociception, analgesia, stress, mood and addiction (see le 
Merrer, et al, 2009).
p-Endorphin is a neurotransm itter and hormone that binds MOPr and DOPr with near 
equal affinity, but has very low affinity for KOPr (for reviews see Kieffer & Gaveriaux-
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Ruff, 2002; Roth-Deri, et al, 2008). p-Endorphin is derived from POMC in the 
intermediate and anterior pituitary and the arcuate nucleus of the hypothalamus 
(Stengaard-Pedersen & Larsson, 1981). p-Endorphin-containing neurons project from 
the arcuate nucleus to forebrain limbic areas, including the Acb, hippocampus, 
amygdala and septum, as well as other hypothalamic nuclei (see Berrendero, et al,
2010). Direct administration of p-endorphin to either the striatum or hypothalamus 
increases DA uptake, an effect thought to be mediated by opioid receptors as it can be 
prevented by naltrexone treatm ent (George & Van Loon, 1982).
In terms of psychological effect, there is an increase in MOPr expression in severely 
depressed patients concomitant with reduced p-endorphin. Lower levels of p- 
endorphin are associated with depression and negative affect while elevated levels 
are associated with positive affect or euphoria (see Hegadoren, et al, 2009).
There is evidence that increased accumbal DA induces p-endorphin release, and there 
are even indications that the reverse process can occur (see Roth-Deri, etal ,  2008). It 
is possible that p-endorphin stimulates DA release indirectly in a similar way to 
nicotine by inhibition of VTA GABAergic neurons (Johnson & North, 1992). MOPr and 
DOPr agonists stimulate the release of accumbal DA via disinhibition of DAergic 
neurons (Devine, e ta l ,  1993); similarly, intra-VTA infusion of p-endorphin elevates 
DA release in the Acb via MOPr and DOPr (De Vries & Shippenberg, 2002). Moreover, 
the reinforcing effects of p-endorphin are only observed at doses that cause DA 
release (Spanagel, etal ,  1991), indicating that p-endorphin acts upstream of DAergic 
synapses in the Acb in a manner similar to nicotine, and that p-endorphin 
reinforcement requires DA release.
It appears that, unlike other drugs of abuse, such as cocaine, acute nicotine does not 
increase p-endorphin levels in the Acb itself (see Roth-Deri, et al, 2008). Chronic 
nicotine treatment, however, results in upregulation of MOPr in the rat striatum, with 
a complimentary decrease in striatal POMC mRNA, an effect which persists for 21 
days of withdrawal (Gudehithlu, etal ,  2012; Rasmussen, 1998; Wewers, eta l ,  1999). 
Similarly, both acute and chronic nicotine treatm ent cause a reduction of p-endorphin 
in the hypothalamus, as well as in the endorphinergic terminals in the striatum and 
hippocampus (Gudehithlu, et al, 2012). Treatment with mecamylamine or 
haloperidol reversed the acute, but not the chronic, effect of nicotine, implicating
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nAChRs and DzRs specifically in mediating this response. Thus, nicotine targets 
downregulation of POMC expression in forebrain areas with a compensatory 
upregulation of MOPr.
In acute withdrawal there is a decrease in hypothalamic, but not pituitary, p- 
endorphin in mice, with levels slightly less reduced after 7 days' continuous cessation 
(Rosecrans, et al, 1985). However, following 14 days cessation p-endorphin levels 
become elevated to 50% above normal. These studies indicate a dysregulation of the 
endogenous opioid system in nicotine withdrawal, with p-endorphin-containing 
neurons unable to adapt.
The evidence from KO mice shows that MOPr mediates nicotine reward and somatic 
withdrawal symptoms, but does not appear to mediate the locomotor effects of 
nicotine (see Berrendero, et al, 2002). The opioid antagonist naloxone prevents 
nicotine reward in the CPP paradigm with WT mice (Walters, eta l ,  2005). Moreover, 
there is a dose-dependent increase in withdrawal symptoms and cigarette cravings in 
acute abstinence following naloxone challenge in smokers (Krishnan-Sarin, et al, 
1999), while cessation of nicotine treatm ent in rats increases somatic withdrawal 
symptoms similar to those characterised in opioid withdrawal (Malin, et al, 1993; 
1992). These studies indicate that opioid receptors may play a role in nicotine 
withdrawal, as well as in reward.
The anxiolytic effects of nicotine are reversed by the selective MOPr antagonist p- 
funaltrexamine, but augmented by the DOPr agonist naltrindole; the KOPr does not 
appear to be involved in mediating this effect (Trigo, eta l ,  2010). Moreover, Trigo et 
al  (2009) found decreased nicotine-induced anxiolysis and reward in p-endorphin 
KO mice. In another KO study, repeated administration of nicotine provoked 
behavioural sensitisation in WT but not MOPr KO mice (Berrendero, et al, 2002). 
Therefore, it appears that the anxiolytic effect of nicotine is mediated not only by the 
HPA axis, but also by the opioid system through the action of p-endorphin on MOPr.
Together, these studies indicate that p-endorphin plays an important role in 
mediating DA release following nicotine administration, via action at MOP and DOP 
receptors. Therefore, further knowledge of the neuronal localisation of MOP and DOP
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receptors would be beneficial in further understanding their role in nicotine 
addiction and withdrawal.
1.6.6 BDNFin nicotine addiction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of 
growth factors and is known to promote neuronal survival and plasticity (Binder & 
Scharfman, 2004; Russo etal ,  2009). BDNF preferentially binds to the TrkB receptor, 
but can also bind to the generic neurotrophin receptor p75 (Russo eta l ,  2009). BDNF 
and TrkB protein have been detected throughout the brain, but they are most 
prevalent in the hippocampus (Binder & Scharfman, 2004), with BDNF expression 
localised in the presynaptic terminals of adult mice (Dieni, eta l,  2012).
Bhang e ta l  (2010) found lower baseline levels of plasma BDNF in smokers compared 
with non-smokers. In addition, BDNF levels rose significantly during withdrawal, 
though levels began to decline again after 4 weeks abstinence. While acute nicotine 
decreases (Kenny, et al, 2000), chronic nicotine increases BDNF mRNA in the rat 
cortex, hippocampus, amygdala (Czubak, etal ,  2009; Kenny, eta l ,  2000), Acb, SN and 
VTA (Kivinummi, eta l ,  2011). Following acute withdrawal BDNF is augmented in the 
Acb only, and additionally in the VTA and SN after chronic withdrawal (Kivinummi, et 
al, 2011). As these alterations were observed in DAergic areas, it is possible that 
BDNF levels are modulated by DA release in these areas. Massey et al  (2006) 
demonstrated a BDNF-induced upregulation of a7 nAChRs in the rat hippocampus, an 
effect blocked by inhibition of the NMDA receptor. Moreover, transfection of 
hippocampal neurons from BDNF KO mice with BDNF upregulated the number of 
glutamatergic synaptic terminals, but downregulated GABAergic synapses (Singh, et 
al, 2006). These studies indicate that BDNF regulates hippocampal a l  nAChR activity 
in a glutamate-dependent manner, and may mediate the nicotine response via 
modulation of synaptic plasticity.
1.7 Smoking cessation
In the UK, currently only 49% of those using the NHS Stop Smoking Service (SSS) 
successfully quit smoking (The Health and Social Care Information Centre, 2012). 
Moreover, the NHS define a 'successful quitter' as someone who self-reports as having
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quit at a 4-week follow-up meeting. Therefore, there is no national data available for 
the effectiveness of interventions used in quit attempts in the longer term.
Table 1-3 presents the percentage of clients using each available intervention under 
the NHS-SSS, and the number of those clients considered to have successfully quit at 
the four-week follow-up. Although varenicline is the most successful of the 
pharmacotherapies offered, there is little difference between the successes of the 
other interventions available, or those not using any pharmacotherapy or NRT 
intervention. Pharmacotherapy is prescribed on a case-by-case basis, and the 
numbers presented in Table 1-3 represent only those attempting to quit using the 
NHS-SSS; Kotz e t a l ’s (2009] survey of over three and a half thousand smokers found 
that while 48.4% had tried a pharmacotherapy-based intervention, only 6.2% of 
respondents had used the NHS-SSS.
Table 1-3: Percentage of all quitters and successful quitters according to type of 
pharmacotherapy intervention in the UK (The Health and Social Care 
Information Centre, 2012).
Intervention % clients % successful clients
Nicotine replacement therapy (NRT)* 
only 66 46
Varenicline only 25 60
Bupropion only 1 53
NRT and Varenicline 1 1
NRT and Bupropion <0.1 <0.1
No NRT or pharmacotherapy 4 50
Treatment unknown 3 2
* N R T  i n c l u d e s  n i c o t i n e  g u m ,  t r a n s d e r m a l  p a t c h e s  a n d  e l e c t r o n i c  c i g a r e t t e s .  S u c c e s s f u l  q u i t  a t t e m p t  
r e f e r s  t o  s e l f - r e p o r t e d  a s  c i g a r e t t e - f r e e  a t  f o u r - w e e k  f o l l o w - u p .
In a review of one year outcomes for nine primary care trusts in England, Ferguson et 
al. (2005) found that 14.6% of smokers were carbon monoxide (CO)-validated as 
having quit; even with self-reported, non-validated, quit rates included this value only 
rises to 17.7%. Relapse to smoking was reported at 75%, and was most likely to occur 
during the first six months. Similarly, Bauld et al (2011) found CO-validated quit 
rates at 4 weeks were 22.5%, but only 3.6% after one year. It is clear that there are
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many people for whom the currently available interventions do not lead to a 
successful quit attempt.
Nicotine replacement therapies (NRTs) administered via nicotine gum, transdermal 
patches or electronic cigarettes can help to reduce the severity of withdrawal 
symptoms [see Hajek, et al, 2009). Non-nicotine pharmacotherapies can be used 
alone or in combination with NRTs. Bupropion is an atypical anti-depressant which 
aids smoking cessation by blocking dopamine and noradrenaline reuptake 
mechanisms, as well as being an nAChR antagonist (see Paterson, 2009). This means 
that the rewarding properties of a single cigarette are prolonged, helping the smoker 
to gradually reduce the number of cigarettes smoked. Varenicline is a nAChR partial 
agonist which has two modes of action. As a (32* nAChR partial agonist and full a7 
agonist (Mihalak, e ta l ,  2006) it stimulates the release of dopamine in the VTA and 
AcbSh (Repérant, et al, 2010), thereby helping to reduce cravings and withdrawal 
symptoms (Gonzales, eta l ,  2006; Jorenby, eta l ,  2006; Tonstad, e ta l ,  2006). Since it 
is a nAChR agonist, varenicline prevents nicotine from binding to the receptors itself, 
thereby blocking nicotinic activation of the dopaminergic system, so that if the 
smoker relapses, any cigarettes that are consumed would not have the normal 
DAergic effect.
Nicotine vaccines, which would use antibodies to sequester nicotine in the blood 
preventing it from entering the brain, are currently being investigated as a possible 
future therapy for smoking cessation (for review see Fahim, e ta l ,  2013). Proof-of- 
concept clinical trials demonstrated nicotine vaccines to be well tolerated, but 
ineffective in relation to relapse -  even having a higher relapse rate than the placebo 
group in one study (see Fahim, et al, 2013). Therefore, further development is 
required before nicotine vaccines become a viable intervention.
1.7.1 Exercise as an intervention
There are no national data available on the use of alternative interventions such as 
exercise. In fact, some smoking cessation advisors are reluctant to recommend 
exercise to patients, feeling that it may be one lifestyle change too many, while other 
advisors think that the best way to effectively cease smoking is to make an overall 
lifestyle change, of which exercise would be an essential part (Everson, eta l ,  2010). 
In the case of pregnant women NRT is the only pharmacotherapy that has been
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licensed for use, but there are still concerns over possible harmful effects to the 
foetus (DiFranza, et al, 2002). Hence, many pregnant women are reluctant to use NRT 
at all, but are open to trying non-intensive forms of exercise such as isometric 
stretching (Ussher, e ta l ,  2006; 2007a; 2008). It is clear that there is a need for the 
development of non-pharmacotherapy interventions to aid in smoking cessation, of 
which exercise may be a plausible option.
Clinical and acute laboratory studies concerning exercise and smoking will be 
reviewed in more detail in Chapter 2. Briefly however, cigarette withdrawal and 
cravings have been shown to be reduced both during and after exercise (for review 
see Ussher, eta l ,  2012). Nevertheless, the biological mechanisms underlying exercise 
as an intervention are not yet understood, although theories have been posited 
regarding the involvement of BDNF, the HPA axis and the endogenous opioid system 
(for example see Taylor, et al, 2007).
1.8 Nicotine and mental wellbeing
There is a higher prevalence of smoking among mental health patients than the 
general population, with cigarette smoking found to be comorbid with various 
psychiatric disorders, including schizophrenia, autism, Tourette's syndrome and 
depression (Adler, et al, 1998; Gotti, et al, 2006b). Moreover, nAChRs have been 
implicated in the pathophysiology of these disorders. For example, loss of striatal 
a6p3* or cortical a4p2* receptors is associated with Parkinson's and Alzheimer's 
disease, respectively (Gotti, et al, 2006a). In schizophrenia, smoking is thought to 
alleviate negative symptoms, such as attention and memory deficits, indicating that 
these patients may smoke in order to self-medicate (Glassman, 1993; Kumari & 
Postma, 2005). Therefore, whilst it has been possible to implicate some nAChR 
subtypes in the pathology of psychiatric disorders, their exact role and how they 
interact with nicotine in these disease states is poorly understood (Gotti, et al, 
2006a).
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1.9 Thesis hypothesis and aims
The behavioural and neurochemical mechanisms of nicotine addiction and 
withdrawal are not fully understood, particularly due to nicotine and nAChRs 
interacting with a wide range of neuronal pathways, and nicotine addiction being 
comorbid with a number of other psychiatric disorders. There is emerging evidence 
from psychological studies that exercise may be effective as an intervention for 
smoking cessation, and exercise has been shown to be effective in reducing 
withdrawal to drugs of abuse other than nicotine. However, the underlying 
mechanisms are currently unknown. It is therefore hypothesised that nicotine 
interacts with diverse neurochemical pathways and that exercise reduces nicotine 
withdrawal severity. The research within this thesis will consequently investigate the 
effect of exercise in nicotine withdrawal in both humans and mice in order to gain a 
translational perspective, as well as examining the interaction of nicotine with 
various neuronal receptors in a schizophrenic mouse model. Finally, the location of 
opioid receptors thought to be involved in mediating the nicotine response will be 
determined using conditional knockout mice. The specific objectives of each chapter 
are as follows:
Chapter 2: Role of perception of exercise intensity in mediating cigarette 
withdrawal and craving in humans
• To assess the relative effectiveness of prescribed moderate intensity exercise 
compared with moderate intensity exercise as perceived by the participant.
• To investigate the role of sedentary versus physically active lifestyles on the 
effectiveness of prescribed versus perceived moderate intensity exercise in 
temporarily abstinent smokers.
• To determine if salivary cortisol is altered depending on lifestyle following 
prescribed or perceived moderate intensity exercise in temporarily abstinent 
smokers.
Chapter 3: Effect of different intensities of exercise on hrain neurochemistry 
and behaviour in nicotine withdrawal
• To identify if chronic nicotine administration alters the activity profile of 
C57B1/6 mice.
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• To investigate the effect of different intensities of exercise on acute MEC- 
precipitated nicotine withdrawal following chronic nicotine administration in 
mice.
• To determine if different intensities of exercise affect a4(B2* or a l  nAChRs, 
MOPr or Dz receptor binding by quantitative autoradiography of these 
receptors following mecamylamine-precipitated withdrawal of chronically 
nicotine-treated mice.
• To determine if different intensities of exercise affect plasma corticosterone 
and brain BDNF levels following mecamylamine-precipitated withdrawal of 
chronically nicotine-treated mice.
Chapter 4: Effect of nicotine on nicotinic and oxytocin receptor binding in a 
mouse model of schizophrenia
• To assess the effect of G72 insertion (G72Tg) on a4p2* and a l  nAChR and 
oxytocin (OTR) receptor binding using quantitative autoradiography in 
transgenic (G72Tg) and WT mice.
• To investigate the effect of G72 insertion on the regulation of a4p2* and a l  
nAChR and OTR binding following chronic nicotine treatm ent using 
quantitative autoradiography.
Chapter 5: Localisation of 5- and p-opioid receptors in GABAergic neurons using 
conditional gene knockout mice
• To determine the localisation of DOPrs in conditional KO (cKG) mice 
containing a specific deletion of DOPr in forebrain GABAergic neurons using 
quantitative autoradiography in DOPr cKO, constitutive KO and WT mice.
• To determine the localisation of MOPrs in conditional KO (cKO) mice 
containing a specific deletion of MOPr in forebrain GABAergic neurons using 
quantitative autoradiography in MOPr cKO, constitutive KO and WT mice.
48
C H A P T E R  2
R o l e  o f  p e r c e p t i o n  o f  
e x e r c i s e  i n t e n s i t y  i n  
m e d i a t i n g  c i g a r e t t e  
w i t h d r a w a l  a n d  c r a v i n g  i n
h u m a n s
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CHAPTER 2. ROLE OF PERCEPTION OF EXERCISE INTENSITY IN MEDIATING 
CIGARETTE WITHDRAWAL AND CRAVING IN HUMANS 
2.1 Introduction
2.1.1 Using exercise as a smoking cessation aid
As outlined in Section 1.8, exercise is not currently prescribed as an aid to smoking 
cessation. In addition, there appears to be disagreement among smoking cessation 
advisors as to whether exercise should be promoted as an intervention (Everson- 
Hock, et al, 2010b). However, studies have shown positive relationships between 
self-efficacy, smoking cessation and exercise (see King, etal ,  1996).
The transtheoretical model, as applied by Prochaska and DiClemente (1983) to 
smoking, suggests that cessation programmes should be targeted according to an 
individual smoker's stage of change, rather than assuming that all smokers coming for 
treatm ent are ready for action. The stages of change described in this model are pre­
contemplation, contemplation, action, maintenance and relapse. Smokers that have 
undergone cognitive and affective re-evaluation and progressed from the pre­
contemplation to the contemplation stage are more liable to respond to information 
about smoking. In support, a complimentary set of studies applied the 
transtheoretical model to smokers undergoing quit attempts (Everson-Hock, et al, 
2010a) and smoking cessation advisors (Everson, eta l ,  2010). Twenty-two per-cent 
of smokers used physical activity or exercise as an aid to control their smoking, while 
35% had used it during a previous quit attem pt (Everson-Hock, e ta l ,  2010a). The 
stage of readiness to use physical activity was found to be positively correlated with 
self-efficacy and belief in their own ability to use physical activity, indicating that 
smokers with an existing physically active lifestyle would be more likely to use 
exercise to aid their quit attempt. Similarly, the readiness of cessation advisors to 
promote physical activity and exercise was related to their own self-efficacy and 
belief in the importance of physical activity during cessation (Everson, e ta l ,  2010). 
This suggests that for exercise to be effective as an intervention, the stage of 
readiness of change of both the smoker and the cessation advisor must be considered. 
It also indicates that GET would be an important adjunctive therapy to exercise in 
order to facilitate the re-evaluation processes that underlie progression through the 
stages of change. Nevertheless, the mechanisms of how exercise works as an
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intervention to reduce withdrawal and cravings needs to be further investigated in 
order to maximise its application.
Self-determination theory (SDT; see Ryan & Deci, 2000) emphasises the contributions 
of competence, autonomy and relatedness in behaviour and well-being. In a 
systematic review of studies applying SDT to exercise participation, Teixeria et al  
(2012) found competence, satisfaction and intrinsic motivation predicted exercise 
participation. While identified motivation (i.e., working towards an identified goal) 
was predictive of short-term exercise participation, intrinsic motivation was more 
predictive in the long-term. Teixeria, e ta l  identified autonomous regulation as one of 
the most im portant factors in increasing physical activity, therefore application of 
SDT suggests that autonomous control over exercise participation, perhaps including 
the choice of exercise type or intensity, may mediate its effectiveness as an 
intervention for smoking cessation.
The transtheoretical model and SDT inform the current study, indicating that current 
exercise participation may mediate the effect of exercise in smoking abstinence, as 
may the ability to control the intensity of that exercise.
2.1.2 Chronic exercise programmes in human smoking cessation studies
Several studies have examined the effectiveness of exercise programmes in a clinical 
setting as part of real life quit attempts. Marcus et al (1999) conducted a twelve 
month study, comparing combined exercise and GET interventions against GET alone 
in female smokers. In addition, exercise participants were required to undergo three 
supervised exercise sessions per week, while the control group attended health 
education lectures. Those in the exercise condition were more likely to be abstinent 
from smoking and were continuously abstinent for a significantly longer period of 
time. Exercise also delayed post-cessation weight gain, a fear of many female 
smokers, which may prevent quit attempts or precipitate relapse (John, e ta l ,  2005; 
Mackey, eta l ,  2008).
Female smokers with concerns over post-cessation weight gain were the focus of a 
study by Copeland et al (2006). They found a significant difference between group 
and individually tailored exercise sessions when exercise was used as part of a six 
week combined relapse prevention programme that included dietary and
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psychological components; abstinence rates were higher among those undergoing the 
individual sessions compared with group sessions. While there was no difference 
between the groups in terms of actual weight gain, weight gain was associated with 
relapse liability in the group exercise condition. This indicates that whilst general 
guidelines as to the use of exercise interventions could be developed, actual clinical 
use would require tailoring advice to each individual's circumstance. Therefore, 
exercise has been shown to increase the chance of successfully maintaining smoking 
abstinence during real-life quit attempts and the associated health benefits of 
exercise may help to encourage some smokers to consider cessation.
Abrantes et al. (2009) found that regular exercise preceding 12 weeks smoking 
cessation treatm ent might be protective against relapse. Whilst no data was available 
on exercise levels during the quit attempt, smokers who exercised regularly (27% 
participants) prior to treatm ent had higher abstinence rates than sedentary smokers 
at the end of the intervention period, but rates for both groups converged around 
20% by the 52 week follow-up. Another study investigated 12 weeks of cessation 
treatm ent with or without a follow-up relapse prevention programme, including 
sessions focused on physical activity (Prochaska, et al, 2008). Participants in the 
physical activity group increased their participation in moderate to high intensity 
exercise compared with controls, which was predictive of smoking abstinence at 24 
weeks follow-up. These studies suggest that exercising prior to smoking cessation 
and promotion of physical activity during cessation as part of a structured 
programme increases the chances of maintaining abstinence from smoking.
2.1.3 Acute exercise in human laboratory studies
A summary of studies investigating the effect of acute exercise in human laboratory 
studies is provided in Table 2-1. Early laboratory experiments demonstrated that 
aerobic exercise, e.g. cycling, walking or running, could decrease withdrawal 
symptoms in temporarily abstinent smokers compared with sedentary condition 
participants (Thayer, et al, 1993). Ussher et al. (2001) conducted the first time- 
course study into the effects of a short bout of exercise on withdrawal severity before, 
during and after exercise, demonstrating that just 10 mins of moderate intensity 
exercise could decrease withdrawal symptoms and cravings for up to 15 mins post­
exercise. Ussher et al. (2001) identified distraction and expectation effects as
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potential confounds to their own study; in particular, participants were asked to 
monitor their own heart rate. However, the roles of distraction (Daniel, etal,  2006) 
and expectation (Daniel, et al, 2007) have since been evaluated and assessed to be 
insufficient to fully explain the effects of exercise, indicating that other psychological 
or biological mechanisms are involved.
Low intensity exercise has been shown to be less effective than high intensity (Daniel, 
et al, 2004), while Everson et al  (2008) showed both moderate and high intensity 
exercise to be effective at reducing withdrawal symptoms and cravings during 
exercise. However, high intensity exercise also promoted negative affect during 
exercise. Only moderate intensity continued to reduce withdrawal and improve mood 
post-exercise (Everson, et al, 2008). Overall, these studies show that exercise does 
help to reduce withdrawal symptoms and cigarette cravings, as well as helping to 
improve mood; moderate intensity exercise appears to be the most effective, while 
high intensity exercise may even be detrimental. However, these studies do not help 
us understand what biological mechanisms may underlie these effects.
Some indications of possible mechanisms were indicated in a study by Janse van 
Rensburg and Taylor (2009). Functional magnetic resonance imaging (fMRl) of 
temporarily abstinent smokers after 10 mins moderate intensity exercise found 
hypoactivation in brain regions associated with reward (Acb, CPu), motivation 
(orbital frontal cortex) and visuospatial attention (parietal lobe, parahippocampus, 
fusiform gyrus). In contrast, the sedentary control group showed hyperactivation of 
the same regions. This indicates that exercise may regulate neurocognitive-affective 
processes in withdrawal, particularly through signalling pathways connected with 
these regions, including the cholingergic and DAergic systems, CRF and the stress 
response. These results have been linked to the incentive sensitisation theory of 
addiction (see Section 1.2.1; Dishman, etal ,  2006), suggesting that hypoactivation of 
these regions following exercise reduces sensitivity to the incentive salience of 
nicotine and smoking-related stimuli during cigarette withdrawal.
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2.1.4 Exercise and mental wellbeing
Exercise is associated with a range of psychological benefits, for example endurance 
running is reported to relieve stress [Rosch, 1985], anxiety (Morgan, 1985) and promote 
general mental wellbeing (Steptoe & Butler, 1996; Ussher, et al, 2007b; Warburton, et 
al, 2007). In addition, exercise has been found to increase positive affect (Harte, et al, 
1995; Janal, etal ,  1984; Wildmann, etal ,  1986) and decrease negative affect (Harte, et 
al, 1995). Therefore, exercise may be useful in relieving the affective symptoms of 
withdrawal.
King et al (1993) conducted a twelve month study into the effects of high intensity 
group-based exercise compared with high or low intensity home-based exercise 
programmes. Increased exercise participation, irrespective of intensity, was positively 
correlated with decreased stress and depressive symptoms, particularly in smokers. 
However, no significant difference was observed between the effects of the two exercise 
intensities, indicating that any level of exercise is sufficient to help reduce stress and 
depression, which are both symptoms of cigarette withdrawal.
There is evidence that any form of exercise induces brain plasticity; various studies have 
shown exercise to be associated with neurogenesis, neuroadaptation and 
neuroprotection. Consequently, exercise is thought to be beneficial in the treatment and 
management of neuropsychiatrie disorders, for example depression, anxiety, 
schizophrenia and degenerative disorders such as Parkinson's (PD) and Alzheimer's 
disease (for review see Dishman, et al, 2006). Intensive treadmill running enhanced 
motor performance via changes in DAergic transmission in an animal model of PD 
(Petzinger, etal,  2007). Twenty-eight days of exercise resulted in decreased striatal DAT 
protein expression and decay of DA, and elevated stimulus-evoked release of DA, 
indicating that exercise leads to an overall increase of extracellular DA. Wheel running 
stimulated neurogenesis and long-term potentiation in the dentate gyrus and improced 
spatial memory (van Praag, etal,  1999a), as well as cell survival and differentiation (van 
Praag, etal,  1999b). In support, Eadie e ta l  (2005) found exercise caused morphological 
changes in the dentate gyrus leading to increased plasticity. These studies indicate that 
exercise may help to improve learning and memory, which as well as being potentially
61
beneficial for Alzheimer's patients, may aid in altering learned behaviours in nicotine 
addiction.
2.1.5 Exercise and the stress response in withdrawal
As discussed in Section 1.6.4, nicotine activates the HPA axis and smokers have an 
elevated level of plasma cortisol compared with non-smokers. Scerbo e ta l  (2010) found 
that salivary cortisol levels drop following even a short abstinence from smoking (three- 
hours) compared with time-matched pre-abstinence levels. Ten mins of moderate 
intensity exercise on an exercise bike was sufficient to attenuate this effect, and cortisol 
levels began to rise back to baseline levels during and after exercise; walking was not 
sufficient physical activity to alter cortisol levels and was no different to the sedentary 
condition in this measure. Similarly, both cortisol and CRF have been found to be 
increased following running (Harte, et al, 1995). In addition, positive affect was 
associated with elevated plasma CRF and (S-endorphin. As stress is considered to be a 
major factor in stimulating relapse (for review see Koob, 2008) exercise may be effective 
in reducing stress-related withdrawal symptoms, by stimulating cortisol release.
2.1.6 Factors mediating response to exercise
Leading a physically active or sedentary lifestyle may moderate the effect of exercise on 
mood. In a study by Reed e ta l  (1998) moderate intensity exercise was only effective at 
elevating positive mood in participants (smoking status unknown) with a physically 
active lifestyle. In addition, the affective responses of both physically active and 
sedentary groups were moderated by pre-exercise affect levels. This indicates that while 
most studies investing the effect of exercise as an intervention for smoking cessation 
have used sedentary participants (Section 2.3), exercise may only be beneficial in terms 
of affect for physically active smokers. It may be necessary for sedentary smokers 
attempting to quit to undergo GET first in order to facilitate transition to the 
contemplation stage of change for exercise (see Section 2.1).
Most of the studies on the use of exercise as an intervention in smoking cessation use an 
intensity of exercise calculated with the Karvonen formula (Karvonen & Vuorimaa, 
1988), which uses the participant's resting heart rate. Only two studies (Taylor &
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Katomeri, 2006 and Taylor, eta l, 2005) have examined the effect of self-paced exercise. 
According to SDT (Ryan & Deci, 2000), increasing a person's feeling of choice and control 
increases the chance of psychological wellbeing. Therefore, allowing the participant to 
exercise at an intensity of exercise they have chosen, or what they personally perceive a 
particular intensity of exercise to be, may be more beneficial, and less stressful, in 
helping a smoker quit successfully than exercise at a prescribed intensity. For example, 
Ussher et al. (2001) found that moderate intensity exercise (40-60% HRR) was 
frequently reported by participants with a sedentary lifestyle as feeling harder than 
moderate intensity, for example according to Borg's (1998) Rating of Perceived Exertion.
2.1.7 Aims and Objectives
Cigarette addiction remains a major health issue in the UK that requires further research 
to better understand the condition in order to help prevent and treat dependence. 
Whilst smoking and exercise are negatively correlated (Emmons, et al, 1994), and 
therefore sedentary smokers are more representative of the general smoking population, 
previous studies have already demonstrated the effect of exercise on sedentary smokers 
in withdrawal. To date, there is no study which has assessed the effects of a prescribed 
(objectively determined) level of exercise against the perceived same level on cigarette 
withdrawal, nor compared sedentary smokers against physically active smokers under 
these conditions. Therefore, the aim of the present research was to compare the effects 
of exercise that participants perceive to be of moderate intensity (according to Borg's 
(1998) RPE rating) against the effects of moderate intensity exercise determined by 
heart rate reserve (HRR) on withdrawal, craving and affect in both sedentary and 
physically active smokers; withdrawal, craving and affect were also assessed during a 
passive waiting condition. This study used saliva sample analysis in order to assess 
cortisol levels as a measure of HPA axis activity.
Therefore, it is hypothesised that the severity of withdrawal symptoms and cravings will 
be reduced, positive affect will be increased and negative affect decreased during and 
after exercise. Perceived moderate intensity exercise will increase positive affect and 
decrease negative affect, cigarette cravings and withdrawal symptoms to a greater extent 
than moderate intensity exercise determined according to resting heart rate. It is also
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hypothesised that exercise will attenuate a reduction in salivary cortisol during 
withdrawal. For smokers with a sedentary lifestyle, perceived moderate intensity 
exercise will be more beneficial than prescribed (objectively determined) moderate 
intensity exercise.
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2.2 Study design and methods
2.2.1 Participants
This study was approved by the University of Surrey Ethics Committee 
[EC/2010/FHMS&FAHS; Appendix 1]. The recruitment criteria for participants were as 
follows: 18 -  35 years of age, male or female, not receiving any form of psychiatric or 
medical treatment and not pregnant. Participants were also required to smoke at least 
10 cigarettes a day for at least two years and have an expired carbon monoxide (ECO) 
concentration of >10 parts per million (ppm); smokers who consume >10 cigarettes a 
day are more likely to experience the cravings and withdrawal symptoms which make 
abstinence difficult (O'Loughlin, et al, 2003). Individuals were considered to lead a 
sedentary lifestyle if they did not engage in high intensity physical activity three or more 
times a week for at least 20 mins, or moderate intensity physical activity at least five 
times a week for 30 mins (Franklin, 2000); individuals were considered to lead an active 
lifestyle if they were engaged in more physical activity per week than this. Following 
screening, participants were separated according to whether they had a 'physically 
active' (PA) or 'sedentary' (SED) lifestyle. Volunteers were considered ineligible if they 
possessed medical conditions that are contraindicative for exercise, such as a history of 
heart disease, were currently taking any prescribed medication (except for the 
contraceptive pill) or were pregnant.
Participants were recruited through advertisement of the study on the School of 
Psychology's SONA recruitment system, posters emailed to all University of Surrey staff 
and students, as well as via personal invitation and snowball sampling. In other within- 
subject counterbalanced studies a sample size of 15 has been sufficient for a moderate to 
high effect size, with a power (1 -  p) of 0.8, and an a-value of 0.05 (Taylor & Katomeri, 
2006; Taylor, et al, 2005). A priori power analysis (G*Power Version 3.1; Paul, et al, 
2009) determined that a sample size of 18 for both the SED and PA groups would be 
sufficient to achieve power of 0.8 and an a-value of 0.05. Therefore, we aimed to recruit 
20 participants per group.
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2.2.2 Psychological measures
Nicotine dependence was assessed using the Fagerstrom Test for Nicotine Dependence 
(FTND; Heatherton, et al, 1991). Recent physical activity was assessed by self-report 
using the Seven Day Physical Activity Recall Questionnaire (7-DPARQ; Sallis, eta l, 1985). 
This questionnaire draws out information about the duration, intensity and type of 
physical activity over the previous seven days. A motivation for smoking questionnaire 
[SMQ; West, et al, 1999) and the Motives for Physical Activity Measure -  Revised 
[MPAM-R; Frederick & Ryan, 1993; Ryan, et al, 1997) was also completed by 
participants. Withdrawal symptoms were assessed using the following items: [1) "I have 
a desire for a cigarette right now" [Tiffany & Drobes, 1991). This item is rated on a 7- 
point scale ranging from l=strongly disagree, 4 = neutral, to 7 = strongly agree. The 
items (2) irritability, [3) depression, (4) tension, [5) restlessness, (6) difficulty 
concentrating and [7) stress were rated on a 7-point scale ranging from 1 = not at all, 4 = 
somewhat, to 7 = extremely (MPSS; West & Hajek, 2004). A final item was also included: 
(8) strength of desire to smoke [Tiffany & Drobes, 1991; West, et al, 1989), which is 
rated on a 7-point scale ranging from 1 = strongly disagree, 4 = neutral, to 7 = strongly 
agree. Affect was assessed using the Positive and Negative Affect Scale (PANAS; Watson, 
eta l, 1988), the items of which describe feelings and emotions. It consists of ten positive 
adjectives (e.g. enthusiastic) and ten negative adjectives (e.g. distressed) which are rated 
on a 5-point scale ranging from 1 = very slightly or not all, to 5 = extremely. The mean 
values for positive affect and negative affect were determined separately. Participants 
gave a subjective measure of their exertion during exercise using the Rating of Perceived 
Exertion (RPE) scale (Borg, 1998), which has been found to be a reliable measure of 
perceived exertion (Whaley, e ta l,  1997). The scale ranges from 0 = nothing at all, 3 = 
moderate, to 10 = very, very hard.
In a comparison of different withdrawal scales. West et a l (2006) found the scales 
assessed to be of equal robustness, particularly for the items measured in the MPSS. 
Longer scales that used more than one item to assess each symptom, e.g. Wisconsin 
Smoking Withdrawal Scale, were not considered to be any more sensitive than shorter 
scales such as the MPSS. A shorter scale would be easier to administer with participants
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engaged in physical exercise and has already been widely used in smoking and exercise 
studies (see Table 2-1). The PANAS scale has been used previously within our lab 
(Daniel, e ta l,  2006) and others (Janse Van Rensburg, e ta l,  2013) to measure affect in 
exercise and smoking withdrawal studies. Similarly to the MPSS, it is shorter than 
alternative scales; the shortened version Profile of Mood States (POMS; Shacham, 1983) 
used in (Taylor, et al, 2005, 2006) comprises 37 items compared with 10 each for 
positive and negative affect in the PANAS.
2.2.3 Saliva cortisol measurement
Saliva samples were collected from each patient, with pre-abstinence samples collected 
during the screening session time-matched within 30 mins of the start of the post­
abstinence experimental session to minimise possible diurnal variations. Ten saliva 
samples were collected per participant: one during the screening session (pre­
abstinence) and nine during the experimental session (post-abstinence). During the 
experimental session, samples were collected at 0 mins (baseline), 15 mins (immediately 
post-intervention) and 30 mins (end of the rest period) for each of the three 
interventions.
Saliva samples were collected by passive expectoration; approximately 3 ml of 
unstimulated whole resting saliva were collected into a plastic bijou on ice. Samples were 
stored on ice (up to 2 hours) before freezing at -20°C for subsequent handling. 
Radioimmunoassay analysis was performed on saliva samples to determine cortisol 
concentrations (Stockgrand Ltd., University of Surrey, Surrey, UK; Read, et al, 1977; 
Riad-Fahmy, eta l, 1979; Seth & Brown, 1978).
Measuring saliva rather than plasma levels of cortisol provides a less invasive sampling 
technique; given the use of exercise in the experimental protocol taking blood from 
participants may have been dangerous. Previous studies on exercise in smoking 
withdrawal have shown that saliva samples are sufficient to detect the drop in cortisol 
levels normally observed in plasma during withdrawal (Janse Van Rensburg, eta l, 2013; 
Scerbo, eta l, 2010).
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2.2.4 Experimental Protocol
On initial contact, participants were asked to read the information sheet about the study 
(Appendix 2) and to sign a written consent form (Appendix 3). Participants maintained 
normal smoking behaviour before the screening session. Objective confirmation of 
smoking status was obtained using a Bedfont Micro Smokerlyzer (Bedfont Scientific 
Instruments Ltd, UK] to assess ECO concentration; participants were required to have an 
ECO concentration of >10 ppm. Resting heart rate (RHR) and blood pressure were also 
determined. Additionally, a questionnaire with specific information about age, average 
number of cigarettes smoked per day and medical background was filled in by the 
participant in order to ensure that participants did not have any medical conditions 
contraindicated by exercise. Participants also completed the FTND, 7-DPARQ, SMQ and 
the MPAM-R (see Appendix 4 for screening questionnaires).
Participants were asked to abstain from smoking for 3 hrs before attending the 
laboratory on the test day (see Appendix 5 for test session measures). This was a shorter 
period of abstinence than typically reported in the literature, however previous studies 
by Taylor and Katomeri (2006) and Scerbo etal. (2010) found post-exercise changes in 
cigarette cravings and withdrawal symptoms after an abstinence of just 2 and 3 hours, 
respectively. To confirm abstinence a reading of <10 ppm ECO was required. The start 
time of the experimental session was time-matched within 30 mins of the start of the 
screening session to minimise possible diurnal variations.
Participants were then assigned to complete the three interventions in a counter­
balanced order: i. prescribed (objective) moderate intensity exercise; ii. perceived 
moderate intensity exercise; iii. passive waiting. In the exercise conditions participants 
were required to exercise for 10 mins on a Corival bicylcle ergometer (Lode, B. V., 
Netherlands) at a prescribed moderate intensity of exercise, either objectively 
determined using the Karvonen method (55% HRR; Karvonen, e ta l, 1957), or what the 
participant perceived to be moderate intensity exercise according to the Borg RPE scale 
(level 3; Borg, 1998). Perkins e ta l  (1989) found that just 1 1 -1 5  hrs of abstinence from 
smoking can reduce the average RHR by 8.5 beats per min (bpm) in regular smokers; the 
abstinence period in the current study was only 3 hours, but the HRR equation used the
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RHR measured prior to abstinence as this is more indicative of normal RHR. Heart rate 
was continuously monitored and recorded every 30 secs during each 10 min 
intervention using a Polar RS300X heart rate monitor [Polar Electro, Oy, Finland] chest 
band with readings transmitted to a wrist receiver, providing instant feedback to the 
experimenter while the participants were unable to see the interface. If participants 
were not exercising within the required HR range (± 5 bpm] during the prescribed 
moderate exercise intensity condition, the experimenter asked the participants to either 
speed up or slow down accordingly.
A timeline of instrument administration can be seen in Figure 2-1. Participants 
completed the MPSS and PANAS as baseline measures at 0 and 5 mins of a period sitting 
quietly in a chair. Participants then mounted the bicycle ergometer and undertook a 
warm-up period of 2 mins. During the 10 min exercise period participants completed 
RPE scales after 2.5 and 7.5 mins [RPE 1 and 2, respectively) and the MPSS after 5 and 10 
mins. Participants then dismounted the bicycle, sat down and asked to relax. At 5,10,15 
and 20 mins post-exercise participants completed the MPSS and PANAS again. In the 
passive condition, participants sat quietly with glossy magazines available to read for 10 
mins instead of exercising. Social interaction between the experimenter and the 
participants was kept to a minimum. Following completion of the study all participants 
were debriefed [Appendix 6) and offered £20 payment.
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Figure 2-1: Experimental timeline.
Timeline followed by participants for each of the three experimental conditions: 5 mins baseline
measurement, 10 mins of the intervention [the two different exercise interventions were also
preceded by 2 mins warm-up on the bike], and 15 mins rest. Cigarette withdrawal and craving
[MPSS] and affect [PANAS] were measured every 5 mins throughout the experiment: at 0 and 5
mins baseline, after 5 and 10 mins of exercise, and 5, 10, 15 and 20 mins post-exercise.
Perceived exertion [RPE] was measure after 2.5 and 7.5 mins of the exercise or passive waiting
interventions. Abbreviations: MPSS: Mood and Physical Symptoms Scale [MPSS; West & Hajek,
2004]; PANAS, Positive and Negative Affect Scale [Watson, etal, 1988]; RPE, Rating of Perceived 
Exertion [Borg, 1998].
2.2.5 Data analysis and statistics
All data were analysed using SPSS version 19 [IBM® SPSS® Statistics, 2012; IBM, Chicago]
and are presented as mean ± standard error of the mean [SEM]. One-way ANOVAs were
conducted for baseline data for age, number of years smoked, number of cigarettes per
day, hours abstained, ECO and RHR before and after abstinence, FTND, SMQ and MPAM- 
R scores.
A repeated measures ANOVA was conducted on RPE and HR during the 10 mins
intervention period for the factor Group [perceived intensity, prescribed intensity and 
passive].
Repeated measures ANOVAs were used to compare the baseline scores for all 
withdrawal symptoms, craving and PANAS scores; ANOVAs were assessed using 
Maulchys test for sphericity, and where appropriate a Greenhouse-Geisser correction 
was applied. ANOVAs were conducted for the factor Group [perceived intensity.
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prescribed intensity and passive] to assess the change in MPSS and PANAS scores over 
time (exercise +10 and +15 mins, resting +20, +25, and +30 mins]. The two baseline 
scores (0 mins and +5 mins] were averaged for each group to control for differences 
between groups at baseline; averaged baseline scores were included as a covariate in the 
analysis. A composite variable for total withdrawal was calculated from the mean of the 
eight individual MPSS and craving items and analysed in the same way. PANAS scores for 
each individual positive or negative affect item were totalled to give overall positive or 
negative affect scores. Post-hoc tests and multiple comparisons were used where 
appropriate to investigate differences in withdrawal symptoms, cravings and PANAS. 
Pearson's correlation analysis was conducted in order to test for associations between 
MPSS and PANAS scores.
Repeated measures ANOVA was used to assess saliva cortisol levels for each intervention 
[perceived intensity, prescribed intensity and passive] over time [baseline 0 mins, 
exercise +15 mins, resting +30 mins].
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2.3 Results
2.3.1 Post-hoc power analysis
The a priori power analysis (Section 2.1) indicated that a minimum of 18 participants for 
both the PA and SED groups would be required. Therefore, since only 18 participants in 
total were recruited, a post-hoc power analysis was also conducted (G*Power Version 
3.1; Paul, et al, 2009) in order to determine whether statistical tests could be carried out. 
With 12 participants in the SED group and only 6 in the PA group, the actual power of the 
study was indicated to be approximately 0.1. Therefore, data separated into PA and SED 
groups could not be statistically analysed; but as this was part of the main focus of the 
study these results are instead presented on a descriptive level. Statistics were still 
carried out where the two groups were pooled together to give n=18, in order to 
determine overall differences between the three interventions.
2.3.2 Sample baseline characteristics
In total, 32 participants were initially screened to take part in the experiment. Of these 3 
did not meet all of the screening criteria, 3 withdrew themselves from the study after the 
screening session, while a further 8 failed to respond to attempts to contact them to 
complete the main test session. In total, 18 participants completed the testing procedure. 
Of this group, 10 participants were male and 8 were female. Six participants were classed 
as having a PA lifestyle (3 male and 3 female), while 12 were classed as SED [7 male and 
5 female).
Baseline characteristics of the sample are presented in Table 2-2, according to lifestyle. 
One-way ANOVAs revealed no significant difference between participants for baseline 
measures.
There appears to be little difference between participants according to lifestyle for 
baseline characteristics, except for the MPAM-R where the SED group had a lower 
motivation for physical activity than the PA group [118.6 ± 9.94 vs. 141.5 ± 10.1, 
respectively).
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Table 2-2: Baseline characteristics for sample.
Total Sedentary Physically active
Age 23.1 ± 0.9 23.8 ±1.2 21.8 ± 1.4
Years smoked 7.08 ± 0.62 7.75 ± 0.8 5.75 ± 0.9
Number of cigarettes per day 13.7 ± 1.4 13.1 ± 1.0 14.8 ± 4.0
FTND 4.17 ± 0.4 4.17 ± 0.4 4.17 ± 0.7
MPAM-R 126.2 ± 7.7 118.6 ±9.9 141.5 ± 10.1
SMQ 22.9 ± 0.9 23.3 ± 0.9 22.2 ± 2.1
Hours since last cigarette 3.32 ± 0.2 3.2 ± 0.1 3.64 ± 0.4
RHR pre-abstinence 74.3 ± 3.2 74.8 ± 7.6 74.0 ± 3.1
RHR post-abstinence 73.9 ± 2.8 73.8 ± 4.0 74.0 ± 2.5
ECO pre-abstinence 12.7 ±0.7 12.5 ± 1.1 13.0 ± 0.8
ECO pre-abstinence 4.11 ±0.6 4.67 ± 0.8 3.00 ± 1.0
D a t a  a r e  p r e s e n t e d  a s  m e a n  ±  s t a n d a r d  e r r o r  o f  t h e  m e a n  f o r  t h e  t o t a l  s a m p l e  ( n = 1 8 ) ,  s e d e n t a r y  ( n = 1 2 )  
a n d  p h y s i c a l l y  a c t i v e  [ n = 6 ]  g r o u p s .  D a t a  a r e  p r e s e n t e d  a s  m e a n  ±  s t a n d a r d  e r r o r  o f  t h e  m e a n .  O n e - w a y  
A N O V A s  r e v e a l e d  n o  s i g n i f i c a n t  d i f f e r e n c e s  b e t w e e n  p a r t i c i p a n t s  f o r  b a s e l i n e  c h a r a c t e r i s t i c s  in  t h e  t o t a l  
s a m p l e .  A b b r e v i a t i o n s :  E C O , e x p i r e d  c a r b o n  m o n o x i d e ;  F T N D , F a g e r s t r o m  t e s t  f o r  n i c o t i n e  d e p e n d e n c e ;  
M P A M , m o t i v e s  f o r  p h y s i c a l  a c t i v i t y  m e a s u r e  - r e v i s e d ;  R H R , r e s t i n g  h e a r t  r a te ;  S M Q , s m o k i n g  m o t i v a t i o n  
q u e s t i o n n a i r e .
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2.3.3 Heart rate and ratings of perceived exertion
Ratings of perceived exertion were measured 2.5 and 7.5 mins into each 10 mins 
intervention [Figure 2-2). RPE was scored higher in the objective and perceived 
moderate intensity exercise conditions, and appears to be slightly higher in both at the
7.5 mins timepoint than at 2.5 mins.
A repeated measures ANOVA revealed a significant effect of Time [F(i,5i]=8.295, p<0.01, 
partial r|2=o.l40) and Intervention [F[2,5i)=82.708, p<0.001, partial r|2=:0.762). Bonferroni 
post-hoc tests revealed differences in RPE between the perceived and objective moderate 
intensity exercise interventions [p<0.01) and between both exercise interventions and 
the passive waiting intervention [both p<0.001).
Figure 2-3 shows PA smokers had slightly lower RPE scores in the objective moderate 
intensity exercise intervention than SED smokers [5.25 ± 0.7 vs. 5.90 ± 0.5, respectively). 
There is a similar difference between the two groups during the perceived moderate 
intensity intervention, where speed is chosen by the participant [3.90 ± 0.4 vs. 4.38 ± 0.4, 
respectively). In the passive waiting condition, PA and SED smokers both had very low 
RPE scores [0.41 ± 0.2 vs. 0.63 ± 0.4, respectively).
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Figure 2-2: Ratings of perceived exertion of participants during perceived and 
objective moderate intensity exercise and passive waiting interventions.
Ratings of perceived exertion were recorded after 2.5 and 7.5 mins of each intervention (n=18). 
Data are presented as mean ± standard error of the mean. Repeated measures ANOVA with 
Bonferroni post-hoc revealed a significant effect of intervention on perceived exertion; *p<0.05; 
**p<0.01; ***p<0.001 vs. each intervention.
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Figure 2-3: Perceived exertion of participants during each intervention according 
to lifestyle.
The rating of perceived exertion (Borg, 1998) of sedentary and physically active smokers was 
recorded after 2.5 and 7.5 mins during each of the three conditions. Participants with sedentary 
(n=12) or physically active (n=6) lifestyles undertook objective moderate intensity exercise (A), 
perceived moderate intensity exercise (B), and passive waiting (C) interventions. Data are 
presented as mean ± standard error of the mean.
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Heart rate was recorded every 30 secs during each of the interventions (Figure 2-4). 
Heart rate appears to be constant over the 10 mins intervention period for each of the 
interventions. Heart rate was highest during the objective moderate intensity exercise 
condition, then the perceived moderate intensity exercise condtition and lowest in the 
passive waiting condition.
A repeated measures ANOVA revealed significant effects for the factors Intervention 
(F(2,51)=85.784, p <0.001, partial r|2=0.771), Heart Rate (F(6.3i7, 322.i62)=2.170, p<0.05, 
partial r)2=0.041) and Intervention x Heart Rate interaction (F(i2.634, 322.i62)=2.9 2 3, 
p<0.001, partial r|^=0.103); data failed Maulchy's test for sphericity (W=0.001, 
X^(209]=695.878, p<0.001), therefore, F-values are presented with a Greenhouse-Geisser 
correction (s=0.316). Bonferroni post-hoc tests revealed a significant difference between 
each of the three interventions (p<0.001 for all combinations). The highest HR levels 
were measured during the objective moderate intensity exercise condition (141.4 bpm ± 
1.8), compared with perceived moderate intensity exercise (114.7 bpm ± 6.5) and 
passive waiting (68.4 bpm ± 2.0).
Figure 2-5 shows very little difference between smokers with a PA or SED lifestyle for 
the passive waiting or objective moderate intensity exercise interventions (6.40% and 
1.40% difference average HR over the 10 mins, respectively). However, PA smokers 
exercised at a higher HR in the perceived moderate intensity exercise intervention than 
SED smokers (23.1% difference), which was similar to the difference in HR during the 
objective moderate intensity exercise intervention (134 ± 0.9 vs. 143 ± 0.3, respectively).
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Figure 2-4: Heart rate of participants during perceived and objective moderate 
intensity exercise and passive waiting interventions.
Heart rate was recorded every 30 secs during each of the three 10 mins interventions (n=18). 
Data are presented as mean ± standard error of the mean. Repeated measures ANOVA with 
Bonferroni post-hoc revealed a significant effect of intervention on heart rate; ***p<0.001 vs. each 
intervention.
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Figure 2-5: Heart rate of participants during each intervention according to 
lifestyle.
Heart rate v^as recorded every 30 secs during each of three 10 mins interventions. Participants 
with sedentary (n=12) or physically active (n=6) lifestyles undertook objective moderate 
intensity exercise (A), perceived moderate intensity exercise (B), and passive waiting (C) 
interventions. Data are presented as mean ± standard error of the mean.
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2.3.4 Withdrawal symptoms and desire to smoke
Withdrawal symptoms were measured every 5 mins during each session [Figure 2-6). 
Individual withdrawal symptoms were averaged for each time point in order to calculate 
a global withdrawal score. Withdrawal symptoms for each intervention scored ~4 prior 
to the intervention, dropped slightly during each intervention and then rose again post­
intervention.
A repeated measures ANOVA adjusted for non-sphericity (W=0.314, x^(9)=56.073, 
p<0.001, 8=0.604) revealed significant effects for the factors Intervention [F(2,50}=4.483, 
p<0.05, partial r|^=0.152) and Time [F(2.42,i20.90)=5.3 96, p<0.01, partial r|2=0.097). 
Bonferroni post-hoc tests could not identify where the differences between interventions 
lay, but did identify a significant change over time across all three interventions between 
baseline measurements and both exercise time points [10 and 15 mins, both p<0.001), 
and between both exercise time points and each of the rest period time points [20 mins, 
p<0.01; 25 and 30 mins, p<0.001). These data indicate that cigarette withdrawal 
symptoms and cravings are reduced during the interventions, and that these symptoms 
increased post-intervention to levels similar to those recorded at baseline. However, 
there was no difference between the different interventions in their effect on withdrawal 
symptoms and craving levels.
Figure 2-7 shows that PA smokers generally had lower baseline withdrawal and craving 
symptoms than SED smokers [3.1 vs. 4.1 average baseline score, respectively), and that 
this persisted during each 10 mins intervention [2.5 vs. 3.5, respectively). The MPSS 
scores of PA smokers then increased post-intervention until they were similar to those of 
the SED smokers [3.5 vs. 3.9, respectively, after 15 mins rest).
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Figure 2-6: Global withdrawal rating of participants during perceived and 
objective moderate intensity exercise and passive waiting interventions.
Withdrawal symptoms were recorded every 5 mins during each of the three conditions (n=18); 
the mean of individual symptoms were combined to give a global withdrawal rating. Data are 
presented as mean ± standard error of the mean. A repeated measures ANOVA with Bonferroni 
post-hoc revealed a significant effect of intervention on withdrawal over time; ***p<0.001 vs. 
combined baseline masurement (0 and 5 mins); ##p<0.01, ###p<0.001 vs. intervention 
measurements [10 or 15 mins).
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Figure 2-7: Global withdrawal rating of participants during each intervention 
according to lifestyle.
Withdrawal symptoms of sedentary and physically active smokers were recorded every 5 mins 
during each of the three conditions; the mean of individual symptoms were combined to give a 
global withdrawal rating. Participants with sedentary (n=12) or physically active (n=6) lifestyles 
undertook objective moderate intensity exercise (A), perceived moderate intensity exercise (B) 
and passive waiting interventions (C). Data are presented as mean ± standard error of the mean.
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2.3.5 Positive and negative affect
Positive and negative affect were measured every 5 mins during each session (Figure 
2-8). Individual items on the PANAS questionnaire were averaged for each time point in 
order to calculate global positive and negative affect scores. Negative affect scores 
remained fairly constant across all three condititions before, during and after the 
interventions. Positive affect rose by a few points during each intervention, dropping 
again to pre-intervention levels during the rest period.
A repeated measures ANOVA found no significant effects for any of the factors analysed 
for positive affect. However, for negative affect there was a Time x Intervention 
interaction (W=0.401, x^[9)=44.185, p<0.001, £=0.723; F(5.788,i44.690)=1.214, p<0.05, partial 
1)2=0.087). Bonferroni post-hoc identified a significant difference for the passive waiting 
condition only between mid-intervention (10 mins) and all rest period times (20 and 25 
mins, p<0.05; 30 mins, p<0.01).
Figure 2-9 shows that positive affect scores rose for both PA and SED smokers during 
both exercise interventions, but returned to baseline levels by the end of the rest period. 
For SED smokers, positive affect increased by 18.8% and 7.2% compared with baseline 
for the objective and perceived moderate intensity exercise interventions, respectively. 
For PA smokers, positive affect increased by 17.6% and 32.8% compared with baseline 
for the objective and perceived moderate intensity exercise interventions, respectively. 
Physically active smokers experienced higher positive affect than SED smokers in the 
perceived moderate intensity exercise intervention (27.9 ± 3.8 vs. 23.6 ± 1.5, 
respectively). This is the same intervention during which the PA group had a higher 
heart rate than the SED group, and indicates that perceived moderate intensity exercise 
was more beneficial for PA than SED smokers. However, PA smokers reported lower 
positive affect than SED smokers during the objective moderate intensity intervention 
(25.1 ± 2.4 vs. 28.0 ± 2.5, respectively). During the passive waiting condition, the positive 
affect scores of both PA and SED smokers were stable throughout, although the SED 
smokers did have higher positive affect scores than PA smokers during this condition 
(23.1 ± 0.7 vs. 15.6 ± 0.3, respectively).
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Figure 2-10 shows that negative affect was stable throughout each condition for both PA 
and SED smokers, and for the perceived moderate intensity exercise and passive waiting 
conditions these scores overlap. For the objective moderate intensity condition, SED 
smokers had a higher negative affect score than PA smokers (16.0 ± 0.3 vs. 12.6 ± 0.4, 
respectively], suggesting that smokers with a sedentary lifestyle may experience 
increased negative mood during exercise if they have no control over how hard they are 
working.
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Figure 2-8: Affect ratings of participants during perceived and objective moderate 
intensity exercise and passive waiting interventions.
Positive (A) and negative (B) affect were recorded every 5 mins during each condition (n=18); 
individual affect symptoms were added together to give a global positive or negative affect score. 
Data are presented as mean ± standard error of the mean. A repeated measures ANOVA with 
Bonferroni post-hoc revealed significant Intervention x Time interactions for negative affect 
during the passive waiting intervention; *p<0.05, **p<0.01 vs. 10 mins.
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Figure 2-9: Positive affect ratings of participants during each intervention 
according to lifestyle.
Positive affect scores of sedentary and physically active smokers were recorded every 5 mins 
during each of the three conditions; individual symptoms were added together to give a global 
positive affect rating. Participants with sedentary [n=12) or physically active (n=6) lifestyles 
undertook objective moderate intensity exercise (A), perceived moderate intensity exercise (B) 
and passive waiting interventions (C). Data are presented as mean ± standard error of the mean.
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Figure 2-10: Negative affect ratings of participants during each intervention 
according to lifestyle.
Negative affect scores of sedentary and physically active smokers were recorded every 5 mins 
during each of the three conditions; individual symptoms were added together to give a global 
negative affect rating. Participants with sedentary (n=12) or physically active (n=6) lifestyles 
undertook objective moderate intensity exercise (A), perceived moderate intensity exercise (B) 
and passive waiting interventions (C). Data are mean ± standard error of the mean.
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2.3.6 Correlations between withdrawal symptoms and affect
Pearson's correlation coefficients between MPSS items and positive and negative affect 
for each intervention over time were determined. As SED and PA smokers could not be 
separated in the statistical analyses above for withdrawal symptoms or affect, these 
groups have been combined; see Table 2-3.
No significant correlations were observed in the objective moderate intensity exercise 
condition for positive affect. Negative correlations were observed in the perceived 
moderate intensity exercise condition for positive affect at all time-points, but these 
were only significant towards the end of the rest period [25 mins, p<0.01; 30 mins, 
p<0.05). Negative affect was positively correlated in the observed and perceived 
moderate intensity exercise conditions at all time points [p<0.05 -  p<0.001].
No significant correlations were observed in the passive waiting condition for positive 
affect. However, negative affect and withdrawal symptoms were positively correlated at 
all time-points [p<0.01 or p<0.001] except the start of intervention period (10 mins). 
These results show that global withdrawal symptoms are more indicative of negative, 
rather than positive, affect; as withdrawal symptoms increase, so does negative affect.
Table 2-3: Pearson's correlation coefficients between global withdrawal symptoms 
and affect over time.
Global withdrawal
Baseline 10 mins 15 mins 20 mins 25 mins 30 mins
Objective moderate intensity 
exercise
Positive affect 0.039 0.434 0.425 0.035 -0.162 -0.105
Negative affect 0.701** 0.697** 0.326** 0.487* 0.534* 0.542*
Perceived moderate 
intensity exercise 
Positive affect -0.170 0.016 0.021 -0 .246 -0.602** -0.532*
Negative affect 0.689** 0.477* 0.581* 0.688** 0.727*** 0.689**
Passive waiting 
Positive affect 0.179 0.040 0.079 0.060 0.063 0.179
Negative affect 0.613** 0.457 0.697** 0.820*** 0.770*** 0.792***
•=p<0.05, **p<0.01, ***p<0.001
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2.3.7 Salivary cortisol
Samples of saliva collected pre-abstinence were matched for time of day to the start of 
the post-abstinence experimental session (Figure 2-11). For each experimental 
condition, saliva samples were collected at baseline (0 mins), immediately post­
intervention (15 mins) and at the end of the rest period (30 mins). For all participants, 
pre-abstinence cortisol levels were ~9 nmol/L, dropping to roughly half this post­
abstinence. Salivary cortisol levels appeared not to change before, during or after the 
interventions in the experimental session.
A repeated measures ANOVA adjusted for non-sphericity (W=0.290, x^(5)=61.557, 
p<0.001, 8=0.548) revealed significant effects for the factor Time (F(i.663,84.695)=42.2 9 7, 
p<0.001, partial r|2=0.446). A Bonferroni post-hoc test found a significant reduction in 
salivary cortisol for all time points during the experimental session compared with pre­
abstinence levels.
Figure 2-12 shows that PA smokers had slightly higher pre-abstinence salivary cortisol 
levels than SED smokers (11.1 ± 1.3 vs. 7.40 ± 0.9 nmol/L, respectively), but during both 
exercise conditions there were no differences between the two groups. However, 
throughout the passive waiting condition this higher level of salivary cortisol was 
maintained in PA smokers, compared with SED smokers (6.24 ±0.4 vs. 4.15 ± 0.3 nmol/L, 
respectively).
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Figure 2-11: Salivary cortisol measurements before and after abstinence
Saliva samples (n=18) were collected pre-abstinence and during the experimental session at 
baseline [0 mins], immediately post-intervention (15 mins] and at the end of the rest period (30 
mins].' Data are presented as mean ± standard error of the mean. Repeated measures ANOVA 
with Bonferroni post-hoc revealed a significant effect of time on cortisol; ***p<0.001 vs. pre­
abstinence levels.
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Figure 2-12: Salivary cortisol measurements before and after abstinence according 
to lifestyle.
Salivary cortisol levels [nmol/L] of sedentary and physically active smokers were measured pre­
abstinence and during the experimental session at baseline [0 mins], immediately post­
intervention [15 mins] and at the end of the rest period [30 mins]. Participants with sedentary 
[n=12] or physically active [n=6] lifestyles undertook objective moderate intensity exercise (A), 
prescribed moderate intensity exercise (B) and passive waiting interventions (C). Data are 
presented as mean ± standard error of the mean.
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2.3.8 Correlations between cortisol, withdrawal symptoms and affect
Pearson's correlation coefficients between salivary cortisol, global withdrawal and 
positive and negative affect for each intervention over time were determined [Table
2-4]. The only significant correlation found was between global withdrawal and cortisol 
levels at baseline for the objective moderate intensity exercise condition. Otherwise, 
these data indicate no relationship between cortisol, withdrawal and affect during 
temporary abstinence from smoking.
Table 2-4: Pearson's correlation coefficients between salivary cortisol, global 
withdrawal symptoms and affect over time.
Global withdrawal
Baseline Intervention (+15 mins]
Rest
(+30 mins]
Objective moderate intensity 
exercise
Global withdrawal -0.549* -0.169 -0.360
Positive affect 0.063 -0.294 0.071
Negative affect -0.424 -0.006 -0.024
Perceived moderate intensity 
exercise
Global withdrawal -0.042 -0.089 -0.034
Positive affect 0.065 -0.318 0.097
Negative affect 0.248 -0.234 -0.096
Passive waiting
Global withdrawal -0.033 -0.094 -0.012
Positive affect 0.303 0.012 0.141
Negative affect 0.132 0.165 0.137
*=p<0.05
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2.4 Discussion
The present study sought to examine whether physically active and sedentary smokers 
differed in the extent to which perceived or objective moderate intensity exercise altered 
cigarette withdrawal symptoms and affect. Perceived and objective moderate intensity 
exercise and passive waiting all reduced withdrawal symptoms, however scores 
returned to baseline levels by 15 mins post-intervention. Negative affect was increased 
only during the rest period of the passive waiting intervention, while there were no 
changes observed in positive affect. Salivary cortisol was reduced compared with pre­
abstinence levels, but was not affected by any of the interventions.
Ratings of perceived exertion were found to be significantly different between each of 
the three different interventions investigated. Objective intensity exercise, where 
participants were exercising at 55% HRR based on their pre-abstinence RHR, was scored 
a higher RPE by participants compared with perceived moderate intensity exercise, 
meaning that moderate intensity exercise was consistently perceived to be of greater 
intensity than it actually was. For example, during objective moderate intensity exercise 
the average RPE scores after 2.5 and 7.5 mins exercise were 5.39 ± 0.41 and 5.94 ± 0.42, 
respectively. In contrast, on Borg's RPE scale [Borg, 1998], which ranges from 1 [no 
exertion at all] to 10 [very, very hard exertion], moderate intensity exercise is given a 
score of 3. Previous studies, such as Ussher et al [2001], have also found that 
participants persistently reported moderate intensity exercise to be of higher intensity 
than it was. This effect does not appear to be restricted to sedentary participants, as 
indications from the present study are for no marked difference in RPE for any of the 
interventions according to lifestyle.
Withdrawal symptoms and cigarette cravings were reduced in general during each of the 
interventions, but returned to baseline levels by 15 mins post-intervention. There was 
also no difference between the three interventions in terms of the extent that withdrawal 
was reduced or the persistence of that effect. This indicates that perceived and objective 
moderate intensity exercise are equally as beneficial in terms of reducing withdrawal 
symptoms as passive waiting, implying that any kind of activity, whether cardiovascular 
exercise or reading, could aid quit attempts. However, existing studies have shown that
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exercise has a mechanism of action in smoking withdrawal beyond providing a 
distraction [Daniel, et al, 2006; Marcus, et al, 1999] and exercise has increased the 
amount of time smoke-free during real-life quit attempts [Abrantes, et al, 2009; 
Copeland, et al, 2006; Marcus, et al, 1999], rather than just in a laboratory setting with 
current smokers. Pooling the SED and PA smokers into one population may also have a 
masking effect; for example, the data for positive affect shows that there may be 
differences between the two exercise interventions and passive waiting depending on 
lifestyle. However, a greater sample size would be required to investigate this question 
more fully.
Negative affect was not altered by either of the exercise conditions. However, it did 
increase during the post-intervention rest period for passive waiting. Whilst positive 
affect increased in general during the intervention period, there were no differences 
between the alternative interventions. Similarly to withdrawal assessment, it is possible 
that disparity between the interventions was masked by a differential response of SED 
and PA smokers to each of the interventions. For example, PA smokers only appeared to 
demonstrate increased affect during objective moderate intensity exercise. As increases 
in p-endorphin are thought to mediate exercise-induced positive affect [Boecker, et al,
2008], and tolerance is known to develop in the opioid system [see le Merrer, et al,
2009], it is possible that tolerance to the effect of exercise on positive affect may occur. 
Therefore, physically active smokers may need to work at a higher intensity than they 
would normally choose to in order to enhance positive affect during withdrawal.
Williams e ta l  [2008] found that positive affective responses to acute moderate intensity 
exercise to be predictive of physical activity levels at 6 and 12 month follow-ups for their 
participants, all sedentary. This suggests that finding the intensity of exercise which 
stimulates positive affect to the greatest extent for each individual may be the best 
approach to using exercise as a cessation aid, rather than focussing on their basal 
physical activity levels.
Consistent with previous studies that examined the effect of exercise on cortisol in 
temporarily withdrawn smokers [for example, Janse Van Rensburg, e ta l, 2013; Scerbo, 
et al, 2010], the present study found that salivary cortisol levels were reduced post-
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abstinence. In contrast to Scerbo et al, where high intensity exercise attenuated the post­
abstinence reduction in cortisol, the current study found that none of the interventions 
altered cortisol levels. However, Scerbo et al identified this result only following high 
intensity exercise (80-85% HRR], whereas the present study only examined the effect of 
moderate intensity exercise (55% HRR]. Similarly, Janse van Rensburg et al [2013] 
found that high intensity exercise [75% HRR] increased salivary cortisol compared with 
low intensity exercise [40% HRR] or control groups during abstinence. However, pre­
abstinence cortisol levels were not recorded so the effect of abstinence in that study is 
unknown. Nevertheless, Janse van Rensburg and colleagues concluded that there was not 
enough evidence to support exercise-induced cortisol release as a mechanism underlying 
the effects of exercise on nicotine withdrawal or affect. This conclusion is supported by 
the findings in this thesis, indicating that if the HPA axis is involved in mediating the 
effects of exercise in withdrawal then it is not through the action of cortisol.
Although the stage of change of participants was not assessed in this study [see 
transtheoretical model. Section 2.1], it may be that inhabiting the contemplation stage 
for exercise is more important than leading a physically active or sedentary lifestyle. 
Future work in this area should assess whether there is an interaction between lifestyle 
and stage of change on how exercise mediates withdrawal symptoms and affect during 
smoking abstinence.
It was not possible in the current study to statistically compare PA and SED lifestyles due 
to the small sample size recruited, however it was possible to compare the three 
different interventions in a within-participant design when treating the participants as a 
single population of n=18; this sample size is comparable with most of the within- 
participant design studies listed in Table 2-1. Recruitment and retention of participants 
have been highlighted as important, yet highly challenging, processes in human research 
[Berger, et al, 2009; Patel, et al, 2003]. Berger et al [2009] emphasise the difference 
between describing the criteria for recruitment in research articles, e.g. sample size and 
power, and the actual process of how recruitment occurred as this may aid future 
researchers in optimising recruitment. They suggest various strategies for participant 
retention, including decreasing the lag time between recruitment and completion of the
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study and producing a participant 'roles and responsibilities' document. In the current 
study, participants were booked in for screening and experimental sessions at the 
earliest available time convenient to the participant, but it is possible a list describing the 
responsibilities of the participants in addition to informed consent and the participant 
information sheet may be of benefit. Ramo e ta l  [2010] found that the internet was a 
useful tool in the recruitment of young adults aged 18-25 years, with nearly 60% of those 
eligible to take part completing the study. Indeed, 50% of participants in the current 
study were recruited through the online SONA recruitment system, more than any other 
method used, indicating that internet-based recruitment would be the best way forward 
to increase sample size.
Bachetti et al [2011] maintains that a study with a small sample size can still be of value, 
especially as new clinical or translational research must, by necessity, "start small". A 
blind adherence to power levels or p<0.05 is criticised as wasteful of data generously 
provided by volunteers, and researchers should instead focus on whether the 
accumulated results are plausible given existing knowledge. However, Bachetti [2011] 
does highlight that equal-sized experimental groups would be beneficial. The conclusions 
of the present study as regards the effect of exercise perception on nicotine withdrawal 
are logical and plausible in the context of published literature. In contrast, under these 
guidelines it would still be inappropriate to analyse the data according to lifestyle as the 
sample size for the SED group was twice that of the PA group.
In conclusion, this study shows that there are no differences between the interventions 
assessed in their effect on cigarette withdrawal symptoms, positive affect or salivary 
cortisol. However, passive waiting did significantly increase negative affect post­
intervention, while there were no changes in this measure for either of the exercise 
interventions. Indications are that withdrawal symptoms and positive affect are 
differentially mediated in smokers with either a sedentary or physically active lifestyle, 
but a greater sample size would need to be completed in order to draw firm conclusions.
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CHAPTER 3. EFFECT OF DIFFERENT INTENSITIES OF EXERCISE ON BRAIN 
NEUROCHEMISTRY AND BEHAVIOUR IN NICOTINE WITHDRAWAL 
3.1 Introduction
3.1.1 Exercise in animal models of addiction
Evidence from clinical and laboratory studies shows that exercise can reduce the 
severity of nicotine withdrawal and cravings [Ussher, e ta l, 2012; see also Chapter 2 of 
this thesis], and that there may be biological mechanisms underlying this effect [Scerbo, 
eta l, 2010]. To date however, no study has examined this interaction in animal models, 
and there are also very few studies exploring the effect of exercise during withdrawal 
and relapse from drugs of abuse other than nicotine. Nevertheless, what studies there 
are support the evidence from human studies [see Chapter 2] that exercise could be 
beneficial in helping to reduce withdrawal symptoms and prevent relapse [see Table
3-1].
Studies have been conducted in rats on the effects of exercise on the initiation of 
dependence to other drugs of abuse [for review see Lynch, e ta l, 2013]. Kanarek e ta l  
[1995] found that decreased amphetamine oral self-administration was concurrent with 
access to a running wheel. Similarly, acquisition of intravenous cocaine self­
administration behaviour coincided with exercise [Cosgrove, et al, 2002; Lynch, et al,
2010], but self-administration returned to baseline levels when running wheel access 
was removed [Cosgrove, et al, 2002], suggesting the beneficial effects of exercise to be 
transitory. However, exercise does not affect the time taken to acquire self­
administration behaviour for cocaine [Smith, et al, 2008]. Oral ethanol consumption is 
initially inversely correlated to exercise; ethanol consumption decreases when a running 
wheel is introduced, increases when the wheel is removed but holds steady at this level 
when the wheel is reintroduced [McMillan, eta l, 1995]. Exercise does have a sustained 
effect however, as exercise prior to ethanol administration reduces behavioural 
intoxication [Leasure & Nixon, 2010]. Treadmill exercise attenuates morphine self­
administration [Hosseini, eta l, 2009], but the exercise effect is less clear for conditioned 
place preference [CPF]. In one study, pre-exposure to a running wheel prevented
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acquisition of GPP (Lett, eta l, 2002b], while in another exercise enhanced it (Eisenstein 
& Holmes, 2007]. Lett et al (2002] used a brief and intermittent exercise protocol (2 
hrs/day for 8 days], while Eisenstein and Holmes (2007] used chronic voluntary wheel 
running (free access to wheel for 3 weeks]. Therefore, it appears that short-term exercise 
produces cross-tolerance to the rewarding effects of drugs, while longer term exercise 
enhances contextual learning of drug seeking. Consequently, it would be important to 
investigate the relative effects of restricted and free running wheel access in nicotine 
withdrawal. Altogether, the current evidence suggests that the effect of exercise in 
withdrawal may be dependent on the stage of abstinence (i.e., acute versus chronic 
withdrawal], exercise conditions and the drug of abuse. Since evidence indicates that 
forced exercise may induce relapse (Thanos, e ta l, 2013], it would seem that voluntary 
exercise would be the most beneficial, and ethologically valid, paradigm to investigate.
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3.1.2 Effect of exercise on the dopaminergic system
As outlined in Chapter 1 (Section 1.4), nicotine withdrawal is associated with a reduction 
of DAergic tone in the striatum, including augmented DA reuptake (see 
Hadjiconstantinou, e ta l, 2011). Exercise is thought to counteract these effects, thereby 
reducing subsequent withdrawal symptoms, such as negative affect and nicotine craving 
(Fischer-Shofty, e ta l, 2013; Lynch, et al, 2013).
DzRs are acutely downregulated during nicotine withdrawal (Scott, et al, 2007), 
however, in a mouse model of Parkinson's disease (PD) high intensity treadmill running 
in mice (1 hr/day for six weeks) selectively upregulated DzR, but not DiR, protein 
expression and receptor binding levels in striatal synaptosomes and PET imaging, 
respectively (Vucckovic, et al, 2010). Similarly, intensive treadmill exercise (three 
times/week for eight weeks) has been shown to elevate striatal DzRs in early-stage PD 
patients (Fisher, et al, 2013). In addition, exercise attenuated motor deficits following 
striatal 6-hydroxydopamine lesions in rats (O'Dell, et al, 2007; Yoon, et al, 2007). 
However, while Yoon, e ta l  (2007) identified that forced treadmill exercise increased the 
survival of DA neurons in the SN and projections to the striatum, O'Dell et a l (2007) 
found that neither forced nor voluntary wheel running altered DAT binding or neuronal 
survival in the SN. On balance, these studies indicate that exercise may counteract 
hypofunctioning of the DAergic system via upregulation of DzR in the striatum and could 
promote DAergic neuron survival.
3.1.3 Effect of exercise on the HPA axis and stress
Exercise is associated with a range of physiological and psychological benefits including 
prevention and treatment of depression, stress and anxiety (see Section 2.1.4). While one 
human study has shown that acute moderate intensity exercise can attenuate the drop in 
cortisol observed in temporarily abstinent smokers (Scerbo, et al, 2010), no animal 
studies have yet been conducted on the relationship between exercise and nicotine; 
therefore, the exact role of the HPA axis is not yet fully understood.
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3.1.4 Effect of exercise on the opioid system
Studies in the 1980s provided evidence that p-endorphin release is increased following 
exercise in humans (Colt, e ta l, 1981; Fraioli, eta l, 1980; Gambert, e ta l, 1981; Howlett, 
et al, 1984]. The resultant improved mood post-exercise is often attributed to p- 
endorphin in a concept commonly referred to as "runner's high" (Morgan, 1985; Partin, 
1983; Wagemaker & Goldstein, 1980). However, the above studies only showed 
increased levels of plasma p-endorphin; it was not until 2008 that Boecker et al found 
evidence of the release of endogenous opioids in the brain itself. Positron emission 
tomography (PET) scans of long distance runners using the non-selective opioid ligand 
FDPN have shown euphoria after running to be negatively correlated with opioid 
receptor occupancy, indicating opioid receptor activity in anterior limbic areas to be 
associated with affective states. Chronic running reduces sensitivity to MOPr agonists, 
such as morphine and buprenorphine (Smith & Lyle, 2006; Smith & Yancey, 2003). 
These findings are corroborated by studies which found that positive affect following 
endurance running was reversed by administration of the opioid antagonist naloxone in 
humans (Janal, e ta l,  1984), and similarly for wheel running in rats (Lett, eta l, 2002a), 
further suggesting an opioid-dependent effect.
The effect of exercise on P-endorphin release appears to be mediated by the type of 
exercise undertaken. Studies in rats have shown increased levels of plasma p-endorphin, 
but also increased opioid receptor availability, following 2 hours of swimming (Sforzo, et 
al, 1986), while 2 hours of treadmill running caused increased p-endorphin within the 
Acb (Blake, e ta l, 1984). Together, these studies indicate that exercise produces cross­
tolerance to MOPr agonists through augmented p-endorphin levels; however, various 
forms of exercise may differentially mediate opioidergic responses.
3.1.5 Effect of exercise on BNDF
The effect of exercise in mediating brain plasticity is generally associated with the 
induction of BDNF (for example Vaynman, eta l, 2004), which is thought to be controlled 
through epigenetic mechanisms (see Karpova, in press). For example, voluntary wheel 
running for one week was sufficient to elevate BDNF and cAMP response element-
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binding protein [CREE] mRNA in rats, an effect which was associated with faster 
learning in the Morris Water Maze [Vaynman, et al, 2004); inhibition of BDNF 
attenuated the impact of exercise on learning and memory, returning them to the level of 
sedentary controls. Similarly, Gomez-Pinilla et a l [2011) found that wheel running 
increased BDNF expression, specifically via déméthylation of the BDNF promoter IV 
region and acétylation of histone 3. In addition, exercise may increase BDNF by 
facilitating the transition from pro- to mature-BDNF [Ding, et al, 2011).
Drug-induced chromatin remodelling is thought to underlie relapse-liability as BDNF 
expression increases during prolonged abstinence [for review see Lynch, et al, 2013). 
During the early stages of abstinence BDNF is reduced in regions such as the RFC and 
striatum, but levels increase as abstinence progresses, which is thought to sensitise the 
system to relapse. For example, exercise dose-dependently decreased cocaine-seeking 
and attenuated BDNF promoter IV mRNA expression in the PFC. Therefore, exercise 
during early abstinence may be beneficial in helping to avoid relapse by counteracting 
the deficit found during this period.
3.2 Aims and objectives
The present study aimed to use an animal model to investigate the effects of different 
exercise regimes on the severity of nicotine withdrawal and to uncover some of the 
biochemical correlates associated with these effects. Together, the above studies provide 
evidence for the possible involvement of the HPA axis, BDNF, endogenous opioid and 
DAergic systems in mediating the effect of exercise on nicotine withdrawal. Given the 
role of nAChRs in mediating nicotine reward and withdrawal, the effect of exercise on 
these receptors in withdrawal was also investigated. Therefore, it is hypothesised that 
wheel running will reduce nicotine withdrawal symptom severity compared with 
sedentary mice and will include mechanisms involving neuronal nAChRs, DzR, MOPr, 
BDNF and corticosterone.
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3.3 Materials and Methods
3.3.1 Animals
Male C57B1/6 mice (B&K Universal, UK) aged 8 weeks were individually housed in 
Macrolom Type II Long cages fitted with a 13 cm diameter concentric free-turning 
running-wheel, in light-tight, sound-attenuated cabinets. The running wheels were 
connected to a computer to record each wheel revolution (ClockLab, Actimetrics, 
Wilmette, IL). Mice were maintained in a 12:12 hour light/dark cycle in a reverse phase 
light protocol [lights on 1100 hours). Animals had ad libitum access to food and water 
throughout the experiment. Animal work was carried out in accordance with the Animal 
[Scientific Procedures) Act, 1986.
3.3.2 Drugs
For minipump infusion [-)-nicotine hydrogen tartrate and mecamylamine [Sigma 
Aldrich, Poole, UK) were dissolved in physiological saline [0.9% sodium chloride), pH 
7.4. All concentrations are expressed as nicotine free base. Drug concentrations were 
selected based on literature data [Damaj, et al, 2003; Grabus, et al, 2005; Klein, et al, 
2004; Sparks & Pauly, 1999) to be physiologically relevant to plasma nicotine 
concentrations in humans [see Matta, eta l, 2007).
3.3.3 Treatment groups
Mice were randomly assigned to one of three running wheel conditions and treated with 
either nicotine or saline: wheels unlocked 24 hrs/day [n=13); wheels unlocked 2 
hrs/day [n=12-14); and wheels unlocked 0 hrs/day [n=12-13).
3.3.4 Assessmen t of running wheel activity
To determine profiles of average running wheel activity, the total number of wheel 
revolutions/day was converted into distance run for the 7 days of habituation and 14 
days of minipump treatment. Intensity of running wheel activity [number of wheel 
revolutions) on all study days was normalised by z-score and expressed as average 
activity per min. The number of active m ins/hr on all study days was also determined.
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3.3.5 Administration of nicotine
After 7 days habituation to the cages and running wheel routine animals were surgically 
implanted with subcutaneous osmotic minipumps [Model 2002, Alzet®, Cupertino, CA) 
containing [-)-nicotine hydrogen tartrate [24 mg/kg/day; Damaj, et al, 2003) in 0.9% 
sterile saline, or saline alone, delivering a constant flow at a rate of 0.5 pl/hour for a 
period of 14 days. For minipump implantation animals were anaesthetised with volatile 
isoflurane anaesthetic [4.0%; Isoflo, Abbott Laboratories Ltd., Kent, UK), which was 
vaporised in 95% O2 /  5% CO2 gas and delivered by a U400 anaesthetic unit [Univentor, 
Royem Scientific, UK) at a flow rate of approximately 450 ml/min. The animals were 
placed in the anaesthetic chamber for 1 min until the righting reflex was lost and were 
subsequently placed under a mask delivering anaesthesia throughout the surgery. Mice 
were injected with a non-opioid analgesic [Metacam, 1.5 mg/kg, s.c.). An osmotic 
minipump was inserted parallel to the spine through a dorsal mid-line incision, with the 
flow moderator pointing away from the incision. The incision was closed using 2 - 3  
Michele clips [11 x 2.5 mm). Upon completion of the surgical procedure mice were 
allowed to recover in a heated recovery chamber until their righting reflex returned and 
were returned to their home cages.
3.3.6 Assessment ofmecamylamine-precipitated withdrawal syndrome
A pilot study was conducted in order to compare two different nicotine withdrawal 
scales [Castané, eta l, 2002; Damaj, eta l, 2003) and to validate their use in a study using 
running wheels. C57B1/6 male mice had 24 hrs/day access to a running wheel and were 
treated with either saline or nicotine for 14 days as described in Section 3.3.5 [n=3 per 
group). Mecamylamine-precipitated withdrawal was assessed in these mice by two 
observers who were blind to the treatment group and one observer who was aware of 
the treatment groups according to both withdrawal scales. The scale of Castafié et al 
[2002) was determined to best reflect the symptoms displayed by the mice, with the 
additional symptom of rearing, as rearing was recorded by all observers as more 
frequent in nicotine-withdrawn compared with saline-withdrawn mice.
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Fourteen days after minipump implantation all animals were injected with 
mecamylamine (3 mg/kg, s.c.; Damaj, et al, 2003), a general nAChR antagonist, and 
immediately assessed for nicotine somatic withdrawal symptoms. Mice were placed in in 
clear plastic activity cages for 30 mins and videotaped for subsequent analysis of somatic 
withdrawal symptoms according to Castané et al [2002) by two observers who were 
blind to the treatment group and one observer who was aware of the treatment groups. 
A global withdrawal score was calculated for each animal by giving each individual 
symptom a relative weight: 0.5 for each episode of wet dog shake, front paw tremor, 
sniffing, rearing and scratching; and 1 for appearance or 0 for non-appearance within 
each 5 mins bin for the presence of ptosis, genital licks, tremor, piloerection and teeth 
chattering. 30 mins after the end of withdrawal assessment mice were killed by rising 
dose CO2 and trunk blood was collected in eppendorf tubes containing EDTA. Brains 
were also removed for autoradiography and frozen at -20°C in isopentane before being 
stored at -80°C. Trunk blood was centrifuged [1600 rpm at 4°C for 15 mins) and the 
plasma stored at -20°C for subsequent analysis of corticosterone content.
3.3.7 Quantitative receptor autoradiography
3.3.7.1 Autoradiography o f nicotinic cholingeric a4p2* and a7, dopamine D2 and p-opioid 
receptors
Brains were sectioned in a cryostat [Zeiss Hyrax C 25, Carl Zeiss Microimaging CmbH, 
Cermany), with an internal temperature of-21°C. 20 pm coronal sections were cut at 300 
pm intervals, from rostral to caudal levels, and thaw-mounted onto gelatine coated ice- 
cold microscope slides and processed for autoradiography. Adjacent sections were cut 
for determination of total and non-specific [MSB) binding. Sections were stored at -20°C 
prior to radioligand binding.
Quantitative autoradiography provides a highly sensitive and anatomically precise 
visualisation of specific receptors, which can then be quantified for analysis as described 
in the methods referenced below. It should be noted that this method detects receptors 
present both inside and on the extracellular membrane of a cell and it cannot determine 
the functionality of a given receptor. P^SjGTPyS receptor autoradiography can give a 
measure of receptor activity; however, this technique is only available for use with G-
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protein coupled receptors such as opioid receptors [Sôvâgô, et al, 2001], and would 
therefore not be compatible with the ligand-gated ion channel receptors, e.g. nAChRs. As 
a 'first look' into the neurochemistry underlying exercise in nicotine withdrawal, 
quanitative autoradiography is a useful tool for mapping possible receptors that may be 
involved.
Quantitative autoradiography was performed for a4p2, a7, MOP and Dz receptors with 
p25i]epibatidine, a-bungarotoxin, PH]D-Ala2-MePhe4-Gly-ol5 enkephalin (DAMGO) 
and PHJraclopride, respectively. On the day of the experiment, sections were thawed and 
processed according to established protocols [Kitchen, et al, 1997; Lena, et al, 2004; 
Metaxas, et al, 2012; Orr-Urtreger, et al, 1997; Whiteaker, et al, 2000), with minor 
modifications. Sections for analysis were derived from 4-6 brains from each of the six 
treatment groups. Multiple adjacent sections from all groups were processed together in 
a paired binding protocol.
For a4(32* nicotinic receptor binding, sections were pre-incubated for 10 mins in 50 mM 
Tris-HCl buffer containing 0.9% w /v NaCl, 5 mM KCl, 2.4 mM CaClz and ImM MgCh.pH
7.4 at room temperature, to remove endogenous ligands. Binding was carried out in 50 
mM Tris-HCl pre-incubation buffer, pH 7.4 at room temperature, in the presence of 100 
pM psijepibatidine [specific activity 2200 Ci/mmol) for 2 hrs. Two series of adjacent 
sections were used from each mouse to measure total P^sijgpibatidine binding [no 
competing ligand) and P^SQepibatidine binding in the presence of 20 nM cytisine. An 
additional set of adjacent sections were used to determine NSB in the presence of 300 
|iM nicotine salt for 2 hrs. Incubations were terminated after rinsing slides twice in ice- 
cold [4°C) 50 mM Tris-HCl buffer, pH 7.4 for 10 mins and a final rinse in ice cold RO 
water.
For a7 nAChR binding, slides were pre-incubated for 30 mins in 50 mM Tris-HCl pre­
incubation buffer, containing 0.5% w /v BSA, pH 7.4 at room temperature. Pre-incubation 
of NSB slides included ImM nicotine hydrogen tartrate. Binding was carried out in the 
same buffer in the presence of 3 nM P^SQcx-Bgtx [specific activity 108.8 Ci/mmol) for 3 
hrs. NSB was again determined in adjacent sections in the presence of 300 pM nicotine 
salt for 2 hrs. Incubations were terminated after rinsing slides three times in ice-cold
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(4°C] 50 mM Tris-HCl buffer (no BSA), pH 7.4, for 10 mins using RO water between each 
rinse.
For MOPr binding, slides were pre-incubated for 30 mins in 50 mM Tris-HCl pre­
incubation buffer, containing 0.9% w /v NaCl, pH 7.4 at room temperature. The slides 
were then incubated in 50 mM Tris-HCl buffer, pH 7.4 at room temperature in the 
presence of 4 nM PHJDAMCO [specific activity 51.5 Ci/mmol) for 60 mins. Non-specific 
binding was determined in adjacent sections in the presence of 1 pM naloxone. 
Incubation was terminated by rapid rinses [ 3 x 5  mins) in ice-cold 50 mM Tris-HCl 
buffer, pH 7.4 at room temperature, and distilled water [ 3x5 mins), then rapidly cool-air 
dried.
For DzR binding, slides were pre-incubated for 20 mins in 50mM Tris-HCl buffer, 
containing 120mM NaCl, 5mM KCl, 2mM CaClz plus ImM MgClz, pH 7.4, at room 
temperature. The slides were then incubated in pre-incubation buffer in the presence of 
4nM pHjraclopride [specific activity 60 Ci/mmol) for 60 mins. Non-specific binding was 
determined in the presence of 10 pM sulpiride. Incubation was terminated by rapid 
rinses [ 6x1 min) in ice-cold 50mM Tris-HCl buffer and a final rinse in ice cold RO water.
3.3.7.2 Film exposure and development
Following binding, sections were rapidly dried under cold air for 2 hours, and dried for 
up to 7 days using anhydrous calcium sulphate [BDH Chemicals, Poole, UK). Adjacent 
total and non-specific labelled sections were apposed to Kodak BioMax MR-1 film 
alongside autoradiographic microscale standards of known concentration. 
p25i]epibatidine and bound sections were exposed to film for 24 hrs and 7
days, respectively, with a set of microscale standards which had been cross­
calibrated to iodinated standards [Baskin & Wimpy, 1989; Miller & Zahniser, 1987). 
pH]-bound sections were exposed to film with ^H microscale standrds for a period of 6 
weeks for DzR and 10 weeks for MOPr.
For development, films were covered with an aqueous solution of 50% v/v Kodak D19 
developer for 3 mins. The reaction was stopped by 1 min rinse in distilled water 
containing a drop of glacial acetic acid. Images were fixed by submersion in Kodak rapid
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fix solution for 5 mins. Films were then rinsed in distilled water and dried overnight in a 
fume cupboard.
3.3.7.3 Quantitative analysis
Films were analysed by video-based densiometry using an MCID image analyser 
[Imaging Research, Canada) as previously described by Kitchen et al. [1997). In brief, 
fmol/mg tissue equivalents for receptor binding were derived from either or 
microscale standards, and the relationship between tissue radioactivity and optical 
density was calculated using MCID software, with appropriate adjustments to allow for 
radioactive decay of both the standards and the radioligands. Specific receptor binding 
was derived by subtraction of NSB from total binding for a7 nAChRs, MOPrs and DzRs. 
For a4p2* nAChRs, cytisine-resistant epibatidine binding was subtracted from total 
epibatidine binding to give cytisine-sensitive epibatidine binding.
For each region quantified measures were taken from both left and right hemispheres, 
therefore receptor binding represents a duplicate determination for each brain region 
and the n values listed refer to the number of animals analysed. The following structures 
were analysed by sampling 5 - 2 0  times with a box tool: cortex [ 8 x 8  mm), olfactory 
tubercle [ 6 x 6  mm) and hippocampus [ 5 x 5  mm). All other regions were analysed by 
free-hand drawing. Brain structures were identified by reference to the mouse atlas of 
Franklin and Paxinos [2001).
3.3.8 Plasma corticosterone measurement
Plasma samples from trunk blood were assayed for corticosterone content using a 
rat/mouse P^sijcorticosterone radioimmunoassay kit [MP Biomedicals, New York, NY, 
USA), according to manufacturer's instructions.
3.3.9 Brain BDNF measurement
Brain samples were analysed in collaboration with the lab of Dr Rosana Camarini at the 
University of Sao Paulo. Brains were defrosted using distilled water and the frontal 
cortex, striatum and hippocampus removed and weighed. Each sample was homogenised 
by ultrasonification in lysis buffer containing 100 mM PIPES, 500 mM NaCI, 15 mM NaNs,
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20% BSA, 2.5 mM EDTA, 0.2% Triton X-100 and protease inhibitor cocktail [Sigma 
Aldrich, Poole, UK], pH 7 at room temperature. Total BDNF protein levels in 
homogenates were determined using the Promega BDNF Emax® ImmunoAssay System 
with acid treatment [Promega, Madison, WI, USA}.
3.3.10 Statistical analysis
All data are presented as mean ± SEM and were analysed using Statistica [STATsoft, Inc., 
version 10).
3.3.10.1 Running wheel analysis
Running-wheel data for animals in the 24 hrs/day exercise group were analysed using 
two-way ANOVA for the factors Minipump Surgery, Time of Day and interactions 
followed by Bonferroni post-/ioc where appropriate. Data for animals in the 2 hrs/day 
exercise group were analysed using Student's t-test. A Bonferroni correction was applied 
to the a-level for all tests.
3.3.10.2 Nicotine withdrawal
Withdrawal data were normalised by constraining data between 0 -  100 before 
calculating a composite total withdrawal symptom due to high variation between 
individual mice in withdrawal symptoms displayed. Withdrawal data were analysed 
using a Kruskal-Wallis non-parametric test followed by Mann-Whitney U multiple 
comparisons with Duncan's correction of a-level.
3.3.10.3 Autoradiography
Three-way ANOVA for the factors Treatment, Exercise, Brain Region and interactions 
was used for comparison of total binding. Two-way ANOVA for the factors Treatment, 
Exercise and Treatment x Exercise interactions was conducted for each brain region with 
Bonferroni post-hoc test to investigate differences in radioligand binding between groups 
in individual regions. Two-way ANOVA for the factors Treatment, Exercise and 
Treatment x Exercise interactions was used to confirm difference in cytisine-resistant 
and cytisine-sensitive epibatidine binding.
I l l
3.3.10.4 BDNF and corticosterone
Two-way ANOVA for the factors Treatment, Exercise and Treatment x Exercise 
interactions was used for comparison of corticosterone measurement in plasma. Three- 
way ANOVA for the factors Treatment, Exercise, Brain Region and interactions were used 
for comparison of BDNF in brain samples. This was followed by two-way ANOVAs for 
each brain region.
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3.4 Results
3.4.1 Activity profiles of saline- and nicotine- treated mice
Total activity per day, expressed as distance run/day [km], was determined for animals 
in the 2 and 24 hrs/day wheel-running groups throughout the habituation and treatment 
periods in order to assess whether mice reached a steady-state of activity [Figure 3-1]. 
Total distance ran increase across the first 4 days of the habituation period as mice 
accumstomed to the housing and running wheels, before remaining steady for the rest of 
that period. Activity fell after minipump implantation, but returned to pre-surgery levels 
by Day 3 of the treatment period.
Two-way ANOVA with repeated measures found that total activity per day did not alter 
significantly between experimental days for the 2 hrs/day group. In contrast, the activity 
levels of mice in the 24 hrs/day group increased significantly over time during both the 
habituation [F[6,i68)=7.89, p<0.001] and treatment periods [F(i3,336)=2.63, p<0.01]. 
However, Bonferroni post-hoc test could not determine on which days this was 
significant. The activity levels of the 0 hrs/day wheel-running group were analysed as a 
manipulation check -  there was no wheel-running activity detected.
While there was no overall effect of nicotine treatment on running-wheel activity 
[number of active mins per hour], there was a significant effect of minipump surgery on 
the level of activity during the dark phase [Figure 3-2]. Two-way ANOVA revealed a 
significant effect for Surgery [F(i,576)=7.44, p=0.007] and Surgery x Time of Day 
interaction [F(23,S76)=2.54, p<0.001) in saline-treated mice only; Bonferroni-corrected 
a=0.0125. Bonferroni post-hoc identified a significant reduction in activity at ZT 13 
compared with the same time point pre-surgery [p<0.001].
Intensity of activity is presented as normalised data [z-scores] due to high variability 
between individual mice within the same treatment groups [Figure 3-3]. Two-way 
ANOVAs revealed a significant effect for Surgery [F(i,s76)=4.73, p=0.030] in nicotine- 
treated mice only, and a significant effect of Treatment after minipump surgery 
[F(i,s76)=5.95, p =0.015); however, following Bonferroni correction of the a-level 
[a=0.0125] neither of these results reached significance.
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Figure 3-1: Total wheel-running activity per day during habituation and treatment 
phases of the experiment.
Wheel-running activity was recorded and converted into distance run per day during the 7 day 
habituation and 14 day treatment periods. Data are presented as mean ± standard error of the 
mean. Repeated measures ANOVA revealed a significant change in total activity/day over time 
(p<0.001), but Bonferroni post-hoc analysis revealed no individual significant difference.
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Figure 3-2: Number of active mins per hour for mice with 24 hrs/day running 
wheel access.
Double-plotted total number of active mins/hr for saline- (A) and nicotine-treated (B) mice with 
24 hrs/day running wheel access during the habituation and treatment periods. Shaded area 
indicates the dark phase. Data are presented as mean ± standard error of the mean. Repeated 
measures ANOVA revealed significant effect of minipump surgery on the number of active 
mins/hr [p<0.01) and Surgery x Time of Day interactions [p<0.001] for saline-treated mice only; 
Bonferroni corrected a=0.0125. Bonferroni post-hoc found a significant difference between the 
habituation and treatment periods T13; ***p<0.001 vs. habituation period.
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Figure 3-3: Normalised intensity of wheel-running per day for mice with 24 
hrs/day running wheel access.
Double-plotted normalised intensity of wheel-running for saline- (A) and nicotine-treated (B) 
mice with 24 hrs/day running wheel access during the habituation and treatment periods. 
Shaded area indicates the dark phase. For intensity of wheel-running, data were normalised by 
determination of z-scores. Data are presented as mean ± standard error of the mean. Repeated 
measures ANOVA revealed no significant effects.
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3.4.2 Effect of different exercise regimes on severity of nicotine withdrawal 
syndrome
Data from all observers, both those blind to aware of treatment groups, were combined. 
No significant differences were found between observers' scores. Individual withdrawal 
symptoms were normalised by constraining data between 0 -  100 and a composite total 
withdrawal factor calculated. Figure 3-4 shows the range of individual withdrawal 
symptoms recorded for each group. Sniffing and rearing behaviour were the most 
frequently observed symptoms. No incidences of wet dog shakes, ptosis, tremors, 
piloerection or teeth chattering were observed.
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Figure 3-4: Effect of exercise regime on individual nicotine withdrawal symptoms.
Mice underwent one of three exercise regimes: 0, 2 or 24 hrs/day running-wheel access. 
Withdrawal was precipitated by mecamylamine [3 mg/kg, s.c.) following 14 days of either saline 
or nicotine [24 mg/kg/day) treatment via subcutaneous minipumps. Data for individual 
withdrawal symptoms were normalised [constrained between 1-100). Data are presented as 
mean ± standard error of the mean.
Nicotine-treated mice in the 2 and 24 hrs/day running wheel groups showed lower total 
withdrawal symptoms than nicotine-treated mice in the 0 hrs/day running wheel group 
Figure 3-5). Non-parametric Kruskal-Wallis test found a significant effect of exercise on 
withdrawal in nicotine-treated mice [H(2)=8.94, p<0.05). Multiple Mann-Whitney U-tests 
found nicotine-treated mice in the sedentary group displayed significantly higher
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severity of withdrawal symptoms than mice in the 2 or 24 hrs/day wheel access groups 
[U=26.50, z=2.63, p=0.004 and U=32.00, z=2.50, p=0.006, 1-tailed, respectively; 
Bonferroni corrected a-level=0.008).
Nicotine-treated mice in the 0 hrs/day group showed significantly higher withdrawal 
symptoms than saline-treated mice in the same exercise group [Mann-Whitney U-tests 
0=27.50, z=-2.75, p=0.003, 1-tailed). There was no difference between saline- and 
nicotine-treated mice within the 2 or 24 hrs/day groups. There was also no difference in 
severity of withdrawal between nicotine-treated mice in 2 and 24hrs/day wheel access 
groups.
While the total withdrawal values are higher than those recorded in Castané et al 
[2002), on which the scoring protocol used here was based, the current experiment 
included an additional symptom [rearing), therefore this discrepancy might he expected.
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Figure 3-5: Effect of exercise regime on severity of total nicotine withdrawal 
syndrome.
Mice underwent one of three exercise regimes: 0 [n=12-13), 2 [n=13-14) or 24 [n=13) hrs/day 
running-wheel access. Withdrawal was precipitated by mecamylamine [3 mg/kg, s.c.) following 
14 days of either saline or nicotine [24 mg/kg/day) treatment via subcutaneous minipumps. 
Data for individual withdrawal symptoms were normalised [constrained between 1-100) and 
combined to give a total withdrawal measure. Data are presented as mean ± standard error of 
the mean. **p<0.01 compared with nicotine-treated 0 hrs/day; #*p<0.01 compared with saline- 
treated within exercise regime.
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3.4.3 Effect of exercise on a4p2* nAChR binding in nicotine-withdrawn mice
Levels of a4p2* nAChR binding were determined using cytisine-sensitive 
[125J] epibatidine binding in brain regions of saline- or nicotine-treated mice from 0, 2 and 
24 hrs/day exercise groups [Figure 3-6). Non-specific binding was indistinguishable 
from film background. Cytisine-resistant binding was only present in the MHb for all 
groups. A two-way ANOVA found no significant effects within that region. Consequently, 
cytisine-sensitive binding was equivalent to total binding except in the medial habenula.
Binding of a4p2* nAChRs was increased throughout the brains of nicotine-treated 
compared with saline-treated mice, particularly in cortical regions, but there was no 
difference between exercise regimes within those treatment groups [Figure 3-7). A 
three-way ANOVA of cytisine-sensitive P^sjjepjbatidine binding revealed significant 
effects for the factors Treatment [F(i,704)=153.20, p<0.001) and Exercise [F(2,704)=11.28, 
p<0.001). Two-way ANOVA followed by Duncan's post-hoc revealed significant, region- 
specific nicotine-induced upregulation of cytisine-sensitive epibatidine in the 
frontal association, somatosensory, piriform, visual and auditory cortices, medial 
septum, ventral diagonal band, hypothalamus and VTA [p<0.001); olfactory tubercle, 
SNc, Ml, M2 and cingulate cortices [p<0.01); subiculum, prelimbic and retrosplenial 
cortices [p<0.05) compared with saline controls. There were no exercise or interaction 
effects in any of the individual brain regions.
The levels of cytisine-sensitive epibatidine binding measured in saline-treated mice 
in the present study are comparable to those recorded in other studies for saline-treated 
C57B1/6 male mice [Metaxas, etal,  2010; Metaxas, etal,  2012; Pauly, eta l,  1991).
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Figure 3-6: Representative autoradiograms of a4p2* nAChR binding in saline- and 
nicotine-treated withdrawn mice
C o m p u t e r  e n h a n c e d  c o l o u r  a u t o r a d i o g r a m s  o f  t o t a l  a n d  c y t i s i n e - r e s i s t a n t  [ 1251] e p i b a t i d i n e  
b i n d i n g  i n  c o r o n a l  b r a i n  s e c t i o n s  o f  C 5 7 B 1 / 6  m i c e  t r e a t e d  w i t h  c h r o n i c  s a l i n e  o r  n i c o t i n e  [ 2 4  
m g / k g / d a y ]  v i a  s u b c u t a n e o u s  m i n i p u m p s  f o r  1 4  d a y s ,  f o l l o w e d  b y  m e c a m y l a m i n e - p r e c i p i t a t e d  
[ 3  m g / k g ]  w i t h d r a w a l .  M i c e  u n d e r w e n t  o n e  o f  t h r e e  e x e r c i s e  r e g i m e s :  0 ,  2  o r  2 4  h r s / d a y  r u n n i n g  
w h e e l  a c c e s s  i n  t h e i r  h o m e  c a g e .  C o r o n a l  b r a i n  s e c t i o n s  a r e  s h o w n  c u t  a t  t h e  l e v e l  o f  t h e  
t h a l a m u s  [ B r e g m a  - 1 . 4 6  m m ] .  S p e c i f i c  a 4 | 3 2 *  b i n d i n g  w a s  d e t e r m i n e d  b y  s u b t r a c t i n g  2 0  n M  
c y t i s i n e - r e s i s t a n t  b i n d i n g  f r o m  t o t a l  1 0 0  p M  [ i 2 s i ] e p i b a t i d i n e  b i n d i n g .  A d j a c e n t  s e c t i o n s  w e r e  
i n c u b a t e d  w i t h  3 0 0  p M  [ - ] - n i c o t i n e  h y d r o g e n  t a r t r a t e  t o  c a l c u l a t e  n o n - s p e c i f i c  b i n d i n g  [ N S B ] ,  
w h i c h  w a s  i n d i s t i n g u i s h a b l e  f r o m  b a c k g r o u n d .  S e c t i o n s  w e r e  a p p o s e d  t o  K o d a k  B i o M a x  M R - 1  
f i l m  f o r  a  p e r i o d  o f  2 4  h r s .  T h e  c a l i b r a t i o n  b a r  p r e s e n t s  p s e u d o - c o l o u r  i n t e r p r e t a t i o n  o f  b l a c k  a n d  
w h i t e  f i l m  i m a g e s  i n  f m o l / m g  t i s s u e  e q u i v a l e n t .  A b b r e v i a t i o n s :  H i p ,  h i p p o c a m p u s ;  R S ,  
r e t r o s p l e n i a l  c o r t e x ;  T h ,  t h a l a m u s .
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Figure 3-7: Cytisine-sensitive [i^sijepibatidine binding in saline- and nicotine- 
treated mice undergoing different exercise regimes
Cortical (A] and non-cortical (B) regions from brain sections of saline- and nicotine-treated mice 
undergoing different exercise regimes were bound with epibatidine alone or in the presence 
of cytisine. Cytisine-sensitive binding was determined by subtracting cytisine-resistant binding 
from total epibatidine binding. Data are presented as mean ± standard error of the mean. Three- 
way ANOVA found a significant effect of Treatment [p<0.001] and Exercise x Treatment 
interaction (p<0.001). Two-way ANOVA for each brain region: *p<0.05, **p<0.01, ***p<0.001 vs. 
saline-treated mice. Abbreviations: AcbC, nucleus accumbens core; AcbSh, nucleus accumbens 
shell; AuCx, auditory cortex;7AV, anteroventricular thalamic nuclei; CgCx, cingulate cortex; CPu, 
caudate putamen; DC, dentate gyrus; DLG, dorsal geniculate nucleus; fr, fasiculus retroflexus; 
FrA, frontal association; Hip, hippocampus; Hyp, hypothalamus; InG, intermediate grey layer of 
the superior colliculus; IPn, interpeduncular nucleus; LD: laterodorsal thalamic nuclei; Ml, 
primary motor cortex; M2, secondary motor cortex; MHb, medial habenual; MS, medial septum; 
Pir, piriform cortex; Po, posterior thalamic nuclei; PrL, prelimbic cortex; RS, retrosplenial cortex; 
S, subiculum; SNc, substantia nigra pars compacta; SS, somatosensory cortex; SuG, superficial 
grey layer of the superior colliculus; Tu, olfactory tubercles; VDB, vertical diagonal band; ViCx, 
visual cortex; VLG, ventral medial geniculate; VTA, ventral tegmental area.
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3.4.4 Effect of exercise on a?  nAChR binding in nicotine-withdrawn mice
Binding of a7 nAChRs was determined by P^^I]a-Bgtx binding in brain regions of saline- 
or nicotine-treated mice from 0, 2 and 24 brs/day exercise groups (Figure 3-8]. Non­
specific binding was homogenous across sections.
There was region-specific upregulation of a7 nAChR binding of exercising mice, 
particularly in the hippocampus; see Figure 3-9. Three-way ANOVA found a significant 
effect of Treatment (F[i,4i70]=72.76, p<0.001]. Exercise (F(2,4i7)=6.19, p<0.01], Treatment 
X Exercise interactions [F(2,4i7)=4.03 p<0.05] and Exercise x Region interactions 
[F(32,4173=1.76, p<0.01). Two-way ANOVA for each brain region found followed by 
Duncan's post-hoc found significantly upregulated a7 binding in nicotine-treated 
compared with saline-treated mice in the claustrum and the dorsomedial hypothalamus 
(p<0.05); CAl, basomedial amygdala and ventromedial hypothalamus [p<0.01]; and the 
hasolateral amygdala (p<0.001). a7 nAChR binding was upregulated in both the 2 and 24 
hrs/day exercise groups compared with 0 hrs/day in the CAl hippocampal region 
[p<0.01], irrespective of treatment. There was also a significant difference in overall a7 
binding in the Ml and cingulate cortices between the 0 and 24 hrs/day exercise groups 
[both p<0.05).
In the CA2/3 hippocampal region there were significant Exercise x Treatment 
interactions [p<0.05]. The a7 nAChR binding was significantly upregulated in nicotine- 
compared with saline-treated mice within the 24 hrs/day exercise group [p<0.01]. There 
was also a significant increase of a7 binding in nicotine-treated mice in the 2 hrs/day 
exercise group, and in nicotine- and saline-treated mice in the 24 hrs/day group 
compared with mice in the 0 hrs/day group within the same treatment regime.
In accordance with a7 levels in other papers, binding levels ranging from 20 fmol/mg in 
the CgCx to 47 fmol/mg in the zona incerta were similar to values found in other studies 
published previously both by our lab [Metaxas, e ta l ,  2013; Metaxas, e ta l ,  2012) and 
others [Pauly, et al, 1991; Svedberg, et al, 2002], and in particular the levels of a7 
binding found in the hippocampus: 32-40 fmol/mg in the present study and 45 fmol/mg 
in Marks e ta l  [2006].
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Figure 3-8: Representative autoradiograms of [i^sija-bungarotoxin binding in 
saline- and nicotine-treated withdrawn mice.
C o m p u t e r  e n h a n c e d  c o l o u r  a u t o r a d i o g r a m s  o f  t o t a l  [ i 2 s i ] a - b u n g a r o t o x i n  a n d  n o n - s p e c i f i c  [ N S B ]  
b i n d i n g  i n  c o r o n a l  b r a i n  s e c t i o n s  o f  C 5 7 B 1 / 6  m i c e  t r e a t e d  w i t h  c h r o n i c  s a l i n e  o r  n i c o t i n e  v i a  
s u b c u t a n e o u s  m i n i p u m p s ,  f o l l o w e d  b y  m e c a m y l a m i n e - p r e c i p i t a t e d  [ 3  m g / k g ]  w i t h d r a w a l .  M i c e  
u n d e r w e n t  o n e  o f  t h r e e  e x e r c i s e  r e g i m e s :  0 ,  2  o r  2 4  h r s / d a y  r u n n i n g  w h e e l  a c c e s s  i n  t h e i r  h o m e  
c a g e .  C o r o n a l  b r a i n  s e c t i o n s  a r e  s h o w n  c u t  a t  t h e  l e v e l  o f  t h e  h i p p o c a m p u s  [ B r e g m a  - 1 . 4 6  m m ] .  
B r a i n  s e c t i o n s  w e r e  i n c u b a t e d  f o r  3  h r s  w i t h  3  n M  j c c - b u n g a r o t o x i n .  A d j a c e n t  s e c t i o n s  w e r e  
i n c u b a t e d  w i t h  1  m M  [ - ] - n i c o t i n e  h y d r o g e n  t a r t r a t e  t o  c a l c u l a t e  n o n - s p e c i f i c  b i n d i n g  [ N S B ] .  
S e c t i o n s  w e r e  a p p o s e d  t o  K o d a k  B i o M a x  M R - 1  f i l m  f o r  a  p e r i o d  o f  7  d a y s .  T h e  c a l i b r a t i o n  b a r  
p r e s e n t s  p s e u d o - c o l o u r  i n t e r p r e t a t i o n  o f  b l a c k  a n d  w h i t e  f i l m  i m a g e s  i n  f m o l / m g  t i s s u e  
e q u i v a l e n t .  A b b r e v i a t i o n s :  B L A , b a s o l a t e r a l  a m y g d a l a ;  H ip ,  h i p p o c a m p u s .
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Figure 3-9: [i25i]c(_bungarotoxin binding in saline- and nicotine-treated mice 
undergoing different exercise regimes
Regions from brain sections of saline- and nicotine-treated mice undergoing different exercise 
regimes were bound with [i2si]a-bungarotoxin. Data are presented as mean ± standard error of 
the mean. Three-way ANOVA found a significant effect for the factors Treatment [p<0.001], 
Exercise (p<0.01) and Exercise x Treatment interactions [p<0.05]. Two-way ANOVA for each 
brain region followed by Duncan's post-hoc: **p<0.01, ***p<0.001 1 vs. 0 hrs/day running wheel 
access within same treatment group; ^*p<0.01 vs. saline-treated mice within the same exercise 
regime; ^p<0.05, ^^p<0.01 vs. 0 hrs/day running wheel access. Abbreviations: BLA, basolateral 
amygdala; BMA, basomedial amygdala; CgCx, cingulate cortex; CPu, caudate putamen; CAl, 
nucleus of the hippocampus; CA2/3, nucleus of the hypothalamus; Cl, claustrum; DEn, dorsal 
endopiriform nucleus; DC, dorsal dentate gyrus; DM, dorsomedial hypothalamus; FrA, frontal 
association; InG, intermediategrey layer of the superior colliculus; LH, lateral hypothalamus; Ml, 
primary motor cortex; SuG, superficialgrey layer of the superior colliculus; VLG, ventral medial 
geniculate; VMM, ventromedial hypothalamus; Zl, zona incerta.
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3.4.5 Effect of exercise on MOPr binding in nicotine-withdrawn mice
Binding of MOPr was determined by PH]DAMG0 binding in brain regions of saline- or 
nicotine-treated mice from 0, 2 and 24 hrs/day exercise groups (Figure 3-10]. Non­
specific binding was indistinguishable from film background.
There were was no overall difference between nicotine- or saline-treated mice 
undergoing any of the exercise regimes. Three-way ANOVA found a significant effect of 
Exercise (F(2,73i)=12.58, p<0.001] across all regions. Duncan's post-hoc test found a 
significant increase of MOPr binding in 2 and 24 hrs/day [both p<0.001] compared with 
0 hrs/day running wheel access across all brain regions. Exercise increased MOPr 
binding in the PAG, irrespective of treatment. Two-way ANOVA for each brain region 
followed by Duncan's post-hoc found a significant increase of MOPr binding in the 
periaqueductal grey [PAG] of mice in the 2 and 24 hrs/day exercise groups [p<0.05 and 
p<0.01, respectively] compared with 0 hrs/day exercise; see Figure 3-11.
The levels of PHJDAMGO binding measured in saline-treated mice in the present study 
are comparable to those recorded in other studies for saline-treated C57B1/6 male mice 
[Bailey, etal,  2007; Goody, etal,  2002a; Kitchen, etal,  1997].
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Figure 3-11: PHJDAMGO binding in saline- and nicotine-treated mice 
undergoing different exercise regimes
(A) Cortical and (B) non-cortical regions from brain sections of saline- and nicotine-treated 
mice undergoing different exercise regimes were bound with pH]DAMGO. Non-specific 
binding was indistinguishable from background. Data are presented as mean ± standard 
error of the mean. Three-way ANOVA found a significant effect for the factor Exercise 
(p<0.001]. Two-way ANOVA for each brain region followed by Duncan's post-hoc. *p<0.05, 
**p<0.01 vs. 0 hrs/day running wheel access. Abbreviations: AcbC, nucleus accumbens core; 
AcbSh, nucleus accumbens shell; AuCx, auditory cortex; BLA, basolateral amygdala; CgCx, 
cingulate cortex; CL, centrolateral thalamic nuclei; CM, centromedial thalamic nuclei; CPu, 
caudate putamen; cSSCx, caudal somatosensory cortex; DEn, dorsal endopiriform; EntCx, 
entorhinal cortex; FrCx, frontal cortex; FPtACx, frontal parietal cortex; Hip, hippocampus; 
Hyp, hypothalamus; IMD, intermediate thalamic nuclei; InG, intermediate grey layer of the 
superior colliculus; Me, centromedial amygdala; MHb, medial habenula; MtCx, motor cortex; 
OrCx, orbital cortex; PAG, periaqueductal grey; Re, reunions; RSCx, retrosplenial cortex; 
rSSCx, rostral somatosensory cortex; SN, substantia nigra; SuG, superficial grey layer of the 
superior colliculus; TeCx, temporal cortex; ViCx, visual cortex.
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3.4.6 Effect of exercise on DzR binding in nicotine-withdrawn mice
Binding of DzRs was determined by PHJraclopride binding in brain regions of saline- 
or nicotine-treated mice from 0, 2 and 24 hrs/day exercise groups (Figure 3-12). 
Non-specific binding was indistinguishable from background. Three-way ANOVA 
found no significant effects, and two-way ANOVA for each brain region also found no 
significant changes in PH]raclopride binding; see Figure 3-13. The PH]raclopride 
binding levels measure here are comparable with other studies [Bailey, e ta l ,  2008; 
Bailey, etal., 2007; Lena, e ta l,  2004; Yoo, e ta l,  2010}.
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Figure 3-12: Representative autoradiograms of DzR binding in saline- and 
nicotine-treated withdrawn mice.
Computer enhanced colour autoradiograms of total pHJraclopride binding in coronal brain 
sections of C57B1/6 mice treated with chronic saline or nicotine via subcutaneous 
minipumps. Mice underwent one of three exercise regimes: 0, 2 or 24 hrs/day running wheel 
access in their home cage. Brain sections were incubated for 3 hrs with 4 nM pHJraclopride. 
Adjacent sections were incubated with 10 pM sulpiride to calculate non-specific binding 
[NSB], which was indistinguishable from background. Sections were apposed to Kodak 
BioMax MR-1 film for 6 weeks. Images are shown from the level of the caudate putamen 
[Bregma -1.10 mm]. The colour bar represents a pseudo-colour interpretation of black and 
white film images in fmol/mg tissue equivalent. Abbreviations: Acb, nucleus accumbens; CPu, 
caudate putamen; Tu, olfactory tubercle.
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Figure 3-13: pH]raclopride binding in saline- and nicotine-treated mice 
undergoing different exercise regimes
Regions from brain sections of saline- and nicotine-treated mice undergoing different 
exercise regimes were bound with pHJraclopride. Data are presented as mean ± standard 
error of the mean. Three-way ANOVA found no significant effects. Abbreviations: AcbC, 
nucleus accumbens core; AcbSh, nucleus accumbens shell; CPu, caudate putamen; Tu, 
olfactory tubercle.
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3.4.7 Effect of exercise on plasma corticosterone in nicotine-withdrawn mice
Plasma corticosterone levels were determined by radioimmunoassay of saline- or 
nicotine-treated mice from 0, 2 and 24 hrs/day exercise groups; Figure 3-14. Plasma 
corticosterone levels were higher in nicotine-treated compared with saline-treated 
mice. Two-way ANOVA revealed a significant effect of Treatment only (F(i,34)=9.76, 
p<0.01); there was no effect of exercise regime.
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Figure 3-14: Plasma corticosterone levels in saline- and nicotine-treated mice 
undergoing different exercise regimes.
Plasma corticosterone content was determined using a radioimmunoassay for nicotine- 
and saline-treated mice undergoing 0, 2 or 24 hrs/day running wheel access. Data are 
presented as mean ± standard error of the mean. Two-way ANOVA revealed a significant 
effect of Treatment [**p<0.01) on plasma corticosterone, but Bonferroni post-hoc revealed no 
individual significance.
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3.4.8 Effect o f exercise on brain BDNF in nicotine-withdrawn mice
The level of free BDNF in the RFC, striatum and hippocampus of saline or nicotine 
treated mice from 0, 2 and 24 hrs/day exercise groups v\^ as determined using an 
ELISA. Three-way ANOVA revealed no significant effects for any of the factors 
analysed for free BDNF and two-way ANOVA for each brain region also found no 
significant changes (Figure 3-15).
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Figure 3-15: Brain-derived neurotrophic factor levels in saline- and nicotine- 
treated mice undergoing different exercise regimes.
Total brain-derived neurotrophic factor (BDNF) levels from acid-treated samples were 
determined using an enzyme-linked radioimmunoassay for nicotine- and saline-treated mice 
undergoing 0, 2 or 24 hrs/day running wheel access. Data are presented as mean ± standard 
error of the mean. Two-way ANOVA found no significant effects. Abbreviations: Hip, 
hippocampus; RFC, prefrontal cortex; Str, striatum.
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3.5 Discussion
The present study demonstrated that exercise reduced the severity of nicotine 
somatic withdrawal symptoms compared with sedentary mice, with concurrent 
elevated oc7 nAChR binding in the hippocampus. In addition, plasma corticosterone 
levels were elevated following chronic nicotine treatment. Together, these results 
support that exercise may be useful as an intervention to aid smoking cessation by 
reducing withdrawal symptom severity and propose that this may be mediated by a 
mechanism involving regulation of central nAChRs involved in cognition.
a7 nAChR binding was upregulated in nicotine-treated animals, irrespective of 
exercise regime, in several regions including the CAl of the hippocamous, amygdala, 
and hypothalamic nuclei. These results are consistent with other studies that have 
identified a7 upregulation in animal models. For example, Pauly e ta l  (1991) found 
a7 nAChR upregulation following 10 days of nicotine treatm ent at similar doses to 
those used in this study. In addition, Metaxas etal. (2013) identified a? upregulation 
in the same regions as the present study, as well as in the frontal association and 
cingulate cortices, also after 14 days nicotine treatment.
Several human studies have demonstrated that exercise may be beneficial in reducing 
nicotine withdrawal and cravings (for reviews see Haasova, e ta l ,  2013; Taylor, etal,  
2007; see also Chapter 2 of this thesis). In addition, exercise has recently been shown 
to reduce craving in a rodent model of nicotine withdrawal. During the course of the 
work presented in this thesis Sancehz etal. (2013) published a study examining the 
effect of exercise during abstinence on nicotine-seeking in rats. Following 15 days 
self-administration of 5 or 10 pg/kg nicotine, rats were provided with 2 hrs/day 
access to running wheels that were either locked or unlocked during 10 days 
abstinence from nicotine. Wheel running attenuated nicotine-seeking within the 
extinction period following abstinence, but did not affect nicotine-reinstatement. 
Together with the current study, this suggests that exercise may reduce acute 
withdrawal and nicotine craving, but would not reduce cue-induced reinstatem ent of 
smoking behaviour. However, rats in this study only had 2 h rs/day  access to running 
wheels during abstinence; the effect of exercise prior to, or concurrent with, nicotine 
administration, and the effect of unrestricted exercise on the severity of withdrawal 
symptoms, are still unknown. In addition, Sanchez etal. (2013) do not explore any
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biochemical correlates that may help to elucidate the underlying mechanisms of how 
exercise may mediate nicotine withdrawal.
The present study found that both 2 and 24 hrs/day running wheel access reduced 
withdrawal severity in chronically nicotine-treated mice, and that there was no 
difference between the two exercise regimes in the extent to which they had this 
effect. Several recent studies investigating the effect of exercise on withdrawal and 
relapse for other drugs of abuse have found similar results. A variety of exercise 
protocols, including 1 or 2 hrs/day treadmill running during abstinence [Thanos, et 
al, 2013), 6 h rs/day  wheel access prior to drug administration [Zlebnik, e ta l,  2010) 
and free wheel running prior to and concurrent with drug administration [Smith, et 
al, 2012), were all found to reduce cocaine-primed or cue-induced reinstatement. In 
addition, free wheel running reduced morphine withdrawal symptom severity and 
anxiety-like behaviours in withdrawal [Miladi-Gorji, et al, 2012) and attenuated 
depressive-like behaviours following ethanol treatm ent (Brocardo, et al, 2012). 
However, there are indications that exercise itself may be anxiogenic; 3 weeks 
voluntary wheel running in C57B1/6 mice induced anxiety-, but not depressive-like, 
behaviours as well as increased corticosterone metabolites in faeces (Fuss, et al, 
2010). Given that nicotine administration and withdrawal may also modulate anxiety­
like behaviours (Cohen, e ta l ,  2013; Hofmann, e ta l ,  2013; Hsu, e ta l ,  2007), future 
research should assess the effect of exercise on anxiety-like behaviour in nicotine 
withdrawal.
A possible mechanism by which exercise may mediate nicotine withdrawal is through 
modulation of the a7 nAChR. Indeed, mice lacking the a7 receptor demonstrate 
reduced MLA- and MEC-precipitated somatic withdrawal symptoms (Naylor, et al, 
2005), in addition to reduced anxiety (Paylor, et al, 1998; Tritto, et al, 2004) and 
cognitive performance (Pons, et al, 2008). The present study found elevated a7 
nAChR binding in the CAl/2 and 3 regions of the hippocampus of nicotine-withdrawn 
exercising mice, concurrent with reduced nicotine withdrawal severity. Further, 
varenicline, an a7 nAChR full agonist, has been found to attenuate contextual fear 
conditioning during nicotine withdrawal (Raybuck, et al, 2008). This evidence 
suggests that a7 upregulation in the hippocampus may underlie the beneficial effects 
of exercise in nicotine withdrawal. a7 receptors are also associated with
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glutamatergic signalling in the CAl/2 regions of the hippocampus (Lozada, et al, 
2012; Mura, et al, 2012), while nicotine withdrawal causes decreased glutamate 
release and exposure to nicotine cues stimulates the release of mesolimbic glutamate 
leading to cue-induced relapse [Kalivas & O'Brien, 2008). Extinction learning theory 
(Myers, e ta l ,  2011) posits that it may be possible to prevent relapse through the use 
of increased glutamate transmission in combination with attempting to replace 
memories linking cues to smoking with non-smoking memories.
Given the localisation of a? upregulation within the hippocampus of nicotine-treated 
exercising animals it is possible that exercise may be inducing this effect through 
BDNF, as in cultured hippocampal neurons BDNF has been shown to upregulate a7, 
but not p2*-containing, nAChRs (Massey, et al, 2006; Zhou, et al, 2004). Voluntary 
wheel running for three weeks in C57B1/6 mice has been associated with increased 
hippocampal neurogenesis and BDNF (Fuss, e ta l ,  2010), although the current study 
found no significant effect of wheel running or nicotine treatm ent on BDNF. While 
nicotine downregulates BDNF in the short-term (2 -  24 hrs), tolerance does develop 
leading to compensatory increases in BDNF after 7 days of nicotine treatm ent (Kenny, 
et al, 2000). It is therefore possible that 14 days of nicotine administration at a higher 
dose (0.5 mg/kg, i.p. vs. 24 m g/kg/day) may have induced tolerance sooner, allowing 
BDNF to return to control levels by the end of the present study. This result indicates 
that BDNF does not play a direct role in the mechanism underlying exercise as an 
intervention in nicotine addiction.
In saline-treated mice undergoing 2 or 24 hrs/day running wheel activity there was a 
region-specific upregulation of MOPr binding in the PAG, which was reversed by 
nicotine treatment. The PAG mediates various functions, including pain and anxiety 
(Linnman, e ta l ,  2012), therefore it is possible that MOPr mediates exercise-induced 
analgesia in the PAG. Exercise has been shown to decrease sensitivity to pain in 
humans (see Koltyn & Umeda, 2006), while in rats wheel running reduces the 
antinociceptive effects of morphine (Kanarek, e ta l ,  1998; Mathes & Kanarek, 2006; 
Smith & Lyle, 2006). Functional MRl scans have shown that running, but not walking, 
decreases PAG activity in response to pain (Scheef, et al, 2012). Transdural 
stimulation of the motor cortex in rats leads to the attenuation of inhibitory 
GABAergic signalling in the PAG (Pagano, e ta l,  2012). Further, the results in Chapter
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5 of this thesis show approximately 33% reduction of PH]DAMGO binding in MOPr 
cKO mice, indicating as much as a third of MOPr located in this region may mediate 
antinociception via modulation of GABAergic signalling. Altogether, the evidence is 
suggestive of MOPr involvement in the analgesic effect of exercise.
Exercise has previously been shown to upregulate DzRs in humans (Fisher, et al, 
2013) and rodents (Vucckovic, e ta l ,  2010), while in rodents there is also evidence 
that nAChRs and DzRs functionally interact (Grilli, et al, 2009; Quarta, et al, 2007); 
however, the present study found no change in DzR binding following either nicotine 
treatm ent or exercise. Vucckovic et al (2010) found DzR upregulation only in PD 
model mice, not in controls, indicating that exercise-induced upregulation only occurs 
in compensation for loss of DA tone. Therefore, there may not be any loss of DA tone 
in either nicotine-treated or exercising mice.
As discussed in Section 1.3.3 nicotine-induced a4p2* upregulation is a well- 
recognised phenomenon (see reviews by Govind, et al, 2009; Wonnacott, 1990). In 
the present study, a4(32* receptors were also upregulated in nicotine-treated animals 
compared with controls, particuarly in cortical areas. However, there was no 
difference in binding between any of the exercise regimes, indicating that a4(32* 
nAChRs, as well as DzR and MOPr, are not involved in the mechanism by which 
exercise mediates nicotine withdrawal. However, this does not exclude the possibility 
of downstream pathways being affected, for example, dopamine or opioid peptide 
release. Further studies, for example in vivo microdialysis to investigate DA release, 
would be required in order to investigate this question further.
Smokers have a higher basal level of cortisol than non-smokers (al'Absi, e ta l ,  2003; 
Field, et al, 1994; Kirschbaum, et al, 1992), while nicotine administration also 
enhances corticosterone release in animal models (Balfour, e ta l ,  1975; Yu & Sharp, 
2010). Similarly, the present study found that plasma corticosterone was elevated in 
nicotine- compared with saline-treated controls. Corticosterone levels were not 
affected by the exercise regime undertaken, indicating that exercise is unlikely to 
reduce withdrawal via alterations of the HPA axis.
In conclusion, this study suggests that wheel running in mice attenuated nicotine 
withdrawal severity, with no difference between the 2 or 24 hrs/day  exercise regimes
135
in terms of effectiveness. This mirrors human studies where high intensity exercise is 
no more beneficial in reducing withdrawal symptoms than moderate intensity (for 
review see Taylor, et al, 2007). In addition, a7 nAChRs were upregulated in the 
hippocampus of these mice, indicating that a7 receptors may play a role in mediating 
the biological mechanism underlying the effect of exercise on nicotine withdrawal. 
Further experiments are required in order to confirm causality between oc7 nAChRs 
and attenuated nicotine withdrawal following exercise, and the behavioural 
significance of a7 in mediating cognitive impairment in withdrawal.
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The effect of nicotine on 
nicotinic and oxytocin 
receptor binding in a 
mouse model of 
schizophrenia
137
CHAPTER 4. EFFECT OF NICOTINE ON NICOTINIC AND OXYTOCIN RECEPTOR 
BINDING IN A MOUSE MODEL OF SCHIZOPHRENIA
4.1 Introduction
This chapter describes collaborative work undertaken with the lab of Andreas 
Zimmer at the University of Bonn, Germany. Prof. Zimmer's lab characterised a model 
of schizophrenia using mice with a transgenic G72 protein (G72Tg), the behavioural 
phenotype of which is outlined below. My role was to map a number of neuronal 
receptors in the brains of these mice using autoradiography.
Schizophrenia is a brain disorder, or group of associated disorders, typically 
manifesting during adolescence or early adulthood and is characterised by 
hallucinations, delusions, impaired cognitive function and altered emotional response 
(American Psychiatric Association, 2013). Impaired cognitive functioning in 
schizophrenia may include deficits in sensory gating (Adler, e ta l ,  1998) and smooth 
pursuit eye movement (Olincy, et al, 1998), working memory (Gold, et al, 2006; 
Nuechterlein, e ta l ,  2008) and social cognition (Derntl & Habel, 2011).
Genome-wide association studies have implicated the G72/G30 gene locus (13q32- 
q34) in susceptibility to schizophrenia (for review see Drews, et al, 2012). G72 is a 
primate-specific gene encoding the LG72 protein in humans, and a truncated form in 
non-human primates. The G72 protein regulates the activity of D-amino acid oxidase 
(DAOA) in oxidising o-serine, an activator of the NMDA glutamate receptor 
(Chumakov, e ta l ,  2002). G72 was originally thought to activate DAOA (Chumakov, et 
al, 2002), but more recently has been shown to negatively modulate it (Sacchi, eta l,  
2008). In both cases, there is thought to be an end result of hypofunctionality of 
glutamatergic signalling. Abnormalities in the glutamatergic system, particularly in 
the prefrontal cortex, have been associated with schizophrenia pathophysiology (for 
reviews see Ad ell, e ta l,  2012; Olney & Farber, 1995). Specifically, Mohn e ta l  (1999) 
found that transgenic mice expressing only 5% of normal NMDA receptor levels 
displayed behavioural abnormalities similar to those characterised in schizophrenia.
Converging lines of evidence indicate that nAChRs play a significant role in the 
pathophysiology of schizophrenia; smoking prevalence among schizophrenics is 74- 
92%, compared with 35-54% for all psychiatric patients and 20% for the general
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population (for review see Adler, e ta l ,  1998). Smoking behaviour has been found to 
be symptomatic of schizophrenia, as well as potentially predictive of the disorder 
(Levin, et al, 2006). Decreased levels of a7 nAChRs in the frontal cortex and 
hippocampus have been found in the post-mortem brains of schizophrenics (Court, et 
al, 1999; Freedman, e ta l ,  1995; Guan, e ta l,  1999; Marutle, e ta l ,  2001), while there 
are lower levels of high-affinity nAChR binding in the brains of schizophrenic 
smokers compared with control smokers (Breese, et al, 2000). Nicotine has been 
shown to transiently ameliorate deficits in attention (Dépatie, e ta l ,  2002; Harris, et 
al, 2004), working memory (Nuechterlein, e ta l ,  2004) and sensory gating (Adler, et 
al, 1998; Olincy, et al, 1998) of schizophrenic patients, which are associated with 
these cholinergic systems (Leonard, et al, 2000). In accordance, the P50 auditory 
sensory gating deficit has been located on chromosome 15ql3-14, an area which 
includes the a7 subunit gene (Leonard & Freedman, 2006). Therefore, these studies 
suggest that schizophrenics may smoke in order to self-medicate (Glassman, 1993; 
Kumari & Postma, 2005).
The psychopathology of schizophrenia involves deficits in social cognition, including 
impairments in social recognition, emotional interpretation, empathy and mental 
state attribution (Green & Leitman, 2008). Research into the underlying mechanisms 
of these deficits has implicated abnormalities of the oxytocinergic (OTergic) system, 
which is known to be important in mediating social perception. Oxytocin (OT) is a 
neurohypophysial peptide hormone synthesised in the paraventricular (PVN) and 
supraoptic nuclei (SON) of the hypothalamus, and has been shown to play a role in 
mediating maternal behaviour, pair-bonding and stress-related behaviour (Gimpl & 
Fahrenholz, 2001), but more recently has been described as mediating the link 
between social cues, cognition and behaviour (Stoop, 2012). Moreover, reduced levels 
of plasma OT have been found in schizophrenic patients with delusions compared 
with controls (Walss-Bass, e ta l ,  2013). While central OT levels do not differ between 
male schizophrenics and controls, there was a negative correlation between central 
OT and negative symptoms in patients (Sasayama, et al, 2012). Similarly, higher 
peripheral OT was associated with attenuated positive symptoms in women. In 
addition, several OT receptor (OTR) SNPs have been connected with increased 
severity of various symptoms. For example, patients with the SNP rs2254298 score 
higher on the positive and negative symptoms scale, while rs53576 and rs237885 are
139
associated with more severe general psychopathology and negative symptoms, 
respectively. These studies provide evidence that OT levels and OTR gene variants 
may be involved in the underlying psychopathology of schizophrenia, indicating the 
OTergic system as a possible target for pharmacotherapy in schizophrenia.
Recent clinical studies have demonstrated that OT treatm ent may ameliorate some of 
the social deficit symptoms of schizophrenia. Feifel e ta l  (2010) found that use of an 
intranasal oxytocin spray reduced residual positive and negative symptoms in 
patients already being treated with an anti-psychotic drug over a three week period. 
In agreement, Fischer-Shofty et al (2013) demonstrated that a single dose of OT 
increased performance in an interpersonal perception task. These studies indicated 
that OT may be effective in treating social deficits in schizophrenia.
Preclinical studies have shown that administration of drugs such as cocaine, 
morphine and alcohol reduce central OT levels, while treatm ent with exogenous OT 
inhibits self-administration and prevents priming- and stress-induced relapse to drug 
seeking (for review see McGregor & Bowen, 2012). Similarly, simultaneous prenatal 
treatm ent of rats with alcohol and nicotine decreased OT levels (McMurray, et al, 
2008) and increased OTR binding (Williams, et al, 2009) compared with control 
animals. In addition, a review of Phase I and II clinical trials (Miyamoto, e ta l ,  2013) 
found that both a? agonists and OT may reduce social and cognitive deficits in 
schizophrenia. Therefore, nicotine may improve social and cognitive deficits in 
schizophrenia via a mechanism involving both the OTergic and nicotinic systems.
A transgenic mouse model of schizophrenia was recently described, where an 
artificial chromosome containing the G72/G30 locus was integrated into the mouse 
genome (Otte, et al, 2009). Crucially, these G72Tg mice demonstrate several 
schizophrenic phenotypes, including impaired locomotor function, deficits in 
prepulse inhibition and smell recognition and increased compulsive behaviours. As 
outlined previously, behavioural phenotyping of nicotine- and saline-treated WT and 
G72Tg mice was carried out in the lab of Prof. Andreas Zimmer (University of Bonn). 
Briefly, nicotine reduced working memory (Y-maze), social recognition (three- 
chambered box) and prepulse inhibition (acoustic startle response) in WT animals, 
but reversed deficits in these measures caused by G72 expression (Boris Hambsch, 
personal communication, 2012). G72 expression adversely affected spatial learning
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(Morris Water Maze), an effect exacerbated by nicotine treatment. However, G72 
expression protected against nicotine-induced impairment of associative learning 
(operant conditioning). These results suggest that while nicotine had detrimental 
effects in control mice, it was largely protective in the G72 model of schizophrenia.
The molecular mechanisms underlying these effects remain to be elucidated. Hence, 
the present study aimed to determine the effect of chronic nicotine on nAChR and 
OTR binding in wildtype and G72Tg mice, as it was hypothesised that smoking might 
be used to self-medicate the cognitive symptoms of schizophrenia by modulating the 
expression of nAChRs and OTRs. Therefore, we hypothesise that G72Tg insertion will 
affect nAChR and OTR binding and that this effect will be mediated by nicotine 
treatment.
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4.2 Materials and Methods
4.2.1 Animals
Brain sections from female heterozygous G72Tg transgenic mice on a GDI 
background and WT mice were provided by Andreas Zimmer's lab at the University of 
Bonn. As the behavioural effects of nicotine in these mice were more pronounced in 
female mice, autoradiography was undertaken for samples from female mice only. 
Animals were surgically implanted with subcutaneous Alzet® osmotic minipumps 
(Model 2002, Charles River GmBH, KiRlegg, Germany) infusing (-)-nicotine hydrogen 
tartrate salt (24 m g/kg/day freebase; Sigma, St Louis, MO, USA) in saline (0.9% w/v), 
or saline alone for 14 days. After chronic treatment, mice underwent a series of 
behavioural tests as described above. Mice were killed by cervical dislocation before 
brains were removed and stored at -80°C. 20 pm brain sections were provided cut at 
300 pm intervals using a Microm HM505E cryostat (Carl Zeiss, MICRO Laborgerate, 
GmbH, Waldorf, Germany). Animal work was carried out in accordance with German 
and EU regulations (European Communities Council Directive 86/609/EEC) and was 
approved by local authorities (file-no.87-51.04.2010.A070).
4.2.2 Quantitative receptor autoradiography
Quantitative autoradiography was performed on WT and Tg nicotine- and saline- 
treated mice in order to measure binding of a4(32* and a7 nAChRs and OTRs. On the 
day of the experiment, sections were thawed and processed according to established 
protocols (Besson, e ta l ,  2007; Jarrett, e ta l ,  2006; Metaxas, e ta l ,  2010; Metaxas, et 
al, 2012; Orr-Urtreger, e ta l ,  1997), with minor modifications. Sections for analysis 
were derived from four to six brains from each of the four treatm ent groups (n=8-9). 
Multiple, adjacent sections from all groups were processed together in a paired 
binding protocol.
a4(32* and a7 nAChR binding, film exposure, development and analysis was carried 
out as described in Chapter 3. For OTR binding, slides were pre-incubated twice for 
10 mins in 50 mM Tris-HCl, pH 7.4, at room temperature. Binding was carried out in 
50 mM Tris-HCl, 0.1% BSA and 0.05% bacitracin, pH 7.4 at room temperature, in the 
presence of 50 pM ornithine vasotocin analogue (OVTA; specific activity 2200 
Ci/mmol) for 2 hrs. NSB was determined in adjacent sections in the presence of 50 
pM oxytocin for 2 hrs. Incubations were terminated by rinsing slides in ice-cold (4°C)
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rinse buffer containing 50 mM Tris-HCl buffer and 10 mM MgCh, pH 7.4, three times 
for 5 mins each, and then 30 mins in circulating rinse buffer, followed by a final 2 sec 
rinse in RO water. [^^ sijqvTA bound sections were exposed to film for 72 hrs with a 
set of i^C microscale standards which had been cross-calibrated to iodinated 
standards (Baskin & Wimpy, 1989; Miller & Zahniser, 1987). Images were analysed 
using MCID software as described in Chapter 3.
4.2.3 Statistical analysis
Data are presented as mean ± SEM and were analysed using Statistica (STATsoft, Inc., 
version 10). Three-way ANOVA for the factors Treatment, Genotype, Brain Region 
and interactions was used for comparison of cytisine-sensitive [^^^Ijepibatidine, total 
[i25i]a-Bgtx and total P^^ljOVTA binding. This was followed by two-way ANOVA for 
each brain region with Duncan's post-hoc test to investigate differences in radioligand 
binding between groups in individual brain regions. Two-way ANOVA for factors 
Treatment, Genotype and Treatment x Genotype interactions was used for 
comparison of cytisine-resistant and cytisine-sensitive [^^^Ijepibatidine binding.
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4.3 Results
4.3.1 Effect of nicotine on a4p2* nAChR binding in WT and G72Tg mice
Cytisine-sensitive [i^sjepibatidine binding was used to determine a4p2* binding in 
WT and G72Tg mice (Figure 4-1). For control, cytisine-resistant and -sensitive 
binding was compared using two-way ANOVA, and shown to be equal only in the 
medial habenula and the interpenduncular nucleus; therefore, detection of other 
nAChR subtypes was restricted to those regions. Non-specific binding was 
indistinguishable from background.
a4p2* binding was upregulated in nicotine-treated animals compared with saline 
controls, irrespective of genotype, particularly in cortical and thalamic regions. 
Three-way ANOVA revealed a significant effect of Treatment (F(i,7i9)=75.51, p<0.001) 
and Treatment x Region interaction (F(si, 82S)=1.47, p<0.05). Two-way ANOVA 
followed by Duncan's post-hoc test for each brain region found significant differences 
between treatm ents within the same genotype (Figure 4-2). a4p2* binding was 
upregulated in the vertical diagonal band (p<0.001), hypothalamus (p<0.0) and 
cortical regions, including the frontal association, prelimbic, primary and secondary 
motor, somatosensory, piriform and auditory cortices (all p<0.001), cingulate, 
piriform and visual cortices (p<0.01) and the retrosplenial cortex (p<0.05). a4p2* 
binding was reduced in G72Tg mice in the interpenduncular nucleus only (p<0.05), 
irrespective of treatment. While in WT mice nicotine significantly upregulated a4p2* 
binding in the medial septum (p<0.001), olfactory tubercle (p<0.01) and the posterior 
and lateral dorsal thalamic nuclei (p<0.05) in Tg mice this upregulation was not 
significant. There was no significant difference in binding in other regions expressing 
a4p2* receptors. These data indicate that chronic nicotine treatm ent significantly 
upregulates a4p2* binding in many brain regions, irrespective of genotype; however, 
this may be impaired by G72 expression in some areas.
The levels of cytisine-sensitive [i^sjjepibatidine binding measured in saline-treated 
mice in the present study are comparable to those recorded in other studies for 
saline-treated C57B1/6 male mice (Metaxas, e ta l ,  2010; Metaxas, e ta l ,  2012; Pauly, 
et al, 1991).
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Figure 4-1: Representative autoradiograms of a4p2* nAChR binding following 
saline or nicotine treatment in wild type and transgenic mice.
Computer enhanced colour autoradiograms of total and cytisine-resistant [i25i]epibatidine 
binding in coronal brain sections of C57B1/6 WT and G72Tg mice treated with chronic saline 
or nicotine (24 mg/kg/day) via subcutaneous minipumps for 14 days. Coronal brain sections 
are shown cut at the level of the frontal association (FrA; Bregma 1.98), caudate putamen 
(CPu; Bregma 1.10 mm), hippocampus (Hip; Bregma -1.46 mm), substantia nigra (SN; 
Bregma -3.40 mm) and the interpeduncular nucleus (IPn; Bregma -3.64 mm). Specific «4(32* 
binding was determined by subtracting 20 nM cytisine-resistant binding (B) from total 100 
pM [i25i]epibatidine binding (A). Adjacent sections were incubated with 300 pM (-) nicotine 
hydrogen tartrate to calculate non-specific binding (NSB) (C), which was indistinguishable 
from background. Sections were apposed to Kodak BioMax MR-1 film for a period of 24 hrs. 
The calibration bar presents pseudo-colour interpretation of black and white film images in 
fmol/mg tissue equivalent.
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Figure 4-2: Cytisine-sensitive [i^sijepibatidine binding in saline- and nicotine- 
treated wild type and transgenic mice.
Cortical (A) and non-cortical (B) regions from brain sections of saline- and nicotine-treated 
wild type and G72 transgenic mice were bound with [i^sjjepibatidine and cytisine. Cytisine- 
sensitive binding was determined by subtracting cytisine-resistant binding from total 
epibatidine binding. Data are presented as mean ± standard error of the mean. Three-way 
ANOVA found a significant effect of Treatment (p<0.001) and Treatment x Region interaction 
(p<0.05). Two-way ANOVA for each brain region followed by Duncan's post-hoc test: *p<0.05, 
**p<0.01, ***p<0.001 vs. saline within the same genotype. Abbreviations: AcbC, nucleus 
accumbens core; AcbSh, nucleus accumbens shell; AuCx, auditory cortex; AV, 
anteroventricular thalamic nuclei; CgCx, cingulate cortex; CPu, caudate putamen; DG, dentate 
gyrus; DLG, dorsal geniculate nucleus; fr, fasiculus retroflexus; FrA, frontal association; Hip, 
hippocampus; Hyp, hypothalamus; InG, intermediategrey layer of the superior colliculus; IPn, 
interpeduncular nucleus; LD: laterodorsal thalamic nuclei; Ml, primary motor cortex; M2, 
secondary motor cortex; MHb, medial habenual; MS, medial septum; Pir, piriform cortex; Po, 
posterior thalamic nuclei; PrL, prelimbic cortex; RS, retrosplenial cortex; S, subiculum; SN, 
substantia nigra; SsCx, somatosensory cortex; SuG, superficialgrey layer of the superior 
colliculus; Tu, olfactory tubercles; VDB, vertical diagonal band; ViCx, visual cortex; VLG, 
ventral medial geniculate; VTA, ventral tegmental area.
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4.3.2 Effect of nicotine on a7  nAChR in WT and G72Tg mice
p25](x-Bgtx was used to determine a7 nAChR binding in WT and G72Tg mice (Figure 
4-3). Non-specific binding was homogenous across each brain section; see Figure 4-4. 
a7 binding was elevated in G72Tg mice within the same treatm ent group in selected 
regions.
Three-way ANOVA revealed a genotype effect on a? binding (F(i,478j=3.33, p<0.001). 
Two-way ANOVA for each brain region followed by Duncan's post-hoc confirmed 
significant differences between WT and G72Tg mice in specific regions. G72 
expression significantly increased a7 binding in the dorsal endopiriform nucleus 
(F(i,30)=5.73, p < 0 .0 1 ) ,  ventral medial geniculate (F(i,24)=4.46, p<0.05) and the CAl 
region of the hippocampus (F(i,25)=4.30, p<0.05). In addition, nicotine treatm ent 
upregulated a7 nAChR binding in the dentate gyrus (F(i,28)=5.08, p<0.05) and 
ventromedial hypothalamus (F(i,2S)=8.34, p<0.01) of G72Tg mice only. Conversely, 
chronic nicotine treatm ent prevented a7 upregulation in the CgCx (F(i,28)=4.42, 
p<0.05) and basomedial amygdala (F(i,22]=6.87, p<0.05) of saline-treated G72Tg mice. 
There was no significant difference in binding in other regions expressing a7 
receptors. These data indicate that G72 expression may aid a7 upregulation in 
specific regions, especially in the dentate gyrus and CgCx.
In accordance with a7 levels in other papers, binding ranges from 14 fmol/mg in the 
CgCx to 82 fmol/mg in the dDG were similar to values found in other studies 
published previously both by our lab (Metaxas, e ta l ,  2013; Metaxas, e ta l ,  2012) and 
others (Pauly, et al, 1991), and in particular the levels of a7 binding found in the 
Hippocampus: 22-45 fmol/mg in our paper, 12 fmol/mg (Svedberg, e ta l ,  2002) 45 
fmol/mg (Marks, e ta l ,  2006).
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Figure 4-3: Representative autoradiograms of [^^sija-bungarotoxin binding 
following cbronic saline or nicotine treatment in wild type (WT) and transgenic 
(Tg) mice.
Computer enhanced autoradiograms of total [i2si]a-bungarotoxin and non-specific [NSB] 
binding in coronal brain sections of C57B1/6 WT and G72Tg mice treated with chronic saline 
or nicotine [24 mg/kg/day) via subcutaneous minipumps for 14 days. Coronal brain sections 
are shown cut at the level of the caudate putamen [CPu; Bregma 1.10 mm), hippocampus 
[Hip; Bregma -1.46 mm) and the substantia nigra [SN; Bregma -3.40 mm). Brain sections 
were incubated for 3 hrs with 3 nM [i^sijoc-bungarotoxin. Adjacent sections were incubated 
with 1 mM [-)-nicotine hydrogen tartrate to calculate NSB, which was homogenous across 
sections. Sections were apposed to Kodak BioMax MR-1 film for a period of 7 days. The 
calibration bar presents a coloured interpretation of black and white film images in fmol/mg 
tissue equivalent.
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Figure 4-4: [i^sycc-bungarotoxin binding in saline- and nicotine-treated wild 
type and transgenic mice.
Brain sections from saline- and nicotine-treated wild type and transgenic mice were bound 
with [i25i]a-bungarotoxin. Data are presented as mean ± standard error of the mean. Three- 
way ANOVA found a significant effect for the factor Genotype (p<0.001]. Two-way ANOVA for 
each brain region followed by Duncan's post-hoc test showed significant differences between 
wild type and transgenic mice (*p<0.05, **p<0.01). Abbreviations: BLA, basolateral amygdala; 
BMA, basomedial amygdala; CgCx, cingulate cortex; CPu, caudate putamen; CAl, nucleus of 
the hippocampus; CA2/3, nucleus of the hypothalamus; Cl, claustrum; DEn, dorsal 
endopiriform nucleus; DG, dorsal dentate gyrus; DM, dorsomedial hypothalamus; FrA, frontal 
association; InG, intermediategrey layer of the superior colliculus; LH, lateral hypothalamus; 
Ml, primary motor cortex; SuG, superficialgrey layer of the superior colliculus; VLG, ventral 
medial geniculate; VMM, ventromedial hypothalamus; Zl, zona incerta.
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4.3.3 Effect o f nicotine on oxytocin binding in WT and G72Tg mice
[125] OVTA was used to determine OTR binding in WT and G72Tg mice (Figure 4-5). 
OTR binding was only found to be altered in the CgCx (Figure 4-6); two-way ANOVA 
found a significant interaction of genotype and treatm ent (F(i,22)=4.36, p<0.05). 
Duncan's post-hoc test found a significant increase in saline-treated G72Tg mice 
compared with WT controls (p<0.05), which was reversed by nicotine treatm ent in 
the Tg mice (p<0.05). The level of [^^^sjoy^A binding in the present study was similar 
to that in other studies (Jarrett, eta l ,  2006; Zanos, e ta l ,  2013a; Zanos, e ta l ,  2013b).
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Figure 4-5: Representative autoradiograms of [i^sijoVTA binding following 
chronic saline or nicotine treatment in wild type and transgenic mice.
Computer enhanced colour autoradiograms of total [i25i]0VTA binding in coronal brain 
sections of C57B1/6 WT and G72Tg mice treated with chronic saline or nicotine [24 
mg/kg/day] via subcutaneous minipumps for 14 days. Coronal brain sections are shown cut 
at the level of the olfactory nuclei [AOL; Bregma 2.46 mm], cingulate cortex [CgTx; Bregma 
0.86 mm] and hippocampus (Hip; Bregma -2.06 mm]. Brain sections were incubated for 2 hrs 
with 50 pmol psijoVTA. Adjacent sections were incubated with 50 pM oxytocin to calculate 
non-specific binding (NSB], which was homogenous across sections. Sections were apposed 
to Kodak BioMax MR-1 film for a period of 72 hrs. The calibration bar presents an 
interpretation of black and white film images in fmol/mg tissue equivalent.
152
g
I
Iu
II
.E
8i
6 -
4-
2 -
□  W TSal[n=6-8)
■ I  WT Nic [n=5-9)
i
Tg Sal (n=4-7]
TgNic [n=3-7)
uyBoii
A
Figure 4-6: [i^sjjoVTA binding in saline- and nicotine-treated wild type and 
transgenic mice.
Brain sections from saline- and nicotine-treated wild type and transgenic mice were bound 
with [1251] OVTA. Data are presented as mean ± standard error of the mean. Two-way ANOVA 
for each brain region followed by Duncan's post-hoc test showed significant differences 
between wild type and transgenic mice within the same treatment group (*p<0.05) and 
between saline- and nicotine-treated mice within the same genotype [**p<0.05). 
Abbreviations: Acb, nucleus accumbens; AOM, medial anterior olfactory nucleus; AOL, lateral 
anterior olfactory nucleus; AOV, ventral anterior olfactory nucleus; BLA, basolateral 
amygdala; BLP, posterior basolateral amygdala; BMP, posterior basomedial amygdala; CgCx, 
cingulate cortex; CPu, caudate putamen; CA2/3, nucleus of the hypothalamus; DEn, dorsal 
endopiriform nucleus; dDG, dorsal dentate gyrus; Hyp, hypothalamus; LEnt, lateral entorhinal 
cortex; LS, lateral septum; MHb, medial habenula; MS, medial septum; Th, thalamus; Tu, 
olfactory tubercles; VDB, ventral diagonal band.
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4.4 Discussion
In the present study, insertion of G72 altered nAChR and OTR binding in specific 
regions of G72Tg mice compared with WT, In addition, nicotine reversed several 
cognitive deficits in the G72Tg mouse model of schizophrenia, but had detrimental 
effects in WT mice [Boris Hambsch, personal communication, 2012). Together, these 
results support the beneficial effect of nicotine on cognition in schizophrenia, and 
propose that this may be mediated by a mechanism involving regulation of central 
nAChRs and OTRs.
Various studies have identified links between a7 expression and schizophrenia 
related cognitive deficits [Levin, 2012). However, the exact relationship between 
schizophrenia and nAChRs is not clear. A number of studies have identified decreased 
a7 nAChR binding in the post-mortem brains of schizophrenics [Court, et al, 1999; 
Freedman, et al, 1995; Guan, é ta l ,  1999; Marutle, et al, 2001), while the a7 receptor 
gene locus on chromosome 15ql3-14 is also associated with schizophrenia [for 
review see Leonard & Freedman, 2006). However, the sample sizes for these studies 
were fairly small with some large variability in the data, somewhat reducing the 
validity of conclusions, while some more recent studies have failed to replicate these 
findings. For example, in a larger sample size study, Thomsen e ta l  [2011) found no 
difference in a7 nAChR binding between schizophrenic smoker and control brains. In 
the present study, nicotine differentially affected a7 binding in G72Tg mice; increased 
levels of a7 binding were observed in the ventral medial hypothalamus and dentate 
gyrus of G72Tg nicotine-treated mice compared with WT, yet in the CgCx and 
basolateral amygdala nicotine blunted the a7 upregulation seen in saline-treated 
G72Tg mice. Evidence from previous studies supports a7 nAChR involvement in the 
beneficial effects of nicotine in schizophrenia; a7 agonists, such as DMXB-A [3-[-2,4- 
dimethoxybenzyIidene)-anabaseine) [Kem, 2000; Olincy, et al, 2006), have been 
shown to be effective at ameliorating neuropsychiatrie symptoms and P50 gating 
deficits. Indeed, in non-schizophrenic model rodents the a7 agonist AR-R 17779 has 
been found to increase social recognition performance [Kampen, et al, 2004), while 
varenicline, an a4(32 partial agonist with some activity at a7 nAChRs as well that is 
already prescribed clinically for smoking cessation, has been shown to reduce 
nicotine withdrawal-induced learning deficits [Raybuck, e ta l ,  2008). A meta-analysis 
of studies on varenicline treatm ent in schizophrenia found that the drug was not
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detrimental to psychiatric symptoms, however, beneficial effects were still to be 
determined (Cerimele & Durango, 2012). These studies suggest that cognitive deficits 
in schizophrenia may occur through an a7-mediated mechanism, indicating a7 
agonists as a possible treatm ent regime for these symptoms.
Nicotine blunted the upregulation of a7 binding in the CgCx observed in saline- 
treated G72Tg mice compared with WT. The CgCx is associated with learning, 
decision making and error detection (see Behrens, et al, 2009; Shackman, et al,
2011) and there is a high incidence of pathology in schizophrenic post-mortem 
brains, in the cingulate, as well as other cortical areas (Smieskova, e ta l ,  2010). Hong 
et al (2009) found that severity of nicotine dependence was positively associated 
with activity of the dorsal anterior CgCx, whilst acute nicotine treatm ent was 
associated with increased cingulate-neocortical functional connectivity, thought to 
play a role in nicotine's cognitive enhancing effects in schizophrenia. Within the CgCx, 
a7 nAChRs are found on GABAergic interneurons (Timofeeva & Levin, 2011), 
therefore increased inhibition via augmented a7 signalling may be involved in the 
cognitive deficits found in schizophrenia.
Hippocampal a7 activity is associated not only with learning and memory, but with 
improved cognitive performance (see Levin, 2012). The present study found an 
elevated level of a7 nAChR binding in the dentate gyrus of nicotine-treated G72Tg 
mice compared with WT controls, but not in saline-treated mice. Similarly, Mexal et 
al (2010) found increased a7 mRNA and protein levels in the hippocampus of 
schizophrenic smokers compared with non-smoking patients and control smokers. 
This evidence suggests that upregulation of hippocampal a7 nAChRs may underlie 
the beneficial effect of nicotine on cognitive performance in G72Tg mice via a 
mechanism involving interaction with NMDA receptors. Specifically, schizophrenics 
show decreased adult neurogenesis in the dentate gyrus, a symptom associated with 
impaired pattern recognition (for review see Tamminga, e ta l ,  2010). There is also a 
selective decrease in NRl (NMDA receptor subunit) mRNA in the dentate gyrus in 
schizophrenia, resulting in reduced glutamate signalling (see Tamminga, e ta l ,  2010); 
as previously discussed (Section 4.1), the G72 protein is involved in regulating NMDA 
receptor activity (Chumakov, et al, 2002). Presynaptic a7 nAChRs are known to 
mediate glutamate release in various regions, including hippocampal nuclei
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(Mansvelder & McGehee, 2002b). In support of nicotine-NMDA interactions, Kenny et 
al (2008) found that nicotine self-administration upregulated NMDA receptor 
subunit expression in the amygdala of rats. Furthermore, a7 nAChRs are highly Ca^ + 
permeable, especially in comparison to other nAChR subtypes (Séguéla, e ta l ,  1993). 
As calcium signalling is thought to mediate memory and sensory processing (Adler, et 
al, 1998; Timofeeva & Levin, 2011), it is possible that a7 nAChRs may play a major 
role in the beneficial effects of nicotine on cognition in G72Tg mice.
In contrast to a7, there was a genotype independent upregulation of a4(32* binding; 
upregulation of these receptors was found in cortical areas of both WT and G72Tg 
mice, including the CgCx. This upregulation was expected in WT mice as nicotine- 
induced upregulation of the a4(32* subtype has been well characterised (for review 
see Govind, et al, 2009), and G72 insertion does not appear to affect this 
upregulation. This is in accordance with the behavioural tests that show a genotype- 
independent reduced performance in the Morris Water Maze model of spatial 
learning.
It is possible that chronic nicotine administration has adverse effects on cognition. 
Indeed, Sabia et al (2012) found mid- to old-age smokers had an accelerated 
cognitive decline compared with non-smoking counterparts; recent ex-smokers also 
had greater decline in executive function than never-smokers.
In saline-treated G72Tg mice there was a region-specific upregulation of OTR binding 
in the CgCx, which was reversed by nicotine treatment. In conjunction, nicotine 
reversed deficits in the social recognition test (three chambered box) seen in saline- 
treated transgenic mice. Generally, an increase in OT peptide is concomitant with 
desensitisation of OTRs and consequently decreased receptor binding (Evans, et al, 
1997). Therefore, it might be hypothesised that increased OTR binding is caused by a 
reduction in OT peptide levels. A decrease in OTergic signalling has been associated 
with social deficits such as those seen in schizophrenia (Green & Leitman, 2008). 
Indeed, several studies have demonstrated the beneficial effects of OT in treating 
social cognitive deficits of schizophrenia (Feifel & Shilling, 2010; Fischer-Shofty, etal,  
2013; see also Miyamoto, e ta l ,  2013). As previously mentioned in this discussion, the 
CgCx is associated with learning, error detection and decision making. Generalised 
social anxiety disorder patients exhibit heightened activity in the mPFC extending to
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the CgCx in response to images of sad faces, an effect reversed by OT to control levels 
(Labuschagne, et al, 2012). Nicotine has been shown to induce cFos activity in 
catecholminergic projections from the brain stem to the SON, specifically OTergic 
regions (Matta, e ta l ,  1993); limbic regions receiving catecholinergic inputs, such as 
the CgCx, showed a nicotine dose-dependent increase in cFos activity, suggesting a 
nicotine-induced increase in OTergic activity.
This suggests not only that OTergic dysregulation in the CgCx of G72Tg mice may at 
least partly underlie the social recognition deficits evident in these mice, but also 
presents the possibility that nicotine may help to ameliorate these symptoms through 
regulation of neuronal activity in the CgCx. Moreover, in a review of phase 1 and 11 
clinical trials Miyamoto et al (2013) proposed that adjunctive treatm ent with a7 
nAChR agonists and oxytocin may be of benefit.
Not only is there a higher prevalence of smoking among schizophrenics compared 
with the general population, but schizophrenics tend to be heavier smokers, 
obtaining more nicotine per cigarette (de Leon & Diaz, 2005). Similarly, the current 
study found that it was only the highest dose of nicotine tested that had any beneficial 
effects on cognition, indicating why schizophrenics have been found to smoke so 
heavily. Smoking is considered harmful to health in the general population (The 
Health and Social Care Information Centre, 2012), however, nicotine treatm ent may 
be beneficial for patients with certain mental health conditions. In conclusion, G72 
has been shown to mediate cognitive and molecular effects of nicotine treatment. In 
corroboration with existing research, nicotine has been implicated as beneficial for 
the treatm ent of schizophrenia and supports the hypothesis that schizophrenic 
patients may smoke in order to self-medicate.
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CHAPTER 5. LOCALISATION OF 6- AND |i-OPIOID RECEPTORS IN GABAERGIC 
NEURONS USING CONDITIONAL GENE KNOCKOUT MICE
5.1 Introduction
This chapter describes collaborative work undertaken with the lab of Brigitte Kieffer 
at the University of Strasbourg, France. Prof Kieffer's lab developed two new strains 
of mice, each with a conditional deletion of either Orpdl (DOPr) or Oprml (MOPr) in 
GABAergic forebrain neurons, the behavioural phenotypes of which are outlined 
below. My role was to map the OOP and MOP receptor binding in the brains of these 
mice using quantitative autoradiography.
MOP and OOP receptors have been localised to GABAergic neurons in various studies. 
For example, double-immunolabelling for GABA and MOPr was found in several brain 
regions, including the piriform and parietal cortices, hippocampus, striatum and 
thalamus in rats, in addition to co-localisation in the PAG of both rats and monkeys 
(Kalyuzhny & Wessendorf, 1998), suggesting the involvement of GABAergic neurons 
in opioid-mediated antinociception in primates as well as rodents (also see Chapter 3, 
Section 3.4 for further discussion of MOPr signalling in the PAG). However, Kalyuzhny 
& W essendorf (1998) did not identify any co-localisation of DOPr and GABA, in 
contrast to other studies that show DOPr expression on GABAergic neurons, 
particularly in the hippocampus (for example Bausch, et al, 1995; Commons & 
Milner, 1996,1997).
The phenotypes of constitutive DOPr and MOPr KO mice have been previously 
described. For example, constitutive DOPr KO mice demonstrate increased anxiety- 
and depressive-like behaviours (Filliol, et al, 2000). Following nicotine 
administration, DOPr KO mice show loss of CPP and reduced acquisition of self­
administration behaviour with subsequent attenuation of DA release in the Acb, but 
no change in somatic withdrawal, locomotion or tolerance to nicotine-induced 
antinociception (Berrendero, et al, 2012). Constitutive MOPr KO mice display an 
opposing phenotype to DOPr mice in terms of anxiety- and depressive-like 
behaviours (Filliol, e ta l ,  2000), as well as reduced nicotine-induced antinociception, 
CPP and somatic withdrawal (Berrendero, et al, 2002). These studies indicate that 
the MOPr mediates nicotine reward and somatic withdrawal symptoms, while the 
DOPr mediates emotional responses to nicotine.
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5.1.1 Characterisation of MOPr and DOPr conditional KO mice
A transgenic mouse model including conditional gene knockout (cKO) in targeted 
regions was recently proposed as the next step required in order to further map 
behavioural phenotypes to specific neuronal locations and receptors (le Merrer, etal,  
2009). Conditional deletion in defined regions enforces temporal and spatial 
limitations on the receptor being deleted, allowing specific neurons to be targeted. As 
outlined above, behavioural phenotyping of WT and cKO mice was carried out in the 
lab of Prof Brigitte Kieffer (Unversity of Strasbourg, France). The DOPr cKO mice 
displayed decreased anxiety-like behaviours (EPM and novelty-suppressed feeding 
test), the opposite phenotype to that found in constitutive DOPr KO mice. 
Correspondingly, c-fos expression was attenuated in the amygdala. Conditional 
deletion of Orpdl also blocked DOPr agonist-induced hyperlocomotion, indicating 
that DOPr on GABAergic forebrain neurons are required to mediate this effect. 
Compared with WT, MOPr cKO mice maintained the same level of morphine-induced 
analgesia (hot plate), physical dependence (naloxone-induced withdrawal) and 
morphine and heroin reward (CPP), indicating that MOPr located on GABAergic 
neurons are not involved in modulating morphine dependence. However, heroin- 
induced locomotion and sensitisation were reduced, as was ethanol consumption and 
preference (two-bottle choice). DiR agonist-induced locomotion was unchanged at 
lower doses, but increased at 5 mg/kg compared with WT mice. These data suggest 
that MOPrs located on forebrain GABAergic neurons play a role in mediating 
locomotor responses, possibly through DiR-mediated signalling.
The development of a strain of mice with conditional knockout of a receptor from 
specific neurons will be a useful, novel, tool for studying the neurochemistry of 
addiction; in particular, elucidating the role of the opioid system in nicotine addiction. 
As outlined in Chapter 1, Section 1.6.5, MOP and DOP receptors, and their respective 
endogenous ligands, play an important role in modulating the nicotine response. The 
aim of this study was, therefore, to map the remaining DOPr and MOPr binding using 
quantitative autoradiography as it was hypothesised that binding would be reduced 
or abolished in selected regions of their respective cKO strains.
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5.2 Materials and Methods
5.2.1 Animals
Mice with conditional and constitutive Oprdl or Oprml gene deletion were generated 
by Prof Brigitte Kieffer's laboratory (University of Strasbourg, France). Conditional 
KO mice were generated on a C57B1/6 background using MOPr or DOPr floxed mice 
(constitutive KO) crossed with mice expressing Dix 5/6-Cre in GABAergic forebrain 
neurons (manuscript in preparation, but see also Monory, e ta l ,  2006). There were no 
indications of quantitative differences in behavioural tests between males and 
females within all genotype groups; therefore data from both sexes was pooled.
5.2.2 Quantitative receptor autoradiography
5.2.2.1 Autoradiography o f  DOP and MOP receptors
Following decapitation, intact brains were removed, snap frozen at -20°C in 
isopentane and then stored at -80°C until sectioned. Adjacent sections were cut from 
WT (n=3), cKO (n=4) and constitutive KO (n=3) brains and spinal cords for 
determination of total binding for DOPr and MOPr opioid receptors using 
PH]deltorphin-l and PUJDAMGO, respectively. Samples were sectioned and 
prepared for binding as described previously (see Section 3.2.7.1).
MOPr binding was carried out as described in Section 3.2.7.1. For DOPr receptor 
binding, slides were pre-incubated for 30 mins in 50 mM Tris-HCl pre-incubation 
buffer, containing 0.9% w /v  NaOH, pH 7.4 at room temperature. The slides were then 
incubated in 50 mM Tris-HCl buffer, pH 7.4 at room tem perature in the presence of 7 
nM PH]deltorphin-l for 60 mins. Non-specific binding was determined in adjacent 
sections in the presence of 10 pM naloxone. Incubation was terminated by rapid 
rinses ( 3 x 5  mins) in ice-cold 50 mM Tris-HCl buffer, pH 7.4 at room tem perature and 
distilled w ater ( 3 x 5  mins). Slides were then rapidly cool-air dried. Sections were 
exposed to film for 6 weeks. Film exposure, development and analysis were carried 
out as detailed in Section 3.2.7.2 and 3.2.7.3.
5.2.3 Statistical analysis
Data are presented as mean ± SEM and were analysed using Statistica (STATsoft, Inc., 
version 10). Comparison of specific binding in WT and cKO mice was carried out
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using two-way ANOVA for the factors Genotype, Region and Genotype x Region 
interactions, followed where appropriate with Holm-Sidak multiple comparisons.
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5.3 Results
5.3.1 Effect o f genotype on S-opioid receptor binding
Representative autoradiographic images of DOPr density in WT, cKO and constitutive 
KG brain sections are shown in Figure 5-1. MCID analysis of constitutive KG samples 
confirmed genotype with complete DGPr deletion. There was a mean reduction of 
23% in cKG compared with WT mice. Changes in binding were observed throughout 
the brain, however the greatest reduction of binding was in the olfactory bulbs, with 
100% knockdown in cKG mice. Two-way ANGVA revealed significant effect of 
Genotype (F(i,444)=70.97), Region fF(5o,444)=10.98] and Genotype x Region interaction 
(F(50,444)=4.00); where p<0.001 in all cases. Holm-Sfdak multiple comparisons found a 
significant decrease of PH]deltorphin-l binding in cKG mice in the external plexiform 
(EPl) and internal granular layers (IGl) of the olfactory bulbs, lateral and medial CPu 
and olfactory tubercles (all p<0.001), AcbSh (p<0.01) and CA2/3 regions of the 
hippocampus (p<0.05). Specific binding levels for DGPr cKGs and WTs are shown in 
Table 5-1.
Representative autoradiographic images of DGPr density in WT, cKG and constitutive 
KG spinal cords are shown in Figure 5-2. MCID analysis of constitutive KG samples 
confirmed genotype with complete DGPr deletion. Two-way ANGVA revealed 
significant effect of Region only (F(4, 63]=5.49, p<0.001). There was no significant 
difference in receptor density between genotypes (Table 5-2].
The levels of PH]deltorphin-l binding measured in saline-treated mice in the present 
study are comparable to those recorded in other studies for saline-treated C57B1/6 
male mice (Goody, e ta l ,  2002a; Kitchen, e ta l ,  1995; Kitchen, e ta l,  1997; Slowe, etal,  
1999).
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Figure 5-1: Autoradiograms of brain sections in wild type (+/+), conditional and 
constitutive (-/-) DOPr knockout mice.
Computer enhanced autoradiograms of total pH]deltorphin-l binding in coronal brain 
sections of C57B1/6 wild type and conditional DOPr KO mice. Brain sections were incubated 
for 60 mins with 7 nM pH]deItorphin-l. Adjacent sections were incubated with 10 pM 
naloxone to determine non-specific binding (NSB], which was indistinguishable from 
background. Sections were apposed to Kodak BioMax MR-1 film for 6 weeks. Images are 
shown cut at the level of the olfactory nuclei (Bregma 3.56 mm], motor cortex (Bregma 2.46 
mm], caudate putamen (Bregma 1.10 mm] and the hippocampus (Bregma -1.46 mm]. The 
calibration bar presents a pseuco-colour interpretation of black and white film images in 
fmol/m g tissue equivalent. Abbreviations: CPu, caudate putamen; EPl, external plexiform 
nucleus; Hip, hippocampus; MtCx, motor cortex.
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Table 5-1: Quantitative autoradiography of brain DOPr binding in wild type 
(+/+) and conditional (-/-) DOPr mutant mice.
Region Bregma
co-ordinates
PH]DELT-1 specific binding 
(fmol/mg tissue)
WT (n=3) cKO (n=4)
%
change
Olfactory bulb
External plexiform EPl
3.56
200.5 ±27.1 0.0 ± 0.0 *** -100.0
Layer
Internal granular layer IGl 84.3 ± 14.0 0.0 ± 0.0 *** -100.0
Cortical areas 
Motor
Superficial MtCx(Sl]
2.10
105.6 ± 16.4 103.1 ±11.1 -2.34
layers 
Deep layers MtCx(Dl) 92.1 ±13.3 94.6 ± 11.8 2.63
Orbital
Superficial 0rCx(Sl]
2.10
61.8 ± 15.0 69.3 ± 7.7 12.0
layers 
Deep layers OrCx(Dl) 79.7 ± 12.1 83.9 ± 14.0 5.30
Frontal
Superficial FrCx(Sl)
1.98
112.7 ±16.5 100.2 ± 12.4 -11.1
layers 
Deep layers FrCxCDl) 83.2 ±9.8 94.6 ±10.5 13.7
Cingulate
Superficial CgCx(Sl)
1.10
89.5 ± 15.4 87.3 ± 14.3 -2.55
layers 
Deep layers CgCx(Dl) 97.4 ± 14.8 95.8 ±15.1 -1.73
Frontal-Parietal
Superficial FrPCx(Sl)
1.10
93.3 ± 14.3 97.9 ±13.5 4.98
layers 
Deep layers FrPCx(Dl) 93.6 ± 14.3 93.1 ± 15.8 -0.55
Insular
Superficial lnCx(S13
1.10
120.6 ±16.0 112.4 ±20.6 -6.86
layers 
Deep layers lnCx(Dl] 124.1 ± 19.2 115.5 ± 18.0 -6.90
Rostral somatosensory 
Superficial SsRCx(Sl)
1.10
101.1 ±8.6 84.6 ± 13.9 -16.3
layers 
Deep layers SsRCx[Dl] 81.6 ±9.7 78.9 ±12.4 -3.43
Parietal
Superficial PtACx(Sl)
-1.46
124.8 ± 14.9 92.5 ± 14.8 -25.9
layers 
Deep layers PtACx(Dl) 97.0 ± 18.5 87.1 ±11.0 -10.2
Caudal somatosensory 
Superficial SsCCx(Sl)
-2.06
118.7 ±9.5 86.9 ± 11.6 -26.8
layers 
Deep layers SsCCx(Dl) 89.9 ±9.3 92.3 ± 15.2 2.70
Retrosplenial
Superficial RSCx(Sl)
-2.06
70.2 ± 7.1 56.7 ±7.0 -19.2
layers 
Deep layers RSCx(Dl) 78.7 ± 11.6 79.3 ±9.0 0.80
Temporal
Superficial TeACx(Sl)
-2.06
118.0 ± 13.3 85.1 ±15.2 -27.9
layers 
Deep layers TeACx(Dl) 117.5 ± 14.7 96.3 ±11.7 -18.1
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Table 5-1. Continued
Perirhinal PRhCx -2.06 120.5 ± 19.6 106.9 ±11.1 -11.3
Auditory
Superficial AuCx(Sl)
-2.54
104.9 ± 11.8 76.2 ± 10.5 -27.4
layers
Deep layers AuCx(DL) 96.0 ± 10.7 78.6 ± 10.2 -18.2
Visual
Superficial ViCx(Sl)
-3.52
104.3 ± 9.4 89.6 ± 7.5 -14.1
layers
Deep layers ViCx(Dl) 92.9 ±11.7 71.3 ± 10.2 -23.2
Entorhinal EntCx -3.64 54.2 ± 8.6 52.0 ± 7.4 -4.10
Nucleus accumbens 
Core AcbC
1.18
60.0 ± 11.7 24.4 ± 9.2 -59.3
Shell AcbSh 68.2 ± 16.0 20.2 ± 8.3 ** -70.3
Caudate putamen 
Medial CPuL
1.10
77.3 ± 21.5 22.1 ± 7.0 *** -78.8
Lateral CPuM 128.9 ± 34.6 33.2 ±9.2 *** -82.9
Tubercle Tu 1.10 168.4 ±42.7 16.4 ± 6.4 *** -80.3
Septum
Medial MS
0.74
29.7 ±6.7 18.1 ± 7.8 -39.0
Lateral LS 37.0 ± 8.7 22.4 ±9.2 -39.4
Vertical limb of the VDB 0.74 16.9 ± 4.2 19.9 ± 6.3 17.8
diagonal band
Globus pallidus GP -0.22 44.8 ± 12.1 15.5 ± 6.4 -65.3
Preoptic area PoA -0.22 12.6 ±3.7 12.8 ± 5.0 1.40
Thalamus Th -1.46 17.2 ± 2.9 21.0 ±6.3 22.4
Amygdala
Basolateral BLA
-1.46
77.5 ± 17.4 82.6 ± 21.0 6.5
Basomedial BMA 76.7 ±20.8 81.2 ± 13.7 5.8
Medial CeM 43.2 ± 12.1 47.7 ±15.1 10.4
Hypothalamus Hyp -1.46 16.3 ± 3.8 17.3 ± 5.0 6.1
Hipppcampus
CAl CAl -2.06 47.6 ± 7.3 20.3 ± 2.9 -57.3
CA2/3 CA2/3 -2.06 52.1 ±8.6 17.3 ±3.2* -66.8
Dentate gyrus DG -2.06 59.0 ± 8.9 28.5 ±5.6 -51.7
Dorsal dHip -3.80 47.4 ± 7.4 22.7 ±4.7 -52.1
Presubiculum Prs -3.64 53.0 ± 13.3 31.1 ±8.9 -41.4
Values of specific pH]deltorphin-l binding represent mean ± standard error of the mean fmol/mg of 
tissue equivalent in brain regions of C57B1/6 wild type (WT) and conditional DOPr receptor knockout 
mice. Bregma coordinates are taken from the mouse brain atlas of Franklin and Paxinos (1997). 
Specific binding was calculated by subtracting non-specific from total pH]deltorpin-l binding. Percent 
change in binding indicates change in conditional knockout compared with WT mice. Data are 
presented as mean ± standard error of the mean. Two-way ANOVA revealed significant effect of 
Genotype, Region and Genotype x Region, all p<0.001. Holm-Sfdak multiple comparisons revealed 
significant within-region differences compared with WT: *p<0.05; **p<0.01; ***p<0.001.
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Figure 5-2: Autoradiograms of spinal cord sections in wild type (+/+), 
conditional and constitutive (-/-) DOPr knockout mice.
Computer enhanced autoradiograms of total pHJdeltorphin-l binding in spinal cord sections 
of C57B1/6 wild type, conditional and constitutive DOPr KO mice. Sections were incubated for 
60 mins with 7 nM pH]deltorphin-l. Adjacent sections were incubated with 10 pM naloxone 
to determine non-specific binding [NSB], which was indistinguishable from background. 
Sections were apposed to Kodak BioMax MR-1 film for 6 weeks. Images are shown cut at the 
cervival C6 section. The calibration bar presents a pseuco-colour interpretation of black and 
white film images in fmol/m g tissue equivalent.
Table 5-2: Quantitative autoradiography of spinal cord DOPr binding in wild 
type (+/+) and conditional (-/-) DOPr knockout mice.
Region
Segments 
from 
rat atlas
PHJDELT-1 specific 
binding [fmol/mg tissue) 
WT (n=3) cKO (n=4)
%
change
Cervical C6
Whole section 16.0 ± 9.5 21.1 ±7.2 30.0
Superficial layers [lamina 1 and 11] 24.8 ±9.3 29.4 ± 8.8 18.6
Laminas 111-lV 17.9 ± 6.9 21.6 ± 6.3 21.2
Lamina X 16.8 ± 8.5 18.9 ± 7.5 12.4
Ventral horn [laminas VI1 -IX] 18.8 ±6.9 22.1 ± 6.7 17.0
Values of specific PH]deltorphin-l binding represent mean ± standard error of the mean fmol/mg of 
tissue equivalent in spinal cord regions of C57B1/6 wild type [WT] and conditional DOPr knockout 
mice. Bregma coordinates are taken from the rat brain atlas of Paxinos and Watson [1998]. Specific 
binding was calculated by subtracting non-specific from total PH]deltorphin-l binding. Percent change 
in binding indicates change in conditional knockout compared with WT mice. Data are presented as 
mean ± standard error of the mean. Two-way ANOVA found no significant effect for any of the factors.
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5.3.2 Effect o f genotype on p-opioid receptor binding
Representative autoradiographic images of MOPr density in WT, cKO and constitutive 
KG brain sections are shown in Figure 5-3. MCID analysis of constitutive KG samples 
confirmed genotype with complete MGPr deletion. There was a mean reduction of 
21% in cKG compared with WT mice. Changes in binding were observed throughout 
the brain, however the greatest reduction of binding was in the olfactory bulbs, with 
100% knockdown in cKG mice. Two-way ANGVA revealed significant effect of 
Genotype [F(i,259)=33.75], Region [F(so,259)=24.28) and Genotype x Region interaction 
(F(50,259)=1.81]; where p<0.001 in all cases. Holm-Sidak multiple comparisons found 
significant decrease of PH]DAMGG binding in cKG mice in the AcbC and AcbSh 
(p<0.001), EPl, IGl, CPu, olfactory tubercles, medial septum, preoptic area, ventral 
pallidum (VP), basomedial amygdala, hypothalamus and medial geniculate nucleus 
(p<0.05), relative to WT mice (Table 5-3).
Representative autoradiographic images of MGPr density in WT, cKG and constitutive 
KG spinal cords are shown in Figure 5-4. There are no differences between genotypes 
in the spinal cord. MCID analysis of constitutive KG samples confirmed genotype with 
complete MGPr deletion. Two-way ANGVA found no significant effects for any of the 
factors analysed (Table 5-4).
The levels of [^H] DAMGG binding measured in saline-treated mice in the present 
study are comparable to those recorded in other studies for saline-treated C57B1/6 
male mice (Bailey e ta l ,  2007; Goody, e ta l ,  2002a; Kitchen, e ta l ,  1997).
168
WT cKO Full KO
fmol /  mg
Total NSB Total NSB Total NSB
Bregma 
3.56 I
Bregma
2.46
Bregma
1.10
Bregma 
-1.46 I
Figure 5-3: Autoradiograms of brain sections in wild type (+/+), conditional and 
(-/-) MOPr knockout mice.
Computer enhanced autoradiograms of total pH] DAMGG binding in coronal brain sections of 
C57B1/6 wild type and conditional MGPr KG mice. Brain sections were incubated for 60 mins 
with 4 nM pH]DAMGG. Adjacent sections were incubated with 1 pM naloxone to determine 
non-specific binding (NSB], which was indistinguishable from background. Sections were 
apposed to Kodak BioMax MR-1 film for 10 weeks. Images are shown cut at the level of the 
olfactory nuclei [Bregma 3.56 mm], motor cortex [Bregma 2.46 mm], caudate putamen 
[Bregma 1.10 mm] and the thalamus [Bregma -1.46 mm]. The calibration bar presents a 
pseuco-colour interpretation of black and white film images in fm ol/m g tissue equivalent. 
Abbreviations. CPu, caudate putamen; EPl, external plexiform nucleus; MtCx, motor cortex; 
Th, thalamus.
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Table 5-3: Quantitative autoradiography of MOPr binding in wild type (+/+) 
and conditional (-/-) MOPr knockout mice.
Region Bregma
co-ordinates
PH]DAMGO-speclfic binding 
(fmol/mg tissue)
WT (n=3) cKO (n=4)
%
change
Olfactory bulb
External plexiform EPl
3.56
21.4 ±9.1 0.0 ± 0.0 *** -100.0
Layer
Internal granular layer IGl 21.8 ±8.5 0.0 ± 0.1 *** -100.0
Cortical areas 
Motor
Superficial MtCx(Sl)
2.10
41.8 ± 15.4 27.7 ± 9.6 -33.8
layers 
Deep layers MtCx(Dl) 46.7 ± 6.9 30.2 ± 9.4 -35.4
Orbital
Superficial OrCxfSl]
2.10
48.8 ± 14.6 57.2 ± 10.5 17.2
layers 
Deep layers OrCx[Dl] 49.0 ± 9.0 48.1 ± 9.8 -1.7
Frontal
Superficial FrCx(Sl)
1.98
27.9 ±10.4 29.9 ± 9.2 7.2
layers 
Deep layers FrCx(Dl) 33.7 ± 10.6 34.4 ± 10.3 2.3
Cingulate
Superficial CgCx(Sl)
1.10
28.8 ± 10.9 32.1 ±9.4 11.6
layers 
Deep layers CgCx(Dl) 30.6 ± 2.6 32.7 ±11.0 7.1
Frontal-Parietal
Superficial FrPCx(Sl)
1.10
17.1 ±3.7 25.9 ± 10.2 51.9
layers 
Deep layers FrPCx(Dl) 25.8 ±6.2 31.4 ±10.2 21.7
Rostral
sosmatosensory
Superficial SsRCx(Sl)
1.10
14.3 ± 4.3 22.2 ±8.3 55.3
layers 
Deep layers SsRCxCDl) 27.2 ± 7.0 28.3 ±9.1 3.9
Parietal
Superficial PtACx(Sl)
-1.46
17.0 ±9.1 16.0 ± 6.3 -5.9
layers 
Deep layers PtACx(Dl) 25.0 ±9.4 23.1 ±8.1 -7.4
Caudal somatosensory 
Superficial SsCCx(Sl)
-2.06
14.9 ± 5.2 15.6 ± 5.1 4.7
layers 
Deep layers SsCCx(Dl) 25.8 ±8.0 24.0 ± 8.3 -7.0
Retrosplenial
Superficial RSCx(Sl]
-2.06
22.6 ± 6.4 24.1 ± 8.5 6.6
layers 
Deep layers RSCx(Dl] 38.0 ± 5.6 25.6 ±7.1 -32.5
Temporal
Superficial TeACx(Sl)
-2.06
22.8 ± 6.6 25.7 ±5.1 12.7
layers 
Deep layers TeACx(Dl) 35.0 ±8.8 36.9 ± 9.3 5.2
Auditory
Superficial AuCx(Sl)
-2.54
22.5 ± 6.7 23.3 ± 7.6 3.2
layers
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Table 5-3. Continued
Deep layers AuCx(Dl] 33.3 ±11.1 35.6 ± 8.7 7.1
Visual
Superficial ViCx(Sl]
-3.52
32.9 ± 15.9 14.7 ± 7.1 -55.3
layers 
Deep layers ViCx(Dl] 26.6 ± 7.2 18.1 ± 7.7 -31.8
Entorhinal EntCx -3.64 53.5 ± 17.8 77.8 ± 9.5 45.5
Nucleus accumbens 
Core AcbC
1.18
119.5 ±4.5 33.7 ± 5.3 *** -71.8
Shell AcbSh 102.6 ±4.9 32.2 ± 4.4 *** -68.6
Caudate putamen 1.10 56.8 ± 12.7 27.2 ± 2.3 * -52.1
Dorsal endopiriform DEn 1.10 66.6 ± 7.3 73.3 ± 10.4 10.1
nucleus
Septum
Medial MS
0.74
56.6 ± 4.7 25.2 ± 8.1 * -55.4
Lateral LS 35.6 ± 5.6 18.2 ± 6.7 -49.0
Vertical limb of the VBD 49.0 ± 8.2 21.9 ±8.1 -55.4
diagonal band 
Ventral pallidum VP -0.22 66.4 ± 22.9 12.5 ± 1.3 *** -81.1
Preoptic area PoA -0.22 53.4 ±7.6 15.8 ± 6.6 * -70.4
Amygdala
Basolateral BLA
-1.46
98.5 ± 14.9 104.5 ± 17.7 6.1
Basomedial BMA 70.6 ±13.9 32.2 ±10.9* -54.4
Medial Me 59.6 ± 11.8 49.5 ± 13.7 -28.9
Medial habenula MHb -1.46 190.0 ± 19.4 221.0 ±21.6 16.3
Thalamus Th -1.46 61.0 ± 11.8 48.8 ± 11.1 -19.9
Central lateral CL 132.6 ±17.5 112.1 ± 14.7 -15.5
Central medial CM 155.4 ±28.3 140.8 ± 15.4 -9.4
Intermediodorsal IMD 142.9 ± 37.2 157.8 ±20.1 10.5
thalamic nucleus 
Reuniens Re 103.9 ±26.5 69.6 ± 18.4 -33.0
Hypothalamus Hyp -1.46 62.6 ± 10.7 24.8 ± 7.7 * -60.4
Hippocampus Hip -2.06 26.1 ±3.7 10.7 ± 7.0 -59.0
Dorsal hippocampus dHip -3.80 41.1 ±20.2 23.9 ±8.9 -41.8
Substantia nigra SN -3.40 68.6 ± 12.5 40.1 ±11.5 -41.6
Ventral tegmental area VTA -3.40 86.8 ± 9.0 67.7 ± 6.3 -22.0
Superficial grey 
Superficial layer SuG
-3.40
83.0 ± 14.5 78.6 ± 7.9 -5.3
Intermediate layer InG 87.3 ± 7.7 74.6 ± 5.1 -14.4
Medial geniculate nucleus MG -3.40 48.5 ± 12.7 11.7 ±3.0* -75.9
Periaqueductal grey PAG -3.40 59.1 ±6.0 39.4 ±9.2 -33.3
Interpeduncular nucleus IPn -3.64 83.1 ±18.7 67.1 ±33.9 -19.2
Values of specific pH] DAM GO binding represent mean ± standard error of the mean fmol/mg of tissue 
equivalent in brain regions of C57B1/6 wild type (WT] and conditional MOPr knockout mice. Bregma 
coordinates are taken from the mouse brain atlas of Franklin and Paxinos (1997]. Specific binding was 
calculated by subtracting non-specific from total pH]DAMGO binding. Percent change in binding 
indicates change in conditional knockout compared with WT mice. Data are presented as mean ± 
standard error of the mean. Two-way ANOVA revealed significant effect of Genotype, Region and 
Genotype x Region, all p<0.001. Holm-Sidak multiple comparisons revealed significant within-region 
differences compared with WT: *p<0.05; **p<0.01; ***p<0.001.
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Figure 5-4: Autoradiograms of spinal cord sections in wild type (+/+), 
conditional and constitutive (-/-) MOPr knockout mice.
Computer enhanced autoradiograms of total pHJDAMGO binding in spinal cord sections of 
C57B1/6 wild type, conditional and constitutive MOPr KO mice. Sections were incubated for 60 
mins with 4 nM pH]DAMGG. Adjacent sections were incubated with 1 pM naloxone to 
determine non-specific binding [NSB], which was indistinguishable from background. 
Sections were apposed to Kodak BioMax MR-1 film for 10 weeks. Images are shown cut at the 
cervival C6 section. The calibration bar presents a pseuco-colour interpretation of black and 
white film images in fm ol/m g tissue equivalent.
Table 5-4: Quantitative autoradiography of spinal cord MOPr binding in wild
type (+/+) and conditional ( - / - )  MOPr knockout mice.
Region
Segments 
from 
rat atlas
PHJDAMGO-specific 
binding (fmol/mg tissue) 
WT (n=3) cKO (n=4)
%
change
Cervical C6
Whole section 41.7 ± 15.9 55.3 ±12.8 32.5
Superficial layers [lamina 1 and 11] 80.3 ±22.9 95.0 ± 12.9 18.3
Laminas Ill-IV 36.0 ± 8.5 50.7 ± 7.8 40.9
Lamina X 39.6 ± 18.6 48.2 ± 10.3 21.9
Ventral horn [laminas VII -IX] 33.2 ± 8.9 46.1 ± 7.5 38.5
L J  O    1 WiC lllCdH lUlUl/IUg UI UiJ^ UU
equivalent in spinal cord regions of CS7B1/6 wild type [WT] and conditional MOPr knockout mice. 
Bregma coordinates are taken from the rat brain atlas of Paxinos and Watson [1998]. Specific binding 
was calculated subtracting non-specific from total [^ H] DAMGG binding. Percent change in binding 
indicates change in conditional knockout compared with WT mice. Data are presented as mean ± 
standard error of the mean. Two-way ANOVA found no significant effect for any of the factors.
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5.4 Discussion
In the current study, conditional knockout of DOP or MOP receptors located on 
GABAergic forebrain neurons reduced or abolished binding of these receptors in 
several non-cortical brain regions, while no change was found in the spinal cord. In 
addition, DOPr cKO mice demonstrated decreased anxiety-like behaviours, while 
MOPr cKO mice showed no change in morphine response, but did display reduced 
ethanol self-administration (Paul Chu Sin Chung and Pauline Charbogne, personal 
communication, 2013). Therefore, it may be possible to link some behavioural 
phenotypes to DOP and MOP receptors in specific neuronal locations.
There were no MOP or DOP receptors present on GABAergic neurons in any of the 
spinal cord regions analysed. Therefore, while GABAergic signalling in the spinal cord 
plays an im portant role in nociception (Bardoni, e ta l ,  2013), including neuropathic 
pain (Yowtak, e ta l ,  2013), these actions are not mediated by MOPr or DOPr.
The loss of MOPr and DOPr binding in various brain regions of these conditional KO 
mice supports existing evidence that opioid receptors are present on (Bausch, et al, 
1995; Commons & Milner, 1996, 1997), and mediate the activity of (Cohen, et al, 
1992; Hjelmstad, et al, 2013; Lupica, 1995), GABAergic neurons on many brain 
nuclei. In the present study, reduced MOPr binding was identified in the striatum, 
hypothalamus and amygdala, ranging from 52-71% in the present study, indicating 
co-localisation of MOPr and GABA in these regions in agreement with Kalyuzhny and 
W essendorf (1998). Kalyuzhny and W essendorf (1998) also identified double­
labelling of MOPr and GABA in piriform and parietal cortices, hippocampal and 
thalamic nuclei, however the lack of significant change in binding in cKO mice in the 
present study suggests that the majority of MOPr in these regions are located on non- 
GABAergic neurons.
In both genotypes, opioid receptor binding was abolished in the EPl and IGl, 
demonstrating that all DOP and MOP receptors in these regions are located on 
GABAergic neurons. Previous studies have confirmed the presence of GABAergic 
neurons in the plexiform and granular layers of the olfactory bulb (Liberia, et al,
2012) and the abolition of PH]deltorphin-l binding in constitutive DOPr KO (Goody, 
e ta l,  2002b), andpH]DAMGO in MOPr KO mice (Kitchen, e ta l ,  1997).
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It remains to be seen whether opioid receptors specifically located on GABAergic 
neurons are involved in nicotine reward. However, the MOPr antagonist naloxone has 
been shown to induce nicotine withdrawal (Krishnan-Sarin, et al, 1999), while 
activation of MOPrs attenuated GABAergic inhibitory postsynaptic potentials 
(McQuiston, 2008), raising the possibility that opioid involvement in nicotine 
addiction may be mediated through GABAergic signalling. The Acb and VP form part 
of the basal ganglia, with GABAergic medium spiny neurons projecting from the Acb 
towards the VP (for review see Smith, et al, 2009). Local administration of MOPr 
agonists to these regions modulates the incentive salience of sugar (Smith & Berridge, 
2007). The present study confirmed that MOPr in these regions are predominantly 
located on GABAergic neurons, indicating that these receptors may mediate the 
incentive salience of nicotine or exercise. However, the study described in Chapter 3 
found no change in MOPr in these regions due to either exercise or nicotine, although 
other studies have found that nicotine treatm ent alters MOPr binding (Wewers, etal,  
1999) and exercise induces p-endorphin release (Boecker, e ta l ,  2008).
GABAergic projections from the olfactory bulbs to the amygdala contain presynaptic 
a4, a? and p2 nAChR subunits (Barazangi & Role, 2001); local treatm ent with 
nicotine increases firing frequency of GABAergic neurons, indicating that presynaptic 
nAChRs modulate GABAergic transmission in the amygdala. In addition, ACh release 
from the striatum and olfactory bulbs is inhibited by both DOPr and MOPr agonists, 
which is reversible by a low concentration of naloxone (Heijna, et al, 1990), 
indicating cross-reactivity of cholingeric and opioid signalling. Both MOPr and DOPr 
binding was reduced in the olfactory nuclei and striatum, while only MOPr binding 
was affected in the basomedial amygdala, suggesting cross-reactivity or functional 
interactions between nAChRs and opioid receptors located on these neurons.
It should be noted that while MOPr binding in the hippocampus was reduced by 
nearly 60% in the present study, this failed to reach significance. In contrast, DOPr 
binding was significantly reduced in the CA 2/3 region of the hippocampus of DOPr 
cKO mice. This reduction of approximately 66% is in agreement with previous 
research indicating that DOPrs in the hippocampus are predominantly located on 
GABAergic neurons (Commons & Milner, 1997; Erbs, e ta l ,  2012). The antinociceptive 
effect of nicotine is abolished by both MOP and DOP receptor antagonists (Kwon, et
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al, 2008); nicotine-induced antinociception was also attenuated by lesioning the CA3 
region of the hippocampus, as well as formalin treatment, following which MOPr 
expression in the hippocampus was downregulated. Therefore, it is possible that MOP 
and DOP receptors located on GABAergic neurons in the hippocampus may modulate 
nicotine-induced nociception.
In conclusion, conditional KO of DOPr and MOPr receptors allowed these receptors to 
be mapped onto GABAergic neurons in specific regions of the mouse brain. 
Collectively, these data show MOPr expression on GABAergic neurons to be more 
wide-spread than DOPr, and indicate target regions where modulation of MOP or DOP 
receptors may ameloriate nicotine withdrawal.
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CHAPTER 6 
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CHAPTER 6. GENERAL DISCUSSION
This thesis investigated the behavioural and neurochemical mechanisms involved in 
nicotine addiction. Previous clinical and preclinical research has shown that exercise 
is effective in reducing withdrawal symptoms from smoking and cigarette cravings 
and, therefore, may be effective as an intervention in smoking cessation. However, the 
mechanisms underlying this effect remain largely unclear. The studies presented in 
this thesis provide evidence that hippocampal oc7 nAChRs may be involved in 
mediating the beneficial effects of exercise on nicotine withdrawal. In addition, this 
thesis shows that nicotine may be protective against cognitive deficits in 
schizophrenia via an a7-dependent mechanism.
6.1 a? nAChRs and exercise: Novel therapies for prevention of relapse in 
nicotine withdrawal
6.1.1 Novel potential mechanism for exercise as an intervention in nicotine 
withdrawal
In consideration of the present finding that there was no difference between 
perceived and objectively determined moderate intensity exercise and passive 
waiting, it could be suggested that exercise reduces nicotine withdrawal symptoms 
and cravings by acting as a distraction, in contrast to Daniel e ta l  (2006). However, 
the reduction in cortisol levels during withdrawal observed here and in other studies 
(Janse Van Rensburg, e ta l,  2013; Scerbo, e ta l,  2010), as well as the observation of 
elevated hippocampal a7 nAChRs in nicotine-withdrawn exercising mice, suggests 
that while distraction may be a part of the mechanism, there are also biochemical 
correlates mediating the effects of exercise.
The present work demonstrated for the first time that the cholinergic system, 
specifically hippocampal oc7 nAChRs, may be altered by exercise following nicotine 
withdrawal in mice. The effectiveness of current interventions is limited (The Health 
and Social Care Information Centre, 2012), therefore understanding the mechanisms 
underlying possible alternative interventions is essential in order to develop effective 
treatments. The present work adds to evidence from human studies that exercise may 
be effective as an intervention in nicotine withdrawal (Ussher, et al, 2012) as it 
reduces the severity of withdrawal symptoms, which are cited as a major factor in 
relapse to smoking (West, e ta l, 1989). Moreover, the present thesis highlights the a7
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nAChR as part of the potential mechanism by which exercise reduces nicotine 
withdrawal; therefore, future research is required to give greater insight into the role 
of a7 nAChRs. For example, the region-specific pharmacological antagonism of a7 
nAChRs, or an a7 KO mouse model with targeted re-expression of receptors in the 
hippocampus, could be used in order to investigate the functional and behavioural 
significance of this exercise-induced a7 nAChR upregulation in nicotine withdrawal.
Possible mechanisms for how exercise attenuates nicotine withdrawal via a7 nAChRs 
include modulation of GABAergic and glutamatergic signalling. Both GABA and 
glutamate are implicated in nicotine reward and withdrawal (see D'Souza & Markou,
2011), and are known to be affected by exercise (for example Biedermann, et al, 
2012; Schoenfeld, e ta l ,  2013). However, further investigation would be required in 
order to elucidate the relationship between these neurotransmitters, nicotine and 
exercise.
6.1.2 Implications for treatment
The experiments in this thesis investigated only two exercise regimes, finding no 
difference between either 2 and 24 hrs/day running wheel access in mice, or 
perceived and objective moderate intensity exercise in humans, in reducing 
withdrawal symptom severity. There is a need to determine if the threshold level of 
exercise required to reduce withdrawal in an animal model is less than 2 h rs/day 
wheel access. However, the current work does demonstrate that exercise reduces 
nicotine withdrawal in both humans and animals, irrespective of how much exercise 
is actually undertaken. This finding demonstrates that, in addition to being a low cost 
intervention that will benefit the general health of smokers, even a short duration of 
moderate intensity exercise may be sufficient to reduce withdrawal symptoms, thus 
supporting the promotion of exercise as part of an overall lifestyle change during 
cessation (Everson, e ta l,  2010).
The present work allowed animals to habituate to wheel running prior to concurrent 
nicotine administration. It is important to understand the timing of exercise in 
relation to the introduction of nicotine administration in mediating its effect. For 
example, cessation of wheel running reinstated pre-exercise levels of ethanol self­
administration, which was maintained when the running wheel was reintroduced 
(McMillan, e ta l,  1995). Moreover, exercise has also been associated with enhanced
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cocaine-primed reinstatem ent (Thanes, et al, 2013), morphine CPP and self­
administration (Hosseini, et al, 2009). Therefore, it is im portant to determine the 
mechanisms underlying these effects in order to design exercise interventions that 
treat withdrawal and prevent relapse, but avoid the possibility of enhancing drug 
acquisition behaviour.
The present thesis highlights the a7 nAChR as a possible novel target for the 
development of pharmacotherapies to reduce nicotine withdrawal as an adjunct to 
exercise. Varenicline is already prescribed as a pharmacotherapy in smoking 
cessation, with 60% of users maintaining a 'smoke free' status after four weeks (The 
Health and Social Care Information Centre, 2012). However, it is not currently known 
how varenicline interacts with exercise during abstinence. Therefore, additional 
research is required in order to investigate the possibility of using varenicline, or 
other a? agonists, as an adjunct to exercise to treat nicotine withdrawal.
6.2 Exercise therapy for neurodisorders and antinociception
This thesis found that a7 nAChRs are upregulated in the hippocampus, a region 
associated with learning and memory, following nicotine treatm ent in exercising 
mice, demonstrating the need for future studies to investigate the effects of exercise 
on the cognitive consequences of nicotine addiction. Possible behavioural paradigms 
that could be used to investigate this include novel object recognition, the Morris 
Water Maze (Sharma, et al, 2010) and touch-screen operant cages (Bussey, et al,
2012). Indeed, it has already been shown that exercise is beneficial in memory 
disorders, for example in Alzheimer's disease (for reviews see Dishman, e ta l,  2006; 
Erickson, et al, 2012).
Exercise has also been shown to augment adult neurogenesis and attenuate 
behavioural deficits in a mouse model of schizophrenia (Wolf, e ta l,  2011). Voluntary 
wheel running for 10 days reversed deficits in prepulse inhibition and reduced 
rearing, one of the more dominant symptoms displayed during nicotine withdrawal 
in this thesis (Chapter 3). Therefore, exercise may be beneficial in the treatm ent of 
social and cognitive deficits in schizophrenia, particularly as an adjunct to nicotine 
and/or OT therapy.
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Exercise was found to elevate MOPr binding in the PAG, suggesting a role for the 
MOPr in this region in mediating exercise-induced analgesia. Moreover, MOPr cKO 
mice displayed a non-significant decrease in MOPr binding in the PAG, indicating that 
roughly a third of MOPrs are located on GABAergic neurons. Presynaptic MOPrs on 
GABAergic neurons in the PAG have been found to modulate the GABAergic response 
to neuropathic pain in rats (Hahm, e ta l ,  2011), indicating that exercise may be of 
benefit in treating neuropathic pain. Further investigation would therefore be 
warranted into the role of the MOPr in mediating exercise-induced analgesia. 
Moreover, the present work provided evidence that the majority of MOP and OOP 
receptors are located on GABAergic neurons in the hippocampus. These receptors 
have been implicated in mediating the antinociceptive effects of nicotine (Kwon, e ta l, 
2008), therefore the role of these receptors in modulating GABA signalling in nicotine 
addiction and analgesia requires exploration.
6.3 Combined nicotine and oxytocin pharamacotherapy in neurodisorders
Changes in a7 nAChR and OTR binding were restricted to the CgCx in the G72Tg 
study. Nicotine blunted the effect of the G72Tg genotype-induced upregulation of a7 
and OT receptor binding with concurrent reversal of deficits in social cognition in 
G72Tg mice, indicating a dysregulation of the nicotinic and OTergic systems that was 
restored by nicotine. Accordingly, the CgCx is associated with reward-learning and 
social cognition (for reviews see Behrens, et al, 2009; Shackman, et al, 2011) and 
there is a high incidence of pathology in schizophrenic patients (see Smieskova, e ta l, 
2010), with evidence for decreased function of GABAergic neurons in this region (for 
review see Benes, 2000). Treatment with an a7 agonist, DMBX-A, in non-smoking 
schizophrenics ameliorated negative symptoms and reduced activity in the CgCx, 
however this effect was blunted in patients with the CHRNA7 rs3087454 SNP 
(Tregellas, e ta l,  2011). Whilst this SNP has no known function, it often occurs with a 
set of CHRNA7 SNPs that decrease its transcription and are associated with 
schizophrenia (Leonard, e ta l,  2002; Stephens, e ta l,  2009). The a7 nAChR promoter - 
194 C polymorphism is protective against P50 sensory-gating deficits associated with 
schizophrenia (Houy, et al, 2004), while the CHRFAM7A polymorphism is causally 
implicated (Flomen, et al, 2013). Moreover, CHRFAM7A is associated with 
susceptibility to various types of dementia, including Alzheimer's and vascular 
dementia (Fehér, e ta l,  2009). Together, these results suggest that while a7 agonists
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may be useful for the treatm ent of schizophrenia, the genetic variation of a7 in some 
patients may restrict their effectiveness.
GABAa receptors are thought to mediate firing of OTergic neurons in the PVN and 
SON (Moos, 1995), while OT reverses increased activity in the CgCx in generalised 
social anxiety patients (Labuschagne, e ta l,  2012). The OTR polymorphism rs53576G 
enhances the effect of social support in reducing stress (Chen, e ta l,  2011); therefore, 
OT may be a useful adjunct therapy to CBT in smoking cessation or affective 
disorders, particularly in patients with a specific genotype. Collectively, the evidence 
indicates that OT and cholinergic signalling are attenuated in schizophrenia, leading 
to dysregulation of GABAergic neurons in the CgCx, which may be restored by 
nicotine and OT treatment.
Considering that both nicotine and OT may reduce social and cognitive deficits in 
schizophrenia (Miyamoto, e ta l,  2013), it is possible that they may also be of use in 
treating other neurodisorders. Consequently, a multi-therapy approach, including 
nicotine, OT and exercise may be beneficial not only in the treatm ent of 
schizophrenia, but also dementia, anxiety disorders (Hofmann, et al, 2013), and 
psychostimulant addiction (McGregor & Bowen, 2012; Metaxas, e ta l, 2012).
6.4 Use of animal models in scientific research
When using animal models in research certain considerations must be taken into 
account, for example the choice of one strain of mouse over another, the validity of 
modelling human disorders without discrete aetiology in mice and how far one can 
extrapolate behavioural analysis of animals to human conditions. It is clear that 
studying drug addiction in laboratory animals does not directly equate to studying 
genuine addiction as the DSM-5 definition of addiction given in Section 1.2.1 of this 
thesis includes effects on social, occupational, or recreational activities and 
interpersonal relationships. Nevertheless, as discussed by Vanderschuren and Ahmed 
(2013) in their review of animal models of addiction, several DSM-like symptoms can 
be detected in animals and these experiments provide useful tools for understanding 
the neural and genetic mechanisms underpinning addiction.
The mice used in studies in Chapters 3 and 5 of this thesis were of the C57B1/6 strain. 
Strains of mice differentially respond in addiction studies, often depending on the age
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of the mouse (Wilking, et al, 2012) or sex (Klein, et al, 2004). Male mice are often 
used to remove hormonal changes as a possible confounding variable. The C57B1/6 
strain itself is one commonly used in studies of various different drugs of abuse 
(Bailey, e ta l, 2008; Metaxas, e ta l, 2010; Metaxas, e ta l,  2012; Sprow & Thiele, 2012; 
Zanos, et al, 2013a). In terms of nicotine addiction, C57BI/6 mice demonstrate a 
higher nicotine preference compared with other strains, including C3H/J, A/JxNMRI, 
DBA/2, NMRI and ST/bJ (Aschhoff, e ta l,  2000). Nicotine withdrawal severity is also 
more pronounced in C57BI/6 mice than the 129/SvEv strain following minipump 
administration of the drug (Damaj, e ta l, 2003). In addition, all the nAChR KO models 
(see Section 1.5) have been generated on a C57B1/6 background (Marks, 2013), which 
it easier to place studies using this strain in the context of existing literature. 
Therefore, C57B1/6 mice are a well characterised and validated model for use in 
nicotine research.
In Chapter 4 of this thesis mice that were genetically altered to act as a model of one 
possible genetic cause of schizophrenia were used; G72, a protein not normally found 
in mice, was integrated into the genome. As outlined in the introduction to that 
chapter, schizophrenia is a complex disorder, or even a group of disorders, and as 
such there are thought to be several genetic and social triggers. While G72 has been 
implicated in susceptibility to schizophrenia (Drews, e ta l,  2012), indeed G72Tg mice 
display several schizophrenic phenotypes, it remains a model - one of G72 over 
expression as a model of one possible aspect of schizophrenia. The problem with 
investigating complex disorders in humans with the condition is just that -  they are 
complex, often with unclear aetiology. However, our knowledge would never expand 
if only apparently 'perfect' animal models were used. Perhaps then the aim is not one 
of perfection, but of utility, as concluded by Baker in her review of animal models 
(Baker, 2011). Animal models provide a clear of control over experimental variables 
that is simply not possible in humans. One has to be clear of the restrictions in 
extrapolating data from animals to humans, that animal models are simply that -  a 
model. Similar considerations must be made in human studies, when one considers 
the ethological validity of generalising from laboratory studies to the 'real world'. 
Animal models have their limitations, as does any experiment, but as long we are 
open about this then they can provide rich data that can be used to better understand 
human disease.
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6.5 Concluding remarks
The results in this thesis show that the a7 nAChR may be involved in modulating 
behavioural responses in nicotine addiction [see proposed mechanism in Figure 6-1). 
Furthermore, dysregulation of a7 and OT receptors may underlie the mechanism of 
cognitive and social deficits in schizophrenia [see Figure 6-2). These results are 
supportive of the a7 nAChR and OTR as novel targets for the treatm ent of 
schizophrenia, in particular when comorbid with nicotine addiction, and indicate 
exercise as a useful adjunct therapy. They also implicate the GABAergic and 
glutamatergic systems as possible underpinning mechanisms in these effects. Given 
the benefits already seen for nicotine and OT in the treatm ent of schizophrenia, and 
exercise for various neurodisorders, a multi-modal approach may be of benefit.
Hippocampus
Changes 
GABAergic and 
Glu activity
Î  a7 nAChR Exercise
Nicotine 
withdrawal [ c r a v in g s ,  
d e p r e s s i o n ,  r e s t l e s s n e s s )
Relapse to 
smoking
Figure 6-1: Proposed mechanism for the reduction of nicotine withdrawal by 
exercise.
A b s t i n e n c e  f r o m  n i c o t i n e  l e a d s  t o  t h e  d e v e l o p m e n t  o f  w i t h d r a w a l  s y m p t o m s ,  t h e  s e v e r i t y  o f  
w h i c h  i s  i m p l i c a t e d  i n  r e l a p s e  t o . s m o k i n g .  E l e v a t e d  l e v e l s  o f  h i p p o c a m p a l  « 7  n i c o t i n i c  
r e c e p t o r s  f o l l o w i n g  e x e r c i s e  m a y  a c t  a s  a  p r o t e c t i v e  m e c h a n i s m  b y  r e d u c i n g  n i c o t i n e  r e w a r d  
p r i o r  t o  a b s t i n e n c e .  C h a n g e s  i n  g l u t a m a t e r g i c  a n d  G A B A e r g i c  a c t i v i t y  a r e  a s s o c i a t e d  w i t h  
r e d u c e d  n i c o t i n e  r e i n f o r c e m e n t ,  p a r t l y  t h r o u g h  a t t e n u a t i n g  d o p a m i n e  r e l e a s e .  G r e e n  l i n e s  
i n d i c a t e  a c t i v a t i o n ,  r e d  l i n e s  i n d i c a t e  i n h i b i t i o n  a n d  d a s h e d  l i n e s  i n d i c a t e  h y p o t h e t i c a l  e f f e c t  
o f  n e u r o n a l  r e c e p t o r  m o d u l a t i o n .  A b b r e v i a t i o n s :  G A B A , y - a m i n o  b u t y r i c  a c i d ;  G lu ,  g l u t a m a t e ;  
n A C h R ,  n i c o t i n i c  a c e t y l c h o l i n e  r e c e p t o r .
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Schizophrenia
-i O T  p e p t i d e
±,
a7 n A C h R / O T R  
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Î  O T  p e p t i d e
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Figure 6-2: Proposed mechanism for the amelioration of social cognitive 
deficits in schizophrenia following nicotine administration.
S c h i z o p h r e n i a  i s  c h a r a c t e r i s e d  b y  a  v a r i e t y  o f  s o c i a l  a n d  c o g n i t i v e  d e f i c i t s ,  i n c l u d i n g  r e d u c e d  
p r e p u l s e  i n h i b i t i o n ,  w o r k i n g  m e m o r y  a n d  s o c i a l  r e c o g n i t i o n .  F o l l o w i n g  i n s e r t i o n  o f  t h e  
h u m a n  G 7 2  p r o t e i n  i n  a  m o u s e  m o d e l  o f  s c h i z o p h r e n i a ,  t h e s e  d e f i c i t s  w e r e  o b s e r v e d  
c o n c o m i t a n t  w i t h  e l e v a t e d  a 7  n i c o t i n i c  a n d  o x y t o c i n  r e c e p t o r  b i n d i n g  i n  t h e  c i n g u l a t e  c o r t e x .  
N i c o t i n e  t r e a t m e n t  r e v e r s e d  s o c i a l  c o g n i t i v e  d e f i c i t s  w h i l e  a t t e n u a t i n g  b i n d i n g  o f  t h e s e  
r e c e p t o r s .  M u l t i - m o d a l  t h e r a p y  t a r g e t i n g  a7 a n d  o x y t o c i n  r e c e p t o r s  m a y  p r o v i d e  a  n o v e l  
t h e r a p e u t i c  a p p r o a c h  t o  t h e  t r e a t m e n t  o f  s c h i z o p h r e n i a .  G r e e n  l i n e s  i n d i c a t e  a c t i v a t i o n ,  r e d  
l i n e s  i n d i c a t e  i n h i b i t i o n  a n d  d a s h e d  l i n e s  i n d i c a t e  h y p o t h e t i c a l  e f f e c t  o f  n e u r o n a l  r e c e p t o r  
m o d u l a t i o n .  A b b r e v i a t i o n s :  G A B A , y - a m i n o  b u t y r i c  a c i d ;  n A C h R ,  n i c o t i n i c  a c e t y l c h o l i n e  
r e c e p t o r ;  O T ,  o x y t o c i n ;  O T R , o x y t o c i n  r e c e p t o r .
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U N IV E R S IT Y  O F
SURREY
Ethics Committee
Mrs Helen Keyworth
Biosciences
FHMS
27 January 2011 
Dear Mrs Keyworth
Study on the effect o f perception of exercise intensity on smoking withdrawal 
symptoms and crayfnqs EC/2010/125/FHMS&FAHS
On behalf of the Ethics Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the submitted protocol and supporting 
documentation.
Date of confirmation of ethical opinion: 27 January 2011.
The final list of documents reviewed by the Committee is as follows:
Document
Summary of the project_______
Detailed protocol for the project
Information sheet for participants
Consent form
Questionnaires/Interview schedule
Debriefing sheet
Recruitment advert
Risk assessment
This opinion is given on the understanding that you will comply with the University's Ethical 
Guidelines for Teaching and Research. If the project includes distribution of a survey or 
questionnaire to members of the University community, researchers are asked to include a 
statement advising that the project has been reviewed by the University's Ethics Committee.
The Committee should be notified of any amendments to the protocol, any adverse reactions 
suffered by research participants, and if the study is terminated earlier than expected with 
reasons. Please be advised that the Ethics Committee is able to audit research to ensure that 
researchers are abiding by the University requirements and guidelines.
You are asked to note that a further submission to the Ethics Committee will be required in the 
event that the study is not completed within five years of the above date.
Please inform me when the research has been completed.
Yours sincerely
Glenn Moulton
Secretary, University Ethics Committee 
Registry
cc: Professor S Williamson, Chairman, Ethics Committee 229
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UNIVERSITY OF
SURREY
Participant Information Sheet
Study on the effect of perception of exercise intensity on smoking withdrawal
symptoms and cravings.
I am a PhD student conducting a study as part of my degree. The aim of the study is to 
investigate the effects of a short bout of exercise on cigarette withdrawal symptoms and 
cravings. The experiment involves taking part in two 10 min sessions of supervised 
exercise and sitting quietly for the same amount of time. The exercise will be of a 
moderate intensity and will take place on a stationary exercise bike.
I am looking for participants that smoke, on average, 10 cigarettes or more a day and 
have been a smoker for at least 2 years.
If you wish to take part you will be asked to attend a screening session at the University of 
Surrey, Guildford which will last no more than 30 mins and will involve gaining 
background medical information. Only volunteers who are not currently taking 
prescribed medication (except for the contraceptive pill) will be eligible for the study. On 
a separate day you will asked not to smoke for 3 hours, and then attend the experimental 
lab session. Once in the lab you will first fill out a number of questionnaires, concerning 
the amount of exercise you do, your motivation to quit and how you feel. After this you 
will sit quietly for five mins and you will be asked to complete a further questionnaire. 
You will then complete three experiments in a random order. One involves sitting quietly, 
while two involve an exercise session, each consisting of 10 mins moderate intensity 
exercise, based either on your resting heart rate or what you perceive to be moderate 
intensity exercise. The experimenter will explain how the exercise equipment works to 
you. Every few mins you will be asked to complete a questionnaire verbally. You will then 
sit quietly for a further 15 mins. The entire test procedure will take approximately 2 
hours. At the start of the test you will be asked to blow into a machine that measures 
your exposure to cigarette smoke. The aim will be to confirm you have not smoked for 3 
hours. You will be asked to provide saliva samples during the experiment, this is so we 
can measure levels of a stress hormone called cortisol and other related substances.
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If at any point during the exercise session you feel uncomfortable or no longer wish to 
take part you are free to withdraw from the study at any point during the experiment, 
without having to explain why. All questionnaires and data will be kept strictly 
confidential, with data only being available to the principle investigator. This is in 
accordance with the Data Protection Act 1998.
This study has been given a favourable ethical opinion by the University of Surrey Ethics 
Committee.
If you have any queries please contact:
Helen Keyworth
01483 689701
h.l.kevworth(g)surrev.ac.uk
Supervisor: Mark Cropley
01483 876928 
m.croplev@surrev.ac.uk
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study on the effect of perception of exercise Intensity on smoking withdrawal
symptoms and cravings.
• I the undersigned voluntarily agree to take part in the above named study.
• I have read and understood the Information Sheet provided. I have been given a full 
explanation by the investigators of the nature, purpose, location and likely duration of 
the study, and of what I will be expected to do. I have been advised about any 
discomfort and possible ill-effects on my health and well-being which may result. I 
have been given the opportunity to ask questions on all aspects of the study and have 
understood the advice and information given as a result.
• I agree to comply with any instruction given to me during the study and to co-operate 
fully with the investigators. I shall inform them immediately if I suffer any 
deterioration of any kind in my health or well-being, or experience any unexpected or 
unusual symptoms.
• I consent to my personal data, as outlined in the accompanying information sheet, 
being used for this study and other research. I understand that all personal data 
relating to volunteers is held and processed in the strictest confidence, and in 
accordance with the Data Protection Act (1998).
• I understand that I am free to withdraw from the study at any time without needing 
to justify my decision and without prejudice.
• I acknowledge that in consideration for completing the study I shall receive the sum of 
£20. I recognise that the sum would be less, and at the discretion of the Principal 
Investigator, if I withdraw before completion of the study.
• I understand that in the event of my suffering a significant and enduring injury 
(including illness or disease) as a direct result of my participation in the study, 
compensation will be paid to me by the University subject to certain provisos and 
limitations. The amount of compensation will be appropriate to the nature, severity 
and persistence of the injury and will, in general terms, be consistent with the amount 
of damages commonly awarded for similar injury by an English court in cases where 
the liability has been admitted
• I confirm that I have read and understood the above and freely consent to 
participating in this study. I have been given adequate time to consider my 
participation and agree to comply with the instructions and restrictions of the study.
Name of volunteer (BLOCK CAPITALS)...................................................................................
Signed.....................................................................................
Date...................................................................................
Name of researcher (BLOCK CAPITALS).............................................. ...................................
Signed.....................................................................................
Date...................................................................................
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SCREENING DATA
Date:
Gender: MALE /  FEMALE
Now I need to confirm you are eligible for the study:
How old are you?
1) How many cigarettes do you smoke on average each day?
2) How many years have you been smoking?
3) Can you read and write in English?
4) Are you currently receiving treatment for a mental health problem?
5) Are you currently pregnant or planning a pregnancy?
6) Do you currently have a heart condition or any other condition that
prevents you from exercising?
YES/NO
YES/NO
YES/NO
YES/NO
Medical Questionnaire
I just need to ask you a few questions about your general health. 
Could you please answer YES or NO to the following questions:
YES NO
1. Has your doctor ever said that you have a heart condition and that you should 
only do physical activity recommended by the doctor?
2. Do you feel pain in your chest when you do physical activity?
3. In the last month have you had chest pain at any other time?
4. Do you ever loose your balance because of dizziness, or do you ever faint?
5. Do you have any bone or joint problems that become aggravated when you are 
more active?
6. Do you suffer from asthma?
7. Is your doctor currently prescribing you any medication for high blood pressure?
8. Do you know of any reason why you should not do exercise?
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SMOKING SCALE
How many cigarettes per day do you usually smoke?
Please circle the one answer for each question below: 
(FI) 10 or less 0
11 to 19 1
20 to 30 2
31 or more 3
(F2) How soon after you wake up do you
smoke your first cigarette? (circle one response)
(F3) Do you find it difficult to stop smoking in 
no-smoking areas? (circle one response)
(F4) Which cigarette would you most hate to 
give up? (circle one response)
within 5 mins 3
6-30 mins 2
31 or more 1
NO 0
YES 1
The first in the morning 1
Another 0
(F5) Do you smoke more frequently in the first 
hours after waking than during the rest of 
the day? (circle one response)
(F6) Do you smoke even if you are so ill that you are in bed 
most of the day? (circle one response)
NO
YES
NO
YES
1. What is your usual brand of cigarette/nicotine product:.
2. Occupation (please circle): Staff
Student
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SEVEN DAY PHYSICAL ACTIVITY RECALL
DAY MORNING AFTERNOON EVENING Mins of Activity
1 (yesterday)
2
3
4
5
6
7
Weekly totals:
W: Walk, Exh: Sructured home exercise, Exf: Structured exercise facility, H: Housework, 
Sw: Swimming, DIY: Do it yourself, Cyc: Cycling, G: Gardening, D: Dancing,
Spi: Sport/individual, Spt: Sport Team , Occ: Occupational, O: Other ( p l e a s e  s t a t e ) .
Record the number of hours of moderate activity (hrs=(60/mins)/l
Ask the patient if they have done any hard activity (i.e. that which feels harder than how 
they feel when they are on a brisk walk) and enter day, activity type, duration and pulse 
in box:
Record number of mins of 'hard' activity: 
Record the numbers of hours of hard activity:
Ask the patient if they have done any 'very hard' activity, (i.e. that which feels similar to 
how they feel when they are jogging or running) and enter day, activity type, duration 
and pulse in box:
Record mins of 'Very hard' activity:
Record the number of hours of very hard activity:
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Record the numbers of days with 30 mins + of hard or very hard activity:
Record number of days with 30 mins or more of moderate, hard or very hard activity: 
Record main mode of physical activity (circle one item only):
w Exh Exf H Sw DIY Cyc G D Spi Spt Occ 0
1 2 3 4 5 6 7 8 9 10 11 12 13
Compare seven day recall to activity over previous 3 months
Ask the participant "How much physical activity did you do last week compared with the 
previous 3 months?" (circle one number only)
Much less Less About the same More Much more
1 2 3 4 5
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MOTIVES FOR SMOKING MEASURE
Please answer all seven questions (Circle one number for each question)
SI. Do you use smoking to help you cope with stress? Yes very much 5
Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
S2. Do you use smoking to help you socialise? Yes very much 5
Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
S3. Do you use smoking to give you something to do when Yes very much 5
you are bored? Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
S4. Do you use smoking to help you to concentrate and stay Yes very much 5
alert? Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
S5. Do you smoke because you feel uncomfortable if you Yes very much 5
don't? Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
S6. Do you use smoking to help you to keep your weight Yes very much 5
down? Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
S7. Do you enjoy smoking? Yes very much 5
Yes quite a bit 4
Yes a little 3
Not really 2
Not at all 1
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MOTIVES FOR PHYSICAL ACTIVITIES MEASURE -  REVISED (MPAM-R)
The following is a list of reasons why people engage in physical activities, sports and 
exercise. Keeping in mind your primary physical activity/sport, respond to each question 
(using the scale given), on the basis of how true that response is for you.
1 2 3 4 5 6 7
not at all very true
true for me for me
 1. Because I want to be physically fit.
 2. Because it's fun.
 3. Because I like engaging in activities which physically challenge me.
 4. Because I want to obtain new skills.
 5. Because I want to look or maintain weight so I look better.
 6. Because I want to be with my friends.
 7. Because I like to do this activity.
 8. Because I want to improve existing skills.
 9. Because I like the challenge.
 10. Because I want to define my muscles so I look better.
 11. Because it makes me happy.
 12. Because I want to keep up my current skill level.
 13. Because I want to have more energy
 14. Because I like activities which are physically challenging.
 15. Because I like to be with others who are interested in this activity.
 16. Because I want to improve my cardiovascular fitness.
 17. Because I want to improve my appearance.
 18. Because I think it's interesting.
 19. Because I want to maintain my physical strength to live a healthy life.
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. 20. Because I want to be attractive to others.
.21. Because I want to meet new people.
. 22. Because I enjoy this activity.
. 23. Because I want to maintain my physical health and well-being.
24. Because I want to improve my body shape.
25. Because I want to get better at my activity.
26. Because I find this activity stimulating.
27. Because I will feel physically unattractive if I don't.
28. Because my friends want me to.
29. Because I like the excitement of participation.
30. Because I enjoy spending time with others doing this activity.
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Physiological da ta
1. Expired Carbon Monoxide.......... Pre-quit
2. Resting heart rate........................ Pre-quit
3. Blood pressure.............................Pre-quit
Abstinence
Abstinence
Abstinence
4. Have you been abstained from smoking as required? YES/NO
5. At what time did you have your last cigarette? .................. PM/AM
6. Hours since last cigarette:......................................hours
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MOOD AND PHYSICAL SYMPTOMS
Baseline 0 mins
1. Would you say you have a desire for a cigarette right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7
2. How irritable do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
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Baseline 5 mins
1. Would you say you have a desire for a c igarette  right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7
2. How irritable do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
246
Exercise 5 mins
1. Would you say you have a desire for a c igarette  right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7
2. How irritable do you feel right now?
Not at all Somewhat • Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
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Exercise 10 mins
1. Would you say you have a desire for a c igarette  right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7
2. How irritable do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
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Rest 5 mins
1. Would you say you have a desire for a cigarette  right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7
2. How irritable do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
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Rest 10 mins
1. Would you say you have a desire for a cigarette  right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7
2. How irritable do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
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Rest 15 mins
1. Would you say you have a desire for a cigarette  right now?
Strongly
Disagree
Neutral Strongly
Agree
1 2 3 4 5 6 7 I
2. How irritable do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
3. How depressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
4. How tense do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
5. How restless do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
6. Do you find it difficult to concentrate right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
7. How stressed do you feel right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
8. How strong is your desire to smoke right now?
Not at all Somewhat Extremely
1 2 3 4 5 6 7
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POSITIVE AND NEGATIVE AFFECT SCALE
This scale consists of a number of words that describe different feelings and emotions. 
Read each item and then mark the appropriate answer in the space next to that word. 
Indicate to what extent you feel this way right now, that is, at the present moment.
Use the following scale to record your answers.
Very slightly or 
not at all A little Moderately Quite a bit Extremely
1 2 3 4 5
Positive Affect
Baseline 
0 mins
Baseline 
5 mins
Intervention 
5 mins
Intervention 
10 mins
Rest 5 
mins
Rest 10 
mins
Rest 15 
mins
Attentive
Interested
Alert
Excited
Enthusiastic
Inspired
Proud
Determined
Strong
Active
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Read each item and then mark the appropriate answer in the space next to that word. 
Indicate to what extent you feel this way right now, that is, at the present moment.
Use the following scale to record your answers.
Very slightly or 
not at all A little Moderately Quite a bit Extremely
1 2 3 4 5
Negative Affect
Baseline 
0 mins
Baseline 
5 mins
Intervention 
5 mins
Intervention 
10 mins
Rest 5 
mins
Rest 10 
mins
Rest 15 
mins
Distressed
Upset
Hostile
Irritable
Scared
Afraid
Ashamed
Guilty
Nervous
Jittery
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HEART RATE RESERVE
Resting HR: Target HR:
Karvonen Formula
Insert HRR into formula as fraction (i.e. 55% used as 0.55) 
Target HR = 220 -  age -  resting HR x HRR + resting HR
Time (mins) Heart Rate
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
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RATING OF PERCEIVED EXERTION SCALE
This is a scale for rating perceived exertion. Perceived exertion is the overall effort or 
distress of your body during exercise. Then number 0 represents no perceived exertion or 
leg discomfort and the number 10 represents the greatest amount of exertion that you 
have ever experienced. At various times during the exercise test you will be asked which 
number indicates your rating of perceived exertion at that time.
2.5 mins exercise 7.5 mins exercise
0 Nothing at all
1 Very light
2 Fairly light
3 Moderate
4 Some what hard
5 Hard
6
7 Very hard
8
9
10 Very, very hard
Heart rate
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APPENDIX 6. PARTICIPANT DEBRIEF SHEET
Debriefing Sheet
I would like to take this opportunity to thank you for taking part in this experiment; your 
participation has been most valuable.
Due to this being the early stage of the experiment, no data has been analyzed yet, but 
work already completed in this area suggests that exercise can be beneficial in those 
attempting to stop smoking, i.e. a reduction in cigarette cravings. The issue I am 
investigating here is if there is a difference in the effect on mood, smoking withdrawal 
symptoms and desire to smoke between what you perceive to be moderate intensity 
exercise and moderate intensity exercise prescribed according to your resting heart rate. 
I am also comparing these results for participants with low physical activity and those 
with high levels of physical activity.
If you have any questions or worries do not hesitate to contact me. If you wish to know 
what the experiment found then the results will be made available to you once the study 
has been completed.
Thanks again
Helen Keyworth
01483 689701
h.l.kevworth(g)surrev.ac.uk
Supervisor: Mark Cropley 
01483 876928 
m.croplev@surrev.ac.uk
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